Methods for Preparing Analytes and Related Kits - Patent application

By attaching analytes to nucleic acid chimeras and coupling them to solid supports with a minimum 50 nm separation, the method stabilizes analytes for multiple assay cycles, addressing inefficiencies in existing preparation methods and enabling high-throughput analysis.

JP7582676B2Active Publication Date: 2024-11-13ENCODIA INC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2021564491
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-04-30
Filing Date
2020-04-10
Publication Date
2024-11-13
Estimated Expiration
2040-04-10

AI Technical Summary

Technical Problem

Existing methods for preparing analytes, such as proteins, for analysis and sequencing are inefficient and do not allow for stable immobilization on solid supports, making them unsuitable for multiple chemical and enzymatic reactions, and there is a need for improved techniques to capture analytes in a format compatible with nucleic acid-based assays.

Method used

A method involving attaching an analyte to a bait nucleic acid to form a nucleic acid-analyte chimera, which is then hybridized and covalently coupled to a capture nucleic acid on a solid support, ensuring an average separation of at least 50 nm between adjacent chimeras, allowing for stable immobilization and compatibility with nucleic acid-based assays.

Benefits of technology

This approach enables efficient preparation and analysis of analytes, particularly proteins, by maintaining the integrity of both the analyte and nucleic acid components throughout multiple assay cycles, facilitating high-throughput and parallel processing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007582676000008
    Figure 0007582676000008
  • Figure 0007582676000009
    Figure 0007582676000009
  • Figure 0007582676000010
    Figure 0007582676000010
Patent Text Reader

Abstract

Provided herein are methods for preparing and processing analytes (e.g., a macromolecule or macromolecules, peptides, polypeptides, and proteins) for analysis. In some embodiments, the analytes are prepared and processed by methods that include the use of bait and capture nucleic acids, a solid support, and a reaction mixture that includes the bait and capture nucleic acids. In some embodiments, the analyte is coupled to the solid support. Also provided are kits that include components for carrying out the provided methods for preparing analytes.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Related Applications This application claims priority to U.S. Provisional Patent Application No. 62 / 840,675, filed April 30, 2019, the disclosure and contents of which are incorporated by reference in their entirety for all purposes.

[0002] Statement of Federally Funded Research This invention was made with government support awarded by the National Cancer Institute of the National Institutes of Health under Grant No. R44CA203629. Pursuant to this grant, the United States Government has certain rights in the invention.

[0003] ASCII text sequence listing This patent or application file contains a sequence listing submitted in computer readable ASCII text format (Filename: 4614-2001540_20200410_SeqList_ST25.txt, Recorded on: April 10, 2020, Size: 15,601 bytes). The contents of the sequence listing file are incorporated herein by reference in their entirety.

[0004] The present disclosure relates to methods for preparing and processing analytes (e.g., a macromolecule or macromolecules, peptides, polypeptides, and proteins) for analysis. In some embodiments, the analytes are prepared and processed with a method that uses a bait and capture nucleic acid, a solid support, and a reaction mixture that includes the bait and capture nucleic acid. In some embodiments, the analyte is coupled to the solid support. Also provided are kits that include components for carrying out the provided methods for preparing the analyte. In some embodiments, the methods and kits are for preparing the analyte for sequencing. [Background technology]

[0005] The present disclosure relates to methods for preparing and processing analytes for evaluation, for example, preparing proteins for analysis (e.g., sequencing).From existing methodologies, DNA-directed immobilization of DNA-protein conjugates has been used to immobilize antibodies (Kim et al., Sensors (Basel) (2008) 8 (10): 6605-6641; Dahotre et al., PNAS (2018) 115 (17): 4357-4362; Jung et al., Anal. Chem (2007) 79 (17): 6534-6541).Other hybridization methods include using nucleic acids as probes to hybridize and detect target nucleic acids (U.S. Patent Publication No. 5,770,365).

[0006] However, to generate a format of nucleic acid-analyte conjugate compatible with protein analysis (e.g., protein sequencing), a method for efficient preparation of the analyte is required. For example, a desirable method of preparing the analyte may be compatible with degradation-based polypeptide sequencing assays. Furthermore, it may be advantageous to immobilize the analyte on a solid support so that the components remain attached and available for use in protein analysis assays involving various chemical and / or enzymatic reactions. In some embodiments, the assay may involve multiple cycles and treatments with chemical reagents and / or enzymes. In some cases, the analyte and nucleic acid are prepared such that the nucleic acid components are available for use in nucleic acid-based assays. Thus, there remains a need for improved or new techniques related to the preparation of analytes for analysis and / or sequencing, as well as applications for protein sequencing and / or analysis, and products, methods, and kits for achieving the same. There is a need for efficient methods, such as nucleic acid-based assays, for capturing analytes in a format that allows for the evaluation of the analytes. The present disclosure meets these and other related needs. These and other aspects of the invention will become apparent upon reference to the following detailed description of the invention, and to this end, various references are set forth herein which describe in more detail certain background information, procedures, compounds, and / or compositions, each of which is incorporated herein by reference in its entirety. [Prior art documents] [Patent documents]

[0007] [Patent Document 1] U.S. Patent No. 5,770,365 [Non-patent literature]

[0008] [Non-Patent Document 1] Kim et al.,Sensors(Basel)(2008)8(10):6605-6641 [Non-Patent Document 2] Dahotre et al., PNAS(2018)115(17):4357-4362 [Non-Patent Document 3] Jung et al., Anal.Chem(2007)79(17):6534-6541 Summary of the Invention [Means for solving the problem]

[0009] This Summary is not intended to be used to limit the scope of the claimed subject matter. Other features, details, utilities, and advantages of the claimed subject matter will become apparent from the detailed description, including the embodiments disclosed in the accompanying drawings and the appended claims.

[0010] Provided herein is a method for processing an analyte, comprising attaching the analyte to a bait nucleic acid to generate a nucleic acid-analyte chimera, bringing the nucleic acid-analyte chimera into proximity with a solid support by hybridizing a bait nucleic acid in the nucleic acid-analyte chimera to a capture nucleic acid attached to the solid support, and covalently coupling the nucleic acid-analyte chimera to the solid support, wherein a plurality of nucleic acid-analyte chimeras are coupled on the solid support, and any adjacently coupled nucleic acid-analyte chimeras are separated from one another by an average distance of about 50 nm or more.

[0011] Provided herein are nucleic acid-analyte conjugates produced by attaching an analyte to a bait nucleic acid to produce a nucleic acid-analyte chimera, bringing the nucleic acid-analyte chimera into proximity with a solid support by hybridizing a bait nucleic acid in the nucleic acid-analyte chimera to a capture nucleic acid attached to the solid support, and covalently coupling the nucleic acid-analyte chimera to the solid support, wherein a plurality of nucleic acid-analyte chimeras are coupled on the solid support, and any adjacently coupled nucleic acid-analyte chimeras are separated by an average distance of about 50 nm or more.

[0012] Provided herein are kits that include a solid support comprising a plurality of bait nucleic acids, each of which is configured to attach to an analyte, and a plurality of attached capture nucleic acids, each of which comprises a sequence complementary to a corresponding bait nucleic acid, where any adjacently attached capture nucleic acids are spaced apart on the solid support by an average distance of about 50 nm or more.

[0013] Non-limiting embodiments of the present invention will now be described by way of example with reference to the accompanying drawings, which are schematic and not intended to be drawn to scale. For illustrative purposes, not all components will be labeled in all drawings, nor will all components of each embodiment of the present invention be shown unless illustration is necessary to enable those skilled in the art to understand the present invention. The present invention provides, for example, the following items. (Item 1) 1. A method for processing an analyte, comprising: attaching the analyte to a bait nucleic acid to generate a nucleic acid-analyte chimera; bringing the nucleic acid-analyte chimera into proximity with a solid support by hybridizing the bait nucleic acid in the nucleic acid-analyte chimera to a capture nucleic acid attached to the solid support; covalently coupling the nucleic acid-analyte chimera to the solid support; A method wherein a plurality of said nucleic acid-analyte chimeras are coupled on said solid support, such that any adjacently coupled nucleic acid-analyte chimeras are separated from each other by an average distance of about 50 nm or more. (Item 2) 2. The method of claim 1, wherein the analyte is attached to the 3' end of the bait nucleic acid. (Item 3) 2. The method of claim 1, wherein the analyte is attached to the 5' end of the bait nucleic acid. (Item 4) 2. The method of claim 1, wherein the analyte is attached to an internal position of the bait nucleic acid. (Item 5) 5. The method of any one of items 1-4, wherein any adjacently coupled nucleic acid-analyte chimeras are separated by an average distance of about 60 nm or more, 70 nm or more, 80 nm or more, 90 nm or more, 100 nm or more, 200 nm or more, 300 nm or more, 400 nm or more, 500 nm or more, or 1000 nm or more. (Item 6) 5. The method of any one of items 1 to 4, wherein any adjacently coupled nucleic acid-analyte chimeras are spaced apart by an average distance in the range of about 50 to 100 nm, about 50 to 250 nm, about 50 to 500 nm, about 50 to 750 nm, about 50 to 1000 nm, about 50 to 1500 nm, about 50 to 2000 nm, about 100 to 250 nm, about 100 to 500 nm, about 200 to 500 nm, about 300 to 500 nm, about 100 to 1000 nm, about 500 to 600 nm, about 500 to 700 nm, about 500 to 800 nm, about 500 to 900 nm, about 500 to 1000 nm, about 500 to 2000 nm, about 500 to 5000 nm, about 1000 to 5000 nm, or about 3000 to 5000 nm. (Item 7) 5. The method of any one of items 1 to 4, wherein any adjacently coupled nucleic acid-analyte chimeras are separated by an average distance in the range of about 50 to 500 nm. (Item 8) 8. The method of any one of items 1 to 7, wherein the capture nucleic acid, the nucleic acid-analyte chimera, and / or the bait nucleic acid further comprises a barcode. (Item 9) 9. The method of any one of items 1 to 8, further comprising attaching a barcode to the coupled nucleic acid-analyte chimera. (Item 10) 10. The method of claim 8 or 9, wherein the barcode comprises a compartment barcode, a partition barcode, a sample barcode, a fraction barcode, or any combination thereof. (Item 11) 11. The method according to any one of items 8 to 10, wherein the barcode comprises a unique molecular identifier (UMI). (Item 12) 12. The method of any one of items 1 to 11, wherein the capture nucleic acid, the nucleic acid-analyte chimera, the bait nucleic acid, and / or the coupled nucleic acid-analyte chimera further comprises a unique molecular identifier (UMI). (Item 13) 13. The method of any one of items 9 to 12, wherein the barcode comprises a DNA molecule, a DNA with pseudo-complementary bases, an RNA molecule, a BNA molecule, an XNA molecule, an LNA molecule, a PNA molecule, a γPNA molecule, a non-nucleic acid sequenceable polymer, such as a polysaccharide, a polypeptide, a peptide, or a polyamide, or a combination thereof. (Item 14) 14. The method according to any one of items 1 to 13, wherein the nucleic acid-analyte chimera is directly or indirectly covalently coupled to the solid support. (Item 15) 15. The method according to any one of items 1 to 14, wherein the bait nucleic acid is covalently coupled to the capture nucleic acid. (Item 16) 16. The method of claim 15, wherein the covalent coupling is carried out using a ligation reagent. (Item 17) 17. The method of claim 15 or 16, wherein the 5' end of the bait nucleic acid is coupled to the 3' end of the capture nucleic acid. (Item 18) 17. The method of claim 15 or 16, wherein the 3' end of the bait nucleic acid is coupled to the 5' end of the capture nucleic acid. (Item 19) 19. The method of any one of items 1 to 18, wherein the capture nucleic acid comprises a nucleic acid hairpin. (Item 20) 20. The method of any one of items 1 to 19, wherein the capture nucleic acid comprises a splint nucleic acid. (Item 21) 21. The method of claim 20, wherein the splint nucleic acid comprises a sequence complementary to the capture nucleic acid and / or the bait nucleic acid. (Item 22) 22. The method according to any one of items 1 to 21, wherein the capture nucleic acid comprises a reactive coupling moiety. (Item 23) 23. The method of claim 22, wherein the capture nucleic acid is attached to the solid support via the reactive coupling moiety. (Item 24) 23. The method of claim 22, wherein the capture nucleic acid is attached to the bait nucleic acid via the reactive coupling moiety. (Item 25) 25. The method according to any one of items 1 to 24, wherein the analyte is obtained from a biological sample. (Item 26) 26. The method of any one of items 1 to 25, wherein the hybridization of the bait nucleic acid to the capture nucleic acid comprises hybridization of 8 or more complementary bases, 16 or more complementary bases, 24 or more complementary bases, 34 or more complementary bases. (Item 27) 27. The method of any one of items 1 to 26, wherein the hybridization of the bait nucleic acid to the capture nucleic acid comprises hybridization of 18 or more complementary bases. (Item 28) 28. The method according to any one of items 1 to 27, wherein the analyte is a polypeptide. (Item 29) 29. The method of claim 28, wherein the analyte is a protein or peptide. (Item 30) 30. The method according to item 29, wherein the peptide is obtained by fragmenting a protein, for example a protein from a biological sample. (Item 31) 31. The method of claim 30, wherein the fragmentation is carried out by contacting the protein with a protease. (Item 32) 32. The method of claim 31, wherein the protease is trypsin, LysN, or LysC. (Item 33) 33. The method of any one of items 1 to 32, wherein the analyte comprises analytes from a plurality of pooled samples. (Item 34) 34. The method of any one of items 1 to 33, wherein the analyte and / or bait nucleic acid comprises a reactive coupling moiety. (Item 35) 35. The method of any one of items 1 to 34, wherein the analyte is attached to the bait nucleic acid using chemical ligation. (Item 36) 36. The method according to any one of items 1 to 35, wherein the analyte is directly or indirectly attached to the bait nucleic acid. (Item 37) After coupling the nucleic acid-analyte chimera to the solid support, the 5' end of the bait nucleic acid is available for reaction; the 5' end of the capture nucleic acid is available for reaction; the 3' end of the bait nucleic acid is available for reaction, and / or 37. The method according to any one of items 1 to 36, wherein the 3' end of the capture nucleic acid is available for reaction. (Item 38) 38. The method of claim 37, wherein the nucleic acid is available for an extension reaction, such as a PCR extension reaction, and / or a ligation reaction. (Item 39) 39. The method of any one of items 1 to 38, wherein the bait nucleic acid and / or the capture nucleic acid further comprises a spacer polymer. (Item 40) 40. The method of claim 39, wherein the spacer polymer comprises at least 1 nucleotide, at least 2 nucleotides, at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 15 nucleotides, or at least 20 nucleotides or more. (Item 41) The method of claim 39 and claim 40, wherein the spacer polymer comprises a DNA molecule, a DNA with pseudocomplementary bases, an RNA molecule, a BNA molecule, an XNA molecule, an LNA molecule, a PNA molecule, a γPNA molecule, a non-nucleic acid sequenceable polymer, such as a polysaccharide, a polypeptide, a peptide, or a polyamide, or a combination thereof. (Item 42) 42. The method according to any one of items 39 to 41, wherein the bait nucleic acid comprises a spacer polymer at its 5' end and / or 3' end. (Item 43) 42. The method according to any one of items 39 to 41, wherein the capture nucleic acid comprises a spacer polymer at its 5' end and / or 3' end. (Item 44) 44. The method of any one of items 1 to 43, wherein the bait nucleic acid and / or the capture nucleic acid further comprises a universal priming site. (Item 45) 45. The method of claim 44, wherein the universal priming sites comprise priming sites for amplification, sequencing, or both. (Item 46) 46. ​​The method according to any one of items 1 to 45, wherein the capture nucleic acid comprises an adapter nucleic acid sequence for use in sequencing. (Item 47) 47. The method of claim 46, wherein the adapter nucleic acid sequence is for use with an Illumina sequencing platform or a Pacific Biosciences of California sequencing platform. (Item 48) 48. The method according to any one of items 1 to 47, wherein the solid support is a bead, a porous bead, a porous matrix, an array, a glass surface, a silicon surface, a plastic surface, a filter, a membrane, a PTFE membrane, a nylon, a silicon wafer chip, a flow-through chip, a biochip comprising signal transduction electronics, a microtiter well, an ELISA plate, a rotating interferometer disk, a nitrocellulose membrane, a nitrocellulose-based polymer surface, a nanoparticle, or a microsphere. (Item 49) 49. The method of claim 48, wherein the solid support comprises polystyrene beads, polyacrylate beads, polymeric beads, agarose beads, cellulose beads, dextran beads, acrylamide beads, solid core beads, porous beads, paramagnetic beads, glass beads, controlled porosity beads, silica-based beads, or any combination thereof. (Item 50) contacting the analyte with a binding agent capable of binding to the analyte, the binding agent comprising a coding tag having identifying information regarding the binding agent; 50. The method according to any one of items 1 to 49, further comprising transferring the identification information of the coding tag to the bait nucleic acid or capture nucleic acid. (Item 51) contacting the analyte with an additional binding agent capable of binding to the analyte, the additional binding agent comprising a coding tag having identifying information regarding the additional binding agent; 51. The method of claim 50, further comprising transferring the identification information of the coding tag for the additional binding agent to the bait or capture nucleic acid one or more times. (Item 52) 52. The method of claim 50 or 51, wherein the transfer of the identification information of the coding tag to the bait or capture nucleic acid is mediated by a DNA ligase. (Item 53) 52. The method of claim 50 or 51, wherein the transfer of the identification information of the coding tag to the bait or capture nucleic acid is mediated by a DNA polymerase. (Item 54) 52. The method of claim 50 or 51, wherein the transfer of the identification information of the coding tag to the bait or capture nucleic acid is mediated by chemical ligation. (Item 55) 55. The method of any one of items 50 to 54, wherein the coding tag further comprises a spacer, a binding cycle specific sequence, a unique molecular identifier, a universal priming site, or any combination thereof. (Item 56) attaching the analyte to a bait nucleic acid to generate a nucleic acid-analyte chimera; bringing the nucleic acid-analyte chimera into proximity with a solid support by hybridizing the bait nucleic acid in the nucleic acid-analyte chimera to a capture nucleic acid attached to the solid support; and a nucleic acid-analyte conjugate produced by covalently coupling said nucleic acid-analyte chimera to said solid support, A nucleic acid-analyte conjugate, wherein a plurality of nucleic acid-analyte chimeras are coupled on said solid support, and any adjacently coupled nucleic acid-analyte chimeras are separated by an average distance of about 50 nm or more. (Item 57) 57. The nucleic acid-analyte conjugate according to item 56, wherein the analyte is attached to the 3' end of the bait nucleic acid. (Item 58) 57. The nucleic acid-analyte conjugate according to item 56, wherein the analyte is attached to the 5' end of the bait nucleic acid. (Item 59) 57. The nucleic acid-analyte conjugate of item 56, wherein the analyte is attached to an internal position of the bait nucleic acid. (Item 60) 60. The nucleic acid-analyte conjugate of any one of items 56 to 59, wherein any adjacently coupled nucleic acid-analyte chimeras are separated by an average distance of about 60 nm or more, 70 nm or more, 80 nm or more, 90 nm or more, 100 nm or more, 200 nm or more, 300 nm or more, 400 nm or more, 500 nm or more, or 1000 nm or more. (Item 61) Any adjacently coupled nucleic acid-analyte chimera may be about 50-100 nm, about 50-250 nm, about 50-500 nm, about 50-750 nm, about 50-1000 nm, about 50-1500 nm, about 50-2000 nm, about 100-250 nm, about 100-500 nm, about 200-500 nm, about 300-500 nm, about 100-1000 nm 61. The nucleic acid-analyte conjugate according to any one of items 56 to 60, wherein the conjugates are spaced apart by an average distance in the range of about 500 to 600 nm, about 500 to 700 nm, about 500 to 800 nm, about 500 to 900 nm, about 500 to 1000 nm, about 500 to 2000 nm, about 500 to 5000 nm, about 1000 to 5000 nm, or about 3000 to 5000 nm. (Item 62) 62. The nucleic acid-analyte conjugate of any one of items 56 to 61, wherein any adjacently coupled nucleic acid-analyte chimeras are separated by an average distance in the range of about 50 to 500 nm. (Item 63) 63. The nucleic acid-analyte conjugate of any one of items 56 to 62, wherein the capture nucleic acid, the nucleic acid-analyte chimera, and / or the bait nucleic acid further comprises a barcode. (Item 64) 64. The nucleic acid-analyte conjugate of any one of items 56 to 63, wherein the coupled nucleic acid-analyte chimera further comprises a barcode. (Item 65) 65. The nucleic acid-analyte conjugate of item 64, wherein the barcode comprises a compartment barcode, a partition barcode, a sample barcode, a fraction barcode, or any combination thereof. (Item 66) 65. The nucleic acid-analyte conjugate of any one of items 62 to 64, wherein the barcode comprises a unique molecular identifier (UMI). (Item 67) 67. The nucleic acid-analyte conjugate of any one of items 56 to 66, wherein the capture nucleic acid, the nucleic acid-analyte chimera, the bait nucleic acid, and / or the coupled nucleic acid-analyte chimera further comprises a unique molecular identifier (UMI). (Item 68) 68. The nucleic acid-analyte conjugate of any one of items 64 to 67, wherein the barcode comprises a DNA molecule, a DNA with pseudo-complementary bases, an RNA molecule, a BNA molecule, an XNA molecule, an LNA molecule, a PNA molecule, a γPNA molecule, a non-nucleic acid sequenceable polymer, such as a polysaccharide, a polypeptide, a peptide, or a polyamide, or a combination thereof. (Item 69) 69. The nucleic acid-analyte conjugate according to any one of items 56 to 68, wherein the nucleic acid-analyte chimera is directly or indirectly covalently coupled to the solid support. (Item 70) 70. The nucleic acid-analyte conjugate according to any one of items 56 to 69, wherein the bait nucleic acid is covalently coupled to the capture nucleic acid. (Item 71) 71. The nucleic acid-analyte conjugate according to item 70, wherein the covalent coupling is carried out using a ligation reagent. (Item 72) 72. The nucleic acid-analyte conjugate of claim 70 or 71, wherein the 5' end of the bait nucleic acid is coupled to the 3' end of the capture nucleic acid. (Item 73) 72. The nucleic acid-analyte conjugate of claim 70 or 71, wherein the 3' end of the bait nucleic acid is coupled to the 5' end of the capture nucleic acid. (Item 74) 74. The nucleic acid-analyte conjugate according to any one of items 56 to 73, wherein the capture nucleic acid comprises a nucleic acid hairpin. (Item 75) 75. The nucleic acid-analyte conjugate of any one of items 56 to 74, wherein the capture nucleic acid comprises a splint nucleic acid. (Item 76) 76. The nucleic acid-analyte conjugate of claim 75, wherein the splint nucleic acid comprises a sequence complementary to the capture nucleic acid and / or the bait nucleic acid. (Item 77) 77. The nucleic acid-analyte conjugate according to any one of items 56 to 76, wherein the capture nucleic acid comprises a reactive coupling moiety. (Item 78) 78. The nucleic acid-analyte conjugate of claim 77, wherein the capture nucleic acid is attached to the solid support via the reactive coupling moiety. (Item 79) 78. The nucleic acid-analyte conjugate of claim 77, wherein the capture nucleic acid is attached to the bait nucleic acid via the reactive coupling moiety. (Item 80) 80. The nucleic acid-analyte conjugate according to any one of items 56 to 79, wherein the analyte is obtained from a biological sample. (Item 81) 81. The nucleic acid-analyte conjugate of any one of items 56 to 80, wherein the hybridization of the bait nucleic acid to the capture nucleic acid comprises hybridization of 8 or more complementary bases, 16 or more complementary bases, 24 or more complementary bases, 34 or more complementary bases. (Item 82) 81. The nucleic acid-analyte conjugate of any one of items 56 to 80, wherein the hybridization of the bait nucleic acid to the capture nucleic acid comprises hybridization of 16 or more complementary bases. (Item 83) 83. The nucleic acid-analyte conjugate according to any one of items 56 to 82, wherein the analyte is a polypeptide. (Item 84) 84. The nucleic acid-analyte conjugate of item 83, wherein the analyte is a protein or peptide. (Item 85) 85. The nucleic acid-analyte conjugate according to item 84, wherein the peptide is obtained by fragmenting a protein, e.g. a protein from a biological sample. (Item 86) 86. The nucleic acid-analyte conjugate of item 85, wherein the fragmentation is carried out by contacting the protein with a protease. (Item 87) 87. The nucleic acid-analyte conjugate of item 86, wherein the protease is trypsin, LysN, or LysC. (Item 88) 88. The nucleic acid-analyte conjugate of any one of items 56 to 87, wherein the analytes comprise analytes from a plurality of pooled samples. (Item 89) 89. The nucleic acid-analyte conjugate according to any one of items 56 to 88, wherein the analyte and / or the bait nucleic acid comprises a reactive coupling moiety. (Item 90) 90. The nucleic acid-analyte conjugate of any one of items 56 to 89, wherein the analyte is attached to the bait nucleic acid using chemical ligation. (Item 91) 91. The nucleic acid-analyte conjugate according to any one of items 56 to 90, wherein the analyte is directly or indirectly attached to the bait nucleic acid. (Item 92) After coupling the nucleic acid-analyte chimera to the solid support, the 5' end of the bait nucleic acid is available for reaction; the 5' end of the capture nucleic acid is available for reaction; the 3' end of the bait nucleic acid is available for reaction, and / or 92. The nucleic acid-analyte conjugate according to any one of items 56 to 91, wherein the 3' end of the capture nucleic acid is available for reaction. (Item 93) 93. The nucleic acid-analyte conjugate according to item 92, wherein the nucleic acid is available for an extension reaction, such as a PCR extension reaction, and / or a ligation reaction. (Item 94) 94. The nucleic acid-analyte conjugate according to any one of items 54 to 93, wherein the bait nucleic acid and / or the capture nucleic acid further comprises a spacer polymer. (Item 95) 95. The nucleic acid-analyte conjugate of item 94, wherein the spacer polymer comprises at least 1 nucleotide, at least 2 nucleotides, at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 15 nucleotides, or at least 20 nucleotides or more. (Item 96) 96. The nucleic acid-analyte conjugate of claim 94 or 95, wherein the spacer polymer comprises a DNA molecule, a DNA with pseudocomplementary bases, an RNA molecule, a BNA molecule, an XNA molecule, an LNA molecule, a PNA molecule, a γPNA molecule, a non-nucleic acid sequenceable polymer, such as a polysaccharide, a polypeptide, a peptide, or a polyamide, or a combination thereof. (Item 97) 97. The nucleic acid-analyte conjugate according to any one of items 94 to 96, wherein the bait nucleic acid comprises the spacer polymer at its 5' end and / or 3' end. (Item 98) 97. The nucleic acid-analyte conjugate according to any one of items 94 to 96, wherein the capture nucleic acid comprises the spacer polymer at its 5' end and / or 3' end. (Item 99) 99. The nucleic acid-analyte conjugate of any one of items 56 to 98, wherein the bait nucleic acid and / or the capture nucleic acid further comprises a universal priming site. (Item 100) 100. The nucleic acid-analyte conjugate of claim 99, wherein the universal priming site comprises a priming site for amplification, sequencing, or both. (Item 101) 101. The nucleic acid-analyte conjugate according to any one of items 56 to 100, wherein the capture nucleic acid comprises an adapter nucleic acid sequence for use in sequencing. (Item 102) Item 102. The nucleic acid-analyte conjugate of item 101, wherein the adapter nucleic acid sequence is for use with an Illumina sequencing platform or a Pacific Biosciences of California sequencing platform. (Item 103) 103. The nucleic acid-analyte conjugate of any one of items 56 to 102, wherein the solid support is a bead, a porous bead, a porous matrix, an array, a glass surface, a silicon surface, a plastic surface, a filter, a membrane, a PTFE membrane, a nylon, a silicon wafer chip, a flow-through chip, a biochip comprising signal transduction electronics, a microtiter well, an ELISA plate, a rotating interferometer disk, a nitrocellulose membrane, a nitrocellulose-based polymer surface, a nanoparticle, or a microsphere. (Item 104) 104. The nucleic acid-analyte conjugate according to item 103, wherein the solid support comprises polystyrene beads, polyacrylate beads, polymer beads, agarose beads, cellulose beads, dextran beads, acrylamide beads, solid core beads, porous beads, paramagnetic beads, glass beads, controlled porosity beads, silica-based beads, or any combination thereof. (Item 105) A kit comprising: (a) a plurality of bait nucleic acids, each of the bait nucleic acids configured to attach to an analyte; (b) a solid support comprising a plurality of attached capture nucleic acids, each of said capture nucleic acids comprising a sequence complementary to a corresponding bait nucleic acid, and any adjacently attached capture nucleic acids are spaced apart on said solid support by an average distance of about 50 nm or more. (Item 106) 106. The kit of claim 105, wherein at least one of the bait nucleic acids is configured to allow attachment of the analyte to the 3' end of the bait nucleic acid. (Item 107) 106. The kit of claim 105, wherein at least one of the bait nucleic acids is configured to allow attachment of the analyte to the 5' end of the bait nucleic acid. (Item 108) 106. The kit of claim 105, wherein at least one of the bait nucleic acids is configured to allow attachment of the analyte to an internal location of the bait nucleic acid. (Item 109) 109. The kit of any one of items 105-108, wherein any adjacently attached capture nucleic acids are configured to couple the analyte to the solid support at an average distance spaced on the solid support of about 60 nm or more, 70 nm or more, 80 nm or more, 90 nm or more, 100 nm or more, 200 nm or more, 300 nm or more, 400 nm or more, 500 nm or more, or 1000 nm or more. (Item 110) Any adjacently attached capture nucleic acid may have a diameter of about 50 to 100 nm, about 50 to 250 nm, about 50 to 500 nm, about 50 to 750 nm, about 50 to 1000 nm, about 50 to 1500 nm, about 50 to 2000 nm, about 100 to 250 nm, about 100 to 500 nm, about 200 to 500 nm, about 300 to 500 nm, about 100 to 1000 nm, about 500 to 600 nm, 109. The kit according to any one of items 105 to 109, configured to couple the analyte to the solid support at an average distance in the range of about 500 to 700 nm, about 500 to 800 nm, about 500 to 900 nm, about 500 to 1000 nm, about 500 to 2000 nm, about 500 to 5000 nm, about 1000 to 5000 nm, or about 3000 to 5000 nm. (Item 111) 100. The kit of any one of items 105 to 109, wherein any adjacently attached capture nucleic acids are spaced apart on the solid support by an average distance in the range of about 50 to 500 nm and configured to couple the analyte to the solid support. (Item 112) 112. The kit of any one of items 105 to 111, further comprising a plurality of barcodes. (Item 113) The barcode is attached to the bait nucleic acid or the capture nucleic acid, or Item 113. The kit of item 112, wherein the barcode is configured to be attached to the bait nucleic acid or the capture nucleic acid. (Item 114) 114. The kit of claim 112 or 113, wherein the barcode comprises a compartment barcode, a partition barcode, a sample barcode, a fraction barcode, or any combination thereof. (Item 115) 115. The kit of any one of items 112 to 114, wherein the barcode comprises a unique molecular identifier (UMI). (Item 116) 116. The kit of any one of items 105 to 115, wherein at least one of the capture nucleic acids and / or at least one of the bait nucleic acids further comprises a unique molecular identifier (UMI). (Item 117) 117. The kit of any one of items 109 to 116, wherein the barcode comprises a DNA molecule, a DNA with pseudo-complementary bases, an RNA molecule, a BNA molecule, an XNA molecule, an LNA molecule, a PNA molecule, a γPNA molecule, a non-nucleic acid sequenceable polymer, such as a polysaccharide, a polypeptide, a peptide, or a polyamide, or a combination thereof. (Item 118) 118. The kit according to any one of items 105 to 117, wherein at least one of the bait nucleic acids comprises a reactive coupling moiety. (Item 119) 119. The kit according to any one of items 105 to 118, wherein the surface of the solid support comprises a reactive coupling moiety. (Item 120) 120. The kit according to any one of items 105 to 119, wherein at least one of the capture nucleic acids comprises a reactive coupling moiety. (Item 121) 121. The kit of any one of items 118 to 120, wherein the reactive coupling moiety is configured to be activated by application of light energy, a chemical reagent, or an enzymatic reagent. (Item 122) Item 122. The kit according to item 121, wherein the enzyme reagent is a ligase. (Item 123) 123. The kit according to any one of items 105 to 122, further comprising a coupling reagent. (Item 124) Item 124. The kit according to item 123, wherein the coupling reagent is an enzymatic coupling reagent or a chemical coupling reagent. (Item 125) 125. The kit of claim 124, wherein the enzymatic coupling reagent is a ligase. (Item 126) 126. The kit according to any one of items 105 to 125, further comprising a protease. (Item 127) Item 127. The kit of item 126, wherein the protease is trypsin, LysN, or LysC. (Item 128) 128. The kit of any one of Items 105 to 127, wherein at least one of the capture nucleic acids comprises a nucleic acid hairpin. (Item 129) 129. The kit of any one of items 105 to 128, wherein the capture nucleic acid comprises a splint nucleic acid. (Item 130) 130. The kit of claim 129, wherein the splint nucleic acid comprises a sequence complementary to the capture nucleic acid and / or the bait nucleic acid. (Item 131) 131. The kit according to any one of items 105 to 130, wherein the complementary sequence of at least one of the bait nucleic acids to at least one of the capture nucleic acids comprises 8 or more complementary bases, 16 or more complementary bases, 24 or more complementary bases, or 34 or more complementary bases. (Item 132) 131. The kit according to any one of Items 105 to 130, wherein the complementary sequence of at least one of the bait nucleic acids to at least one of the capture nucleic acids comprises 16 or more complementary bases. (Item 133) 133. The kit of any one of items 105 to 132, further comprising a chemical ligation reagent. (Item 134) 134. The kit according to any one of items 105 to 133, wherein at least one of the bait nucleic acids and / or at least one of the capture nucleic acids further comprises a spacer polymer. (Item 135) 135. The kit of claim 134, wherein the spacer polymer comprises a DNA molecule, a DNA with pseudocomplementary bases, an RNA molecule, a BNA molecule, an XNA molecule, an LNA molecule, a PNA molecule, a γPNA molecule, a non-nucleic acid sequenceable polymer, such as a polysaccharide, a polypeptide, a peptide, or a polyamide, or a combination thereof. (Item 136) 136. The kit of any one of items 105 to 135, wherein at least one of the bait nucleic acids and / or at least one of the capture nucleic acids further comprises a universal priming site. (Item 137) 137. The kit of claim 136, wherein the universal priming sites comprise priming sites for amplification, sequencing, or both. (Item 138) 138. The kit according to any one of items 105 to 137, wherein the capture nucleic acid comprises an adapter nucleic acid sequence for use in sequencing. (Item 139) Item 139. The kit of item 138, wherein the adapter nucleic acid sequence is for use with an Illumina sequencing platform or a Pacific Biosciences sequencing platform. (Item 140) 140. The kit according to any one of items 134 to 139, wherein at least one of the bait nucleic acids comprises the spacer polymer at its 5' end and / or 3' end. (Item 141) 141. The kit according to any one of items 134 to 140, wherein at least one of the capture nucleic acids comprises the spacer polymer at its 5' end and / or 3' end. (Item 142) 142. The kit of any one of items 105 to 141, wherein the solid support is a bead, a porous bead, a porous matrix, an array, a glass surface, a silicon surface, a plastic surface, a filter, a membrane, a PTFE membrane, a nylon, a silicon wafer chip, a flow-through chip, a biochip comprising signal transduction electronics, a microtiter well, an ELISA plate, a rotating interferometer disk, a nitrocellulose membrane, a nitrocellulose-based polymer surface, a nanoparticle, or a microsphere. (Item 143) 143. The kit of claim 142, wherein the solid support comprises polystyrene beads, polyacrylate beads, polymeric beads, agarose beads, cellulose beads, dextran beads, acrylamide beads, solid core beads, porous beads, paramagnetic beads, glass beads, controlled porosity beads, silica-based beads, or any combination thereof. [Brief description of the drawings]

[0014] [Figure 1A-1D] 1A-1D show exemplary methods for attaching an analyte to a bait nucleic acid and coupling a nucleic acid-analyte chimera to a bead. In some examples, the analyte is attached directly or indirectly (e.g., via a linker) to the bait nucleic acid. In FIG. 1A, the analyte is attached to an internal position of the bait nucleic acid and the nucleic acid-analyte chimera is attached to the 3' end of the capture nucleic acid. In FIG. 1B, the analyte is attached to the 3' end of the bait nucleic acid and the nucleic acid-analyte chimera is attached to the 3' end of the capture nucleic acid. In FIG. 1C, the analyte is attached to an internal position of the bait nucleic acid and the nucleic acid-analyte chimera is attached to the 5' end of the capture nucleic acid. In FIG. 1D, the analyte is attached to the 5' end of the bait nucleic acid and the nucleic acid-analyte chimera is attached to the 5' end of the capture nucleic acid. In some embodiments, the attachment of the bait nucleic acid to the capture nucleic acid is by ligation. [Figure 2A-2C] A method for photoaffinity labeling and immobilization of protein analytes is shown. A bait nucleic acid with a photoactive benzophenone moiety is used to randomly label proteins upon exposure to UV 365 nm light, thereby forming a nucleic acid-analyte chimera (Figure 2A). This process can also be performed in a two-step procedure using an alkyne-benzophenone and an azide-oligo. The nucleic acid-analyte chimeras are hybridized through their bait nucleic acid to a surface derivatized with a complementary capture nucleic acid with a reactive psoralen moiety (Figure 2B). The complex is covalently crosslinked with the psoralen upon exposure to UV light (Figure 2C). [Figures 3-7] Optionally, exemplary steps and configurations for forming nucleic acid-analyte conjugates on a solid support, including adding a barcode sequence. In some cases, the barcode sequence may include a sample barcode, a fraction barcode, a spatial barcode, a compartment tag, or any combination thereof. Similar methods can be used to add UMIs or other functional nucleic acid moieties, such as universal priming sites, spacer sequences complementary to spacer sequences attached to another nucleic acid moiety, or any combination thereof. [Diagram 3]The following steps for immobilizing an analyte are shown: A barcode template (BC') is hybridized to a nucleic acid-analyte chimera. An extension reaction is used to extend the 3' end of the bait nucleic acid to include the barcode sequence. The nucleic acid-analyte chimera with the newly extended barcode is brought into proximity with a solid support by hybridizing the bait nucleic acid (containing the analyte and barcode) to a capture nucleic acid attached to the solid support. The nucleic acid-analyte chimera is covalently coupled to the solid support by attaching (e.g., via ligation) the capture and bait nucleic acids. [Figure 4] The following steps for immobilizing an analyte are shown: A nucleic acid-analyte chimera is brought into proximity with a solid support by hybridizing a bait nucleic acid (containing the analyte) to a capture nucleic acid attached to the solid support. A nucleic acid-analyte chimera is covalently coupled to a solid support by attaching (e.g., via ligation) the capture and bait nucleic acids. An extension reaction is performed using a barcode template (BC') to extend the 3' end of the bait nucleic acid to include the barcode sequence from the template. A digestion reaction is used to release the barcode template from the nucleic acid-analyte conjugate coupled to the solid support. [Diagram 5] The following steps for immobilizing an analyte are shown: A bait nucleic acid is attached to the barcode using a ligation reaction; The nucleic acid-analyte chimera with the barcode attached is brought into proximity with the solid support by hybridizing the bait nucleic acid (comprising the analyte and barcode) to a capture nucleic acid attached to the solid support; The nucleic acid-analyte chimera is covalently coupled to the solid support by attaching the capture nucleic acid and the bait nucleic acid (e.g., via ligation). In some embodiments, a splint nucleic acid strand is used, where the splint bridges the bait nucleic acid and the barcode via hybridization, allowing for efficient ligation or chemical coupling. In some embodiments, the splint nucleic acid is separate from the bait nucleic acid. [Figure 6]Illustrated is the coupling of a nucleic acid-analyte chimera to a solid support by attachment of a barcode (e.g., via ligation) to the 3' end of the capture nucleic acid, and attachment of a bait nucleic acid (e.g., via ligation) to the 5' capture nucleic acid. In FIG. 6, the barcode hybridizes to a region of the nucleic acid-analyte chimera, and both are brought into proximity with the solid support by hybridizing the bait nucleic acid of the chimera to the capture nucleic acid attached to the solid support. The nucleic acid-analyte chimera is covalently coupled to the solid support by attaching the 5' end of the capture nucleic acid to the bait nucleic acid (e.g., via ligation). The barcode is attached to the 3' end of the capture nucleic acid (e.g., via ligation). In FIG. 7, the nucleic acid-analyte chimera is brought into proximity with the solid support by hybridizing the bait nucleic acid of the chimera to the 5' end of the capture nucleic acid attached to the solid support, and the capture nucleic acid includes a barcode sequence. [Figure 7] Same as above. [Figure 8] The steps for placing a barcode and optionally other nucleic acid moieties on a bait nucleic acid are shown. The nucleic acid-analyte chimera is hybridized to a nucleic acid template that contains multiple dU, UMI, barcode, and / or spacer sequences. Primer extension is performed in a reaction (e.g., with Klenow fragment (exo-) at 25° C.) to place the UMI, barcode, and / or spacer from the template barcode on the bait nucleic acid (attached to the analyte). The resulting dsDNA is treated with USER enzyme to digest the dU sites and heated to remove the digested fragments. In some cases, the bait nucleic acid contains a universal priming site or a portion thereof. [Figure 9]1 illustrates steps for placing a barcode and optionally other nucleic acid components into a bait nucleic acid using reverse transcription. Using an RNA barcode template containing a UMI, barcode, and / or spacer sequence, reverse transcription is carried out in a reaction with reverse transcriptase (RNase H-) at about 50° C. for about 1 hour to place the UMI, barcode, and / or spacer sequence into the bait nucleic acid), and the resulting RNA / DNA hybrid is treated with RNase to digest the RNA barcode template. In some cases, the bait nucleic acid contains a universal priming site or a portion thereof. [Figure 10] 1 is a summary of the encoding efficiency of various peptides assessed in an exemplary peptide analysis assay using modified N-terminal phenylalanine F binders. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0015] Provided herein are methods and kits for preparing an analyte (e.g., a polymer or polymers, peptides, polypeptides, and proteins). In some embodiments, the methods and kits are for processing the analyte in preparation for sequencing and / or analysis. In some embodiments, the methods include attaching the analyte to a solid support. In some embodiments, the immobilized nucleic acid-analyte chimera is configured for analysis of the analyte, e.g., the analysis uses barcoding and nucleic acid encoding of molecular recognition events and / or detectable labels. In some embodiments, the methods include attaching the analyte to a bait nucleic acid to generate a nucleic acid-analyte chimera, bringing the nucleic acid-analyte chimera into proximity with the solid support by hybridizing a bait nucleic acid in the nucleic acid-analyte chimera to a capture nucleic acid attached to the solid support, and covalently coupling the nucleic acid-analyte chimera to the solid support, wherein a plurality of nucleic acid-analyte chimeras are coupled on the solid support, and any adjacently coupled nucleic acid-analyte chimeras are spaced apart from each other by an average distance of about 50 nm or more. In some embodiments, the analyte is obtained from a biological sample. In some cases, the analyte is a protein. In some embodiments, the analyte is a peptide, e.g., a peptide generated from a fragmented protein obtained from the sample. Also provided are nucleic acid-analyte conjugates generated by any of the methods provided herein.

[0016] Also provided are kits that contain components and / or reagents for carrying out the provided methods for processing and preparing analytes for sequencing and / or analysis. In some embodiments, the kits also contain instructions for using the kit to carry out any of the methods for preparing or processing analytes provided herein.

[0017] Existing methodologies for immobilizing and capturing analytes, including those for immobilizing antibodies on solid surfaces, include DNA-directed immobilization of DNA-protein conjugates (Kim et al., Sensors (Basel). (2008) 8(10): 6605-6641; Dahotre et al., PNAS (2018) 115(17): 4357-4362; Jung et al., Anal. Chem (2007) 79(17): 6534-6541). Other known hybridization methods include using nucleic acids as probes to hybridize and detect target nucleic acids (U.S. Patent No. 5,770,365).

[0018] However, to generate a format of nucleic acid-analyte conjugate compatible with protein analysis (e.g., protein sequencing), a method for efficient preparation of the analyte is required. For example, it may be advantageous for the analyte to be immobilized on a solid support such that the analyte and nucleic acid components remain attached and / or immobilized throughout a protein analysis assay involving various chemical and / or enzymatic reactions. In some embodiments, the assay may involve multiple cycles and treatments with chemical reagents and / or enzymes. In some cases, the analyte and / or nucleic acid are coupled to the solid support such that both are available and remain available during the protein analysis assay, including multiple cycles of the assay. In some cases, the analyte and nucleic acid are prepared such that the nucleic acid components are available for use in a nucleic acid-based analyte assay. For example, the nucleic acid used may include components used in downstream analysis, such as components useful for downstream DNA sequencing.

[0019] Thus, there remains a need for improved techniques related to the preparation of analytes for analysis and / or sequencing, as well as applications to protein sequencing and / or analysis, and products, methods, and kits for achieving the same. There is a need to use efficient methods, such as nucleic acid-based assays, to capture analytes in a format that allows for the evaluation of the analytes. The present disclosure meets these and other related needs. In some embodiments, the present disclosure provides, in part, methods for preparing analytes for use with highly parallel, high-throughput digital macromolecule (e.g., polypeptide) characterization and quantification methods with direct application to protein and peptide characterization and sequencing.

[0020] In some embodiments, provided herein are methods for processing an analyte, comprising attaching the analyte to a bait nucleic acid to generate a nucleic acid-analyte chimera, bringing the nucleic acid-analyte chimera into proximity with a solid support by hybridizing a bait nucleic acid in the nucleic acid-analyte chimera to a capture nucleic acid attached to the solid support, and covalently coupling the nucleic acid-analyte chimera to the solid support, wherein a plurality of nucleic acid-analyte chimeras are coupled on the solid support, and any adjacently coupled nucleic acid-analyte chimeras are separated from one another by an average distance of about 50 nm or more. Also provided is a nucleic acid-analyte conjugate produced by attaching an analyte to a bait nucleic acid to produce a nucleic acid-analyte chimera, bringing the nucleic acid-analyte chimera into proximity with a solid support by hybridizing a bait nucleic acid in the nucleic acid-analyte chimera to a capture nucleic acid attached to the solid support, and covalently coupling the nucleic acid-analyte chimera to the solid support, wherein a plurality of nucleic acid-analyte chimeras are coupled on the solid support, and any adjacently coupled nucleic acid-analyte chimeras are spaced apart from one another by an average distance of about 50 nm or more. In some embodiments, the analyte comprises a plurality of macromolecules, e.g., proteins, polypeptides, peptides, or fragments thereof, obtained from a sample. In some embodiments, the sample is obtained from a subject. In some embodiments, the analyte is directly or indirectly coupled to the bait nucleic acid. In some embodiments, the analyte is directly or indirectly coupled to the solid support.

[0021] In some embodiments, the analyte is attached to the 3' end of the bait nucleic acid. In some embodiments, the analyte is attached to the 5' end of the bait nucleic acid. In some embodiments, the analyte is attached to an internal location of the bait nucleic acid. In some embodiments, the capture nucleic acid, the nucleic acid-analyte chimera, and / or the bait nucleic acid further comprises a barcode. In some cases, the method for preparing and processing the analyte further comprises attaching a barcode to the nucleic acid-analyte chimera after it is coupled to the solid support. In some examples, the barcode comprises a compartment barcode, a partition barcode, a sample barcode, a fraction barcode, or any combination thereof.

[0022] In some embodiments, the nucleic acid-analyte conjugates are compatible for use with nucleic acid-based analyte sequencing assays. In some embodiments, after conjugation of the bait nucleic acid-analyte chimera to a solid support, the 5' end of the bait nucleic acid is available for reaction. In some embodiments, after conjugation of the bait nucleic acid-analyte chimera to a solid support, the 5' end of the capture nucleic acid is available for reaction. In some embodiments, after conjugation of the bait nucleic acid-analyte chimera to a solid support, the 3' end of the bait nucleic acid is available for reaction. In some embodiments, after conjugation of the bait nucleic acid-analyte chimera to a solid support, the 3' end of the capture nucleic acid is available for reaction. In some examples, the nucleic acid is available for an extension reaction, e.g., a PCR extension reaction, and / or a ligation reaction.

[0023] In some embodiments, the methods for processing analytes described herein are compatible for analyzing the analyte using an assay that includes contacting the analyte with a binder capable of binding to the analyte (the binder comprises a coding tag having identifying information related to the binder) and transferring the identifying information of the coding tag to a bait or capture nucleic acid. In some examples, the nucleic acid-analyte conjugate on the solid support is generated such that after coupling, both the nucleic acid and the analyte are available for use in an assay that includes contacting the analyte with a binder capable of binding to the analyte (the binder comprises a coding tag having identifying information related to the binder) and transferring the identifying information of the coding tag to a bait or capture nucleic acid. In some examples, the nucleic acid-analyte conjugate on the solid support is compatible for use in a sequencing assay that includes one or more cycles of contacting with the binder and transferring the identifying information.

[0024] Provided herein are kits that include (a) a plurality of bait nucleic acids, each of which is configured to attach to an analyte, and (b) a solid support that includes a plurality of attached capture nucleic acids, each of which includes a sequence complementary to a corresponding bait nucleic acid, where any adjacently attached capture nucleic acids are spaced apart on the solid support by an average distance of about 50 nm or more. In some embodiments, kits are provided that include (a) a plurality of bait nucleic acids, each of which is configured to attach to an analyte, and (b) a plurality of capture nucleic acids, each of which includes a sequence complementary to a corresponding bait nucleic acid.

[0025] In order to provide a thorough understanding of the present disclosure, numerous specific details are set forth in the following description. These details are provided for illustrative purposes, and the claimed subject matter may be practiced according to the claims without some or all of these specific details. It is to be understood that other embodiments may be used and structural changes may be made without departing from the scope of the claimed subject matter. It is to be understood that various features and functions described in one or more of the individual embodiments are not limited in terms of their applicability to the particular embodiment for which they are described. Instead, they may be applied to one or more of the other embodiments of the present disclosure, either alone or in some combination, regardless of whether such an embodiment is described and whether such features are presented as part of the embodiment described. For the sake of clarity, technical material known in the art related to the claimed subject matter will not be described in detail in such a way as not to unnecessarily obscure the claimed subject matter.

[0026] All publications, including patent documents, scientific articles and databases, referred to in this application are incorporated by reference in their entirety for all purposes to the same extent as if each individual publication was individually incorporated by reference. Citation of publications or documents is not intended as an admission that any of them is pertinent prior art, and does not constitute any admission as to the contents or dates of such publications or documents.

[0027] All headings are provided for the convenience of the reader and should not be used to limit the meaning of the text that follows the heading, unless specifically stated.

[0028] definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. To the extent that a definition set forth in this section contradicts or otherwise conflicts with a definition set forth in any patent, application, published application, or other publication incorporated herein by reference, the definition set forth in this section shall take precedence over the definition incorporated herein by reference.

[0029] As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a peptide" includes one or more peptides, or a mixture of peptides. Reference to an "analyte" includes one or more analytes, or a mixture of analytes. Also, as used herein, unless specifically stated or apparent from the context, the term "or" is understood to be inclusive and includes both "or" and "and."

[0030] As used herein, the term "about" refers to the normal error range of each value, which is readily known to those skilled in the art. Reference herein to "about" a value or parameter encompasses (and describes) an embodiment that is directed to the value or parameter itself. For example, a description that refers to "about X" encompasses the description of "X."

[0031] As used herein, the term "polymer" encompasses large molecules that are composed of smaller subunits. Examples of polymers include, but are not limited to, peptides, polypeptides, proteins, nucleic acids, carbohydrates, lipids, macrocycles. Polymers also include chimeric polymers (e.g., peptides linked to nucleic acids) that are composed of combinations of two or more types of polymers that are covalently linked together. Polymers can also include "polymer assemblies" that are composed of non-covalent complexes of two or more polymers. Polymer assemblies can be composed of the same type of polymer (e.g., protein-protein) or even two different types of polymer (e.g., protein-DNA).

[0032] As used herein, the term "polypeptide" encompasses peptides and proteins and refers to a molecule comprising a chain of two or more amino acids joined by peptide bonds. In some embodiments, a polypeptide comprises 2-50 amino acids, e.g., more than 20-30 amino acids. In some embodiments, a peptide does not comprise secondary, tertiary, or higher order structure. In some embodiments, a polypeptide is a protein. In some embodiments, a protein comprises 30 or more amino acids, e.g., more than 50 amino acids. In some embodiments, a protein comprises secondary, tertiary, or higher order structure in addition to the primary structure. The amino acids of a polypeptide are most typically L-amino acids, but may be D-amino acids, modified amino acids, amino acid analogs, amino acid mimetics, or any combination thereof. A polypeptide may be naturally occurring, synthetically produced, or recombinantly expressed. A polypeptide may be synthetically produced, isolated, recombinantly expressed, or produced by a combination of methodologies as described above. A polypeptide may also comprise additional groups that modify the amino acid chain, e.g., functional groups added via post-translational modifications. The polymer may be linear or branched, may comprise modified amino acids, and may be interrupted by non-amino acids. The term also encompasses amino acid polymers that are modified naturally or by intervention, such as disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or other manipulation or modification, such as conjugation with a labeling component.

[0033] As used herein, the term "amino acid" refers to an organic compound containing an amine group, a carboxylic acid group, and a side chain specific to each amino acid that functions as a monomeric subunit of a peptide. Amino acids include the 20 standard, naturally occurring or canonical amino acids, and nonstandard amino acids. Standard natural amino acids include alanine (A or Ala), cysteine ​​(C or Cys), aspartic acid (D or Asp), glutamic acid (E or Glu), phenylalanine (F or Phe), glycine (G or Gly), histidine (H or His), isoleucine (I or Ile), lysine (K or Lys), leucine (L or Leu), methionine (M or Met), asparagine (N or Asn), proline (P or Pro), glutamine (Q or Gln), arginine (R or Arg), serine (S or Ser), threonine (T or Thr), valine (V or Val), tryptophan (W or Trp), and tyrosine (Y or Tyr). Amino acids can be L- or D-amino acids. Non-standard amino acids can be naturally occurring or chemically synthesized modified amino acids, amino acid analogs, amino acid mimetics, non-standard proteinogenic amino acids, or non-proteinogenic amino acids. Examples of non-standard amino acids include, but are not limited to, selenocysteine, pyrrolysine, and N-formylmethionine, β-amino acids, homoamino acids, proline and pyruvic acid derivatives, 3-substituted alanine derivatives, glycine derivatives, ring-substituted phenylalanine and tyrosine derivatives, linear core amino acids, and N-methyl amino acids.

[0034] As used herein, the term "post-translational modification" refers to a modification that occurs on a peptide after its translation by the ribosome is completed. A post-translational modification can be a covalent chemical modification or an enzymatic modification. Examples of post-translational modifications include acylation, acetylation, alkylation (including methylation), biotinylation, butyrylation, carbamylation, carbonylation, deamidation, deiminiation, diphthamide formation, disulfide bridge formation, eliminylation, flavin attachment, formylation, gamma carboxylation, glutamylation, glycylation, glycosylation, glypiation, heme C attachment, hydroxylation, hypusine attachment, and the like. Post-translational modifications include, but are not limited to, iodination, isoprenylation, lipidation, lipoylation, malonylation, methylation, myristolylation, oxidation, palmitoylation, pegylation, phosphopantetheination, phosphorylation, propionylation, retinylidene Schiff base formation, S-glutathionylation, S-nitrosylation, S-sulfenylation, selenation, succinylation, sulfination, ubiquitination, and C-terminal amidation. Post-translational modifications include modifications of the amino and / or carboxyl termini of peptides. Modifications of terminal amino groups include, but are not limited to, desamino, N-lower alkyl, N-di-lower alkyl, and N-acyl modifications. Modifications of terminal carboxy groups include, but are not limited to, amide, lower alkyl amide, dialkyl amide, and lower alkyl ester modifications (e.g., lower alkyl is C1-C4 alkyl). Post-translational modifications also include modifications of amino acids between the amino and carboxy termini, such as, but not limited to, those described above. The term post-translational modification can also include peptide modifications that include one or more detectable labels.

[0035] As used herein, the term "binding agent" refers to a nucleic acid molecule, peptide, polypeptide, protein, carbohydrate, or small molecule that binds to, associates with, integrates with, recognizes, or combines with an analyte, e.g., a polypeptide or a component or mechanism of a polypeptide. A binding agent may form a covalent or non-covalent association with an analyte, e.g., a polypeptide or a component or mechanism of a polypeptide. A binding agent may also be a chimeric binding agent that is composed of two or more types of molecules, such as a nucleic acid molecule-peptide chimeric binding agent or a carbohydrate-peptide chimeric binding agent. A binding agent may be a naturally occurring, synthetically produced, or recombinantly expressed molecule. A binding agent may bind to a single monomer or subunit of a polypeptide (e.g., a single amino acid of a polypeptide) or to multiple linked subunits of a polypeptide (e.g., dipeptides, tripeptides, or higher order peptides of a longer peptide, polypeptide, or protein molecule). A binding agent may bind to a linear molecule or a molecule that has a three-dimensional structure (also called a conformation). For example, an antibody binding agent may bind to a linear peptide, polypeptide, or protein, or to a conformational peptide, polypeptide, or protein. A binding agent may bind to an N-terminal peptide, a C-terminal peptide, or an intervening peptide of a peptide, polypeptide, or protein molecule. A binding agent may bind to an N-terminal amino acid, a C-terminal amino acid, or an intervening amino acid of a peptide molecule. A binding agent may bind to a diamino acid moiety at the N-terminus or C-terminus. A binding agent may preferably bind to a chemically modified or labeled amino acid (e.g., an amino acid functionalized with a reagent (e.g., a compound)) rather than an amino acid that is not modified or labeled. For example, a binding agent may preferably bind to an amino acid functionalized with an acetyl moiety, a Cbz moiety, a guanyl moiety, a dansyl moiety, a PTC moiety, a DNP moiety, a SNP moiety, a biheterocyclic methanimine moiety, or the like, rather than an amino acid that does not have such a moiety. A binding agent may bind to a post-translational modification of a peptide molecule.A binding agent may exhibit selective binding to a component or feature of a polypeptide (e.g., a binding agent may selectively bind to one of the 20 possible naturally occurring amino acid residues and bind with very low affinity or not at all to the other 19 naturally occurring amino acid residues). If a binding agent can bind to multiple components or features of a polypeptide, the binding agent may exhibit low selective binding (e.g., a binding agent may bind with similar affinity to two or more different amino acid residues). A binding agent may include or be attached to a coding tag, which may be joined to the binding agent by a linker.

[0036] As used herein, the term "linker" refers to one or more of a nucleotide, nucleotide analog, amino acid, peptide, polypeptide, or non-nucleotide chemical moiety used to join two molecules. A linker can be used, for example, to join a binding agent to a coding tag, a bait nucleic acid to a polypeptide, a polypeptide to a solid support, or a capture nucleic acid to a solid support. In certain embodiments, the linker joins the two molecules by an enzymatic or chemical reaction (e.g., click chemistry).

[0037] As used herein, the term "proteome" may include the entire set of proteins, polypeptides or peptides (including their conjugates or complexes) expressed by a genome, cell, tissue, or organism of any organism at a particular time. In one embodiment, a proteome is the set of proteins expressed in a given type of cell or organism at a given time under defined conditions. Proteomics is the study of proteomes. For example, a "cellular proteome" may include the collection of proteins found in a particular cell type under a particular set of environmental conditions, such as exposure to a hormonal stimulus. The complete proteome of an organism may include the complete set of proteins from all of the various cellular proteomes. A proteome may also include the collection of proteins in a particular subcellular biological system. For example, all of the proteins in a virus may be referred to as the viral proteome. As used herein, the term "proteome" includes subsets of the proteome, including, but not limited to, the kinome; the secretome; the receptor (e.g., the GPCRome); the immunoproteome; the nutriprotome; proteome subsets defined by post-translational modifications (e.g., phosphorylation, ubiquitination, methylation, acetylation, glycosylation, oxidation, lipidation, and / or nitrosylation), such as the phosphoproteome (e.g., the phosphotyrosine-proteome, the tyrosine-kinome, and the tyrosine-phosphatome), the glycoproteome, etc.; proteome subsets associated with a tissue or organ, a developmental stage, or a physiological or pathological state; proteome subsets associated with a cellular process, such as the cell cycle, differentiation (or dedifferentiation), cell death, senescence, cell migration, transformation, or metastasis; or any combination thereof. As used herein, the term "proteomics" refers to the analysis of the proteome in cells, tissues, and body fluids, and the corresponding spatial distribution of the proteome within cells and tissues. In some embodiments, the analysis may include quantitative and / or qualitative analysis. Furthermore, proteomics studies include the dynamic state of the proteome, which continues to change over time as a function of biology and defined biological or chemical stimuli.

[0038] The terminal amino acid at one end of a peptide chain having a free amino group is referred to herein as the "N-terminal amino acid" (NTAA). The terminal amino acid at the other end of the chain having a free carboxyl group is referred to herein as the "C-terminal amino acid" (CTAA). The N-terminal diamino acid is composed of the N-terminal amino acid and the penultimate N-terminal amino acid. The C-terminal diamino acid is similarly defined for the C-terminus. When a peptide is "n" amino acids in length, the amino acids that make up the peptide can be numbered sequentially. As used herein, the NTAA is considered to be the nth amino acid (also referred to herein as "nNTAA"). Using this nomenclature, the next amino acid is n-1 amino acid, then n-2 amino acids, and so on down the length from the N-terminus to the C-terminus of the peptide. In certain embodiments, the NTAA, CTAA, or both can be functionalized with a chemical moiety.

[0039] As used herein, the term "barcode" refers to a nucleic acid molecule of about 2 to about 30 bases (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 bases) that provides a unique identifier tag or provenance information for a polypeptide, a binder, a set of binders from a binding cycle, a sample polypeptide, a set of samples, a polypeptide in a compartment (e.g., a droplet, a bead, or a separate location), a polypeptide in a set of compartments, a fraction of a polypeptide, a set of polypeptide fractions, a spatial region or set of spatial regions, a library of polypeptides, or a library of binders. Barcodes can be artificial or naturally occurring sequences. In certain embodiments, each barcode in a population of barcodes is different. In other embodiments, a portion of the barcodes in the population of barcodes are different, for example, at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, or 99% of the barcodes in the population of barcodes are different. The population of barcodes can be randomly or non-randomly generated. In certain embodiments, the population of barcodes is an error-correcting barcode. Barcodes can be used in analysis to distinguish sequence reads from individual polypeptides, samples, libraries, etc. Barcodes can also be used to deconvolute polypeptide ensembles distributed in small compartments to enhance mapping. For example, instead of mapping peptides back to the proteome, mapping peptides back to the original protein molecule or protein complex. BC' refers to a spacer sequence complementary to the barcode (BC).

[0040] The "sample barcode," also called the "sample tag," identifies which sample the polypeptide originates from.

[0041] A "spatial barcode" identifies the region of a 2D or 3D tissue section from which a polypeptide originates. Spatial barcodes can be used for molecular pathology of tissue sections. Spatial barcodes allow for multiplex sequencing of multiple samples or libraries from a tissue section.

[0042] As used herein, the term "binding cycle specific tag", "binding cycle specific barcode", or "binding cycle specific sequence" refers to a unique sequence used to identify a library of binding agents used in a particular binding cycle. The binding cycle specific tag may comprise a length of about 2 bases to about 8 bases (e.g., 2, 3, 4, 5, 6, 7, or 8 bases). The binding cycle specific tag may be incorporated into the coding tag of the binding agent as part of the spacer sequence, part of the encoder sequence, part of the UMI, or as a separate component within the coding tag.

[0043] As used herein, the term "spacer" (Sp) refers to a nucleic acid molecule of about 1 base to about 20 bases (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 bases) in length present on the end of a nucleic acid (e.g., a bait or capture nucleic acid) or coding tag. In certain embodiments, the spacer sequence is adjacent to the encoder sequence of the coding tag at one or both ends. Following binding of the binder to the polypeptide, annealing between the complementary spacer sequence on the coding tag and the complementary spacer sequence on the bait or capture nucleic acid allows the transfer of the binding information to the nucleic acid construct (e.g., the bait or capture nucleic acid) via a primer extension reaction or ligation. Sp' refers to a spacer sequence complementary to Sp. Preferably, the spacer sequences in a binder library have the same number of bases. A common (shared or identical) spacer can be used in the binder library. The spacer sequence may have a "cycle-specific" sequence to keep track of the binder used in a particular binding cycle. The spacer sequence (Sp) may be constant over all binding cycles, specific to a particular class of polypeptide, or specific to the number of binding cycles. The polypeptide class-specific spacer allows the coding tag information of a cognate binder present in the extended nucleic acid from a completed binding / extension cycle to be annealed via the class-specific spacer to the coding tag of another binder that recognizes the same class of polypeptide in a subsequent binding cycle. Only sequential binding of the correct cognate pair results in interacting spacer elements and effective primer extension. The spacer sequence may contain a sufficient number of bases to anneal to a complementary spacer sequence in the nucleic acid (e.g., on the bait or capture nucleic acid) to which the identifying information from the coding tag is transferred to initiate a primer extension (also called polymerase extension) reaction, or to provide a "sprint" for a ligation reaction, or to mediate a "sticky end" ligation reaction. The spacer sequence may contain fewer bases than the encoder sequence in the coding tag.

[0044] As used herein, the term "primer extension," also called "polymerase extension," refers to a reaction catalyzed by a nucleic acid polymerase (e.g., a DNA polymerase) whereby a nucleic acid molecule (e.g., an oligonucleotide primer, a spacer sequence) that is annealed to a complementary strand is extended by the polymerase using the complementary strand as a template.

[0045] As used herein, the term "unique molecular identifier" or "UMI" refers to a nucleic acid molecule of about 3 to about 40 bases (3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 bases) in length that provides a unique identifier tag for each polypeptide or binder to which the UMI is linked. Polypeptide UMIs can be used to computationally deconvolute sequencing data from multiple extended nucleic acids to identify extended nucleic acids derived from individual polypeptides. Polypeptide UMIs can be used to accurately count original polypeptide molecules by collapsing NGS reads into unique UMIs. Binder UMIs can be used to identify individual molecular binders that bind to a particular polypeptide. For example, the UMI can be used to identify the number of individual binding events of a single amino acid-specific binder that occur to a particular peptide molecule. It is understood that when UMI and barcode are both referenced in the context of a binder or polypeptide, the barcode refers to identifying information other than the UMI for an individual binder or polypeptide (e.g., sample barcode, compartment barcode, binding cycle barcode).

[0046] As used herein, the term "universal priming site" or "universal primer" or "universal priming sequence" refers to a nucleic acid molecule that can be used in library amplification and / or sequencing reactions. Universal priming sites include, but are not limited to, priming sites (primer sequences) for PCR amplification, flow cell adapter sequences that anneal to complementary oligonucleotides on the flow cell surface to enable bridge amplification in some next-generation sequencing platforms, sequencing priming sites, or combinations thereof. Universal priming sites can be used for other types of amplification, including those commonly used in conjunction with next-generation digital sequencing. For example, extended nucleic acid molecules can be circularized and universal priming sites can be used for rolling circle amplification to form DNA nanoballs that can be used as sequencing templates (Drmanac et al., 2009, Science 327:78-81). Alternatively, the nucleic acid molecule can be circularized and sequenced directly by polymerase extension from the universal priming site (Korlach et al., 2008, Proc. Natl. Acad. Sci. 105:1176-1181). The term "forward" when used in connection with a "universal priming site" or "universal primer" may also be referred to as "5" or "sense". The term "reverse" when used in connection with a "universal priming site" or "universal primer" may also be referred to as "3" or "antisense".

[0047] As used herein, the term "solid support", "solid surface", or "solid substrate", or "sequencing substrate", or "substrate" refers to any solid material, including porous and non-porous materials, to which a polypeptide can be directly or indirectly associated by any means known in the art, including covalent and non-covalent interactions, or any combination thereof. A solid support can be two-dimensional (e.g., planar) or three-dimensional (e.g., gel matrix or bead). A solid support can be any support surface, including, but not limited to, beads, microbeads, arrays, glass surfaces, silicon surfaces, plastic surfaces, filters, membranes, PTFE membranes, PTFE membranes, nitrocellulose membranes, nitrocellulose-based polymer surfaces, nylon, silicon wafer chips, flow-through chips, flow cells, biochips including signal transduction electronics, channels, microtiter wells, ELISA plates, spinning interferometry discs, polymer matrices, nanoparticles, or microspheres. Materials for solid supports include, but are not limited to, acrylamide, agarose, cellulose, dextran, nitrocellulose, glass, gold, quartz, polystyrene, polyethylene vinyl acetate, polypropylene, polyester, polymethacrylate, polyacrylate, polyethylene, polyethylene oxide, polysilicate, polycarbonate, polyvinyl alcohol (PVA), Teflon, fluorocarbon, nylon, silicone rubber, polyanhydrides, polyglycolic acid, polyvinyl chloride, polylactic acid, polyorthoesters, functionalized silanes, polypropyl fumerate, collagen, glycosaminoglycans, polyamino acids, dextran, or any combination thereof. Solid supports further include shaped polymers such as thin films, membranes, bottles, dishes, fibers, woven fibers, tubes, particles, beads, microspheres, microparticles, or any combination thereof.For example, when the solid surface is a bead, the bead may include, but is not limited to, ceramic beads, polystyrene beads, polymer beads, polyacrylate beads, methylstyrene beads, agarose beads, cellulose beads, dextran beads, acrylamide beads, solid core beads, porous beads, paramagnetic beads, glass beads, or controlled porosity beads, silica-based beads, or any combination thereof. The beads may be spherical or irregularly shaped. The beads or supports may be porous. The size of the beads may range from nanometers, e.g., 100 nm to several millimeters, e.g., up to 1 mm. In certain embodiments, the size of the beads ranges from about 0.2 microns to about 200 microns, or from about 0.5 microns to about 5 microns. In some embodiments, the beads may be about 1, 1.5, 2, 2.5, 2.8, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 15, or 20 μm in diameter. In certain embodiments, a "bead" solid support may refer to an individual bead or a plurality of beads. In some embodiments, the solid surface is a nanoparticle. In certain embodiments, the size of the nanoparticle ranges from about 1 nm to about 500 nm in diameter, e.g., from about 1 nm to about 20 nm, from about 1 nm to about 50 nm, from about 1 nm to about 100 nm, from about 10 nm to about 50 nm, from about 10 nm to about 100 nm, from about 10 nm to about 200 nm, from about 50 nm to about 100 nm, from about 50 nm to about 150, from about 50 nm to about 200 nm, from about 100 nm to about 200 nm, or from about 200 nm to about 500 nm. In some embodiments, the nanoparticles may be about 10 nm, about 50 nm, about 100 nm, about 150 nm, about 200 nm, about 300 nm, or about 500 nm in diameter. In some embodiments, the nanoparticles are less than about 200 nm in diameter.

[0048] As used herein, the terms "nucleic acid", "nucleic acid molecule", or "polynucleotide" refer to single- or double-stranded polynucleotides comprising deoxyribonucleotides or ribonucleotides linked by 3'-5' phosphodiester bonds, and polynucleotide analogs. Nucleic acid molecules include, but are not limited to, DNA, RNA, and cDNA. Polynucleotide analogs may have backbones other than the standard phosphodiester bonds found in natural polynucleotides, and, optionally, modified sugar moieties other than ribose or deoxyribose. Polynucleotide analogs contain bases capable of hydrogen bonding to standard polynucleotide bases by Watson-Crick base pairing, and the analog backbone presents the bases in a manner that allows such hydrogen bonding in a sequence-specific manner between the oligonucleotide analog molecule and the bases of a standard polynucleotide. Examples of polynucleotide analogs include, but are not limited to, heterologous nucleic acids (XNA), bridged nucleic acids (BNA), glycol nucleic acids (GNA), peptide nucleic acids (PNA), gamma PNA, morpholino polynucleotides, locked nucleic acids (LNA), threose nucleic acids (TNA), 2'-O-methyl polynucleotides, 2'-O-alkylribosyl-substituted polynucleotides, phosphorothioate polynucleotides, and boronophosphate polynucleotides.Polynucleotide analogs may have purine or pyrimidine analogs, including universal base analogs that can pair with any base, including, for example, 7-deazapurine analogs, 8-halopurine analogs, 5-halopyrimidine analogs, or hypoxanthine, nitroazole, isocarbostyril analogs, azolecarboxamide, and aromatic triazole analogs, or base analogs with additional functionality, such as biotin moieties for affinity binding.In some embodiments, the nucleic acid molecule or oligonucleotide is a modified oligonucleotide.In some embodiments, nucleic acid molecule or oligonucleotide is DNA with pseudocomplementary base, DNA with protected base, RNA molecule, BNA molecule, XNA molecule, LNA molecule, PNA molecule, γPNA molecule, or morpholino DNA, or combinations thereof.In some embodiments, nucleic acid molecule or oligonucleotide is backbone-modified, sugar-modified, or nucleic acid base-modified.In some embodiments, nucleic acid molecule or oligonucleotide has nucleic acid base-protecting group such as Alloc, electrophilic protecting group such as thiolane, acetyl protecting group, nitrobenzyl protecting group, sulfonate protecting group, or conventional base-labile protecting group.

[0049] As used herein, "nucleic acid sequencing" means the determination of the order of nucleotides in a nucleic acid molecule or a sample of nucleic acid molecules.

[0050] As used herein, "next-generation sequencing" refers to high-throughput sequencing methods that allow for parallel sequencing of millions to billions of molecules. Examples of next-generation sequencing methods include sequencing by synthesis, sequencing by ligation, sequencing by hybridization, polony sequencing, ion semiconductor sequencing, and pyrosequencing. Nucleic acid molecules can be hybridized to solid substrates via primers by attaching primers to solid substrates and complementary sequences to nucleic acid molecules, which can then be amplified using polymerase to generate multiple copies in separate regions on the solid substrate (these groupings are sometimes called polymerase colonies or polonies). As a result, nucleotides at specific positions can be sequenced multiple times (e.g., hundreds or thousands of times) during the sequencing process. This depth of coverage is called "deep sequencing." Examples of high-throughput nucleic acid sequencing technologies include platforms offered by Illumina, BGI, Qiagen, Thermo-Fisher, and Roche, as reviewed by the Service (Science 311:1544-1546, 2006), and include formats such as parallel bead arrays, sequencing-by-synthesis, sequencing-by-ligation, capillary electrophoresis, electronic microchips, "biochips," microarrays, parallel microchips, and single molecule arrays.

[0051] As used herein, "single molecule sequencing" or "third generation sequencing" refers to next-generation sequencing methods in which reads from a single molecule sequencing instrument are generated by sequencing a single molecule of DNA. Unlike next-generation sequencing methods that rely on amplification to clone many DNA molecules in parallel for sequencing in a step-by-step approach, single molecule sequencing interrogates a single molecule of DNA and does not require amplification or synchronization. Single molecule sequencing includes methods that require the sequencing reaction to be paused after incorporation of each base ("wash-and-scan" cycles) and methods that do not require stopping between read steps. Examples of single molecule sequencing methods include single molecule real-time sequencing (Pacific Biosciences), nanopore-based sequencing (Oxford Nanopore), duplex interrupted nanopore sequencing, and direct imaging of DNA using advanced microscopes.

[0052] As used herein, "analyzing" an analyte (e.g., a polypeptide) means identifying, quantifying, characterizing, distinguishing, or a combination thereof, all or a portion of the components of the analyte, e.g., a polypeptide. For example, analysis of a peptide, polypeptide, or protein includes determining all or a portion of the amino acid sequence (contiguous or non-contiguous) of the peptide. Analysis of a polypeptide also includes partial identification of the components of the polypeptide. For example, partial identification of amino acids in a polypeptide protein sequence can identify amino acids in a protein as belonging to a subset of possible amino acids. Analysis typically begins with analysis of nNTAA and proceeds to the next amino acid of the peptide (i.e., n-1, n-2, n-3, etc.). This is accomplished by elimination of nNTAA, thereby converting n-1 amino acids of the peptide to the N-terminal amino acid (referred to herein as "n-1 NTAA"). Analysis of a peptide can also include determining the presence and frequency of post-translational modifications of the peptide. This may or may not include information regarding the order of post-translational modifications of the peptide. Analysis of a peptide may also include determining the presence and frequency of epitopes in the peptide, which may or may not include information regarding the order or location of the epitopes within the peptide. Analysis of a peptide may include a combination of different types of analysis, for example obtaining epitope information, amino acid sequence information, post-translational modification information, or any combination thereof.

[0053] As used herein, the term "compartment" refers to a physical area or volume that separates or isolates a subset of analytes (e.g., polypeptides) from a sample of polypeptides. For example, a compartment can separate individual cells from other cells, or a subset of the proteome of a sample from the remaining proteome of the sample. A compartment can be an aqueous compartment (e.g., a microfluidic droplet), a solid compartment (e.g., a plate, a tube, a vial, a picotiter well or a microtiter well on a gel bead), a bead surface, inside a porous bead, or a separated area on a surface. A compartment can include one or more beads to which a polypeptide can be immobilized.

[0054] As used herein, the term "compartment tag" or "compartment barcode" refers to a single-stranded or double-stranded nucleic acid molecule of about 4 bases to about 100 bases (including 4 bases, 100 bases, and any integer therebetween) that contains identifying information for a construct (e.g., the proteome of a single cell) within one or more compartments (e.g., a microfluidic droplet, a bead surface). A compartment barcode identifies a subset of polypeptides in a sample that have been separated into the same physical compartment or group of compartments from multiple (e.g., millions to billions) of compartments. Thus, compartment tags can be used to distinguish components from one or more compartments with the same compartment tag from components of another compartment with a different compartment tag, even after the components are pooled together. By labeling proteins and / or peptides within each compartment or group of two or more compartments with a unique compartment tag, peptides from the same protein, protein complex, or cell within individual compartments or groups of compartments can be identified. The compartment tag optionally comprises a barcode flanked on one or both sides by a spacer sequence and an optional universal primer. The spacer sequence may be complementary to the spacer sequence of the nucleic acid to which the identification information from the coding tag is transferred, allowing the transfer of the compartment tag information to the nucleic acid. The compartment tag may also comprise a universal priming site, a unique molecular identifier (to provide the identity of the peptide attached thereto), or both, particularly for embodiments in which the compartment tag comprises a bait or capture nucleic acid used in the downstream peptide analysis methods described herein. The compartment tag may comprise a functional moiety (e.g., an aldehyde, NHS, mTet, alkyne, etc.) for coupling to a peptide. Alternatively, the compartment tag may comprise a peptide that comprises a recognition sequence for a protein ligase, allowing ligation of the compartment tag to a peptide of interest.A compartment may contain a single compartment tag, multiple identical compartment tags except for an optional UMI sequence, or two or more different compartment tags. In certain embodiments, each compartment contains a unique compartment tag (one-to-one mapping). In other embodiments, multiple compartments from a larger population of compartments contain the same compartment tag (many-to-one mapping). The compartment tag may be attached to a solid support (e.g., a bead) within the compartment, or to a surface of the compartment itself (e.g., the surface of a picotiter well). Alternatively, the compartment tag may be free in solution within the compartment.

[0055] As used herein, the term "partition" refers to the assignment of a unique barcode to a subpopulation of analytes (e.g., peptides) from a population of analytes in a sample. The barcode assignment may be random. In certain embodiments, partitioning may be achieved by distributing analytes into compartments. A partition may be composed of an analyte in a single compartment, or an analyte in multiple compartments from a population of compartments.

[0056] As used herein, a "partition tag" or "partition barcode" refers to a single- or double-stranded nucleic acid molecule of about 4 bases to about 100 bases (including 4 bases, 100 bases, and any integer therebetween) that contains identifying information for a partition. In certain embodiments, the partition tag of a polypeptide refers to the same compartment tag that results from partitioning the polypeptide into compartments labeled with the same barcode.

[0057] As used herein, the term "fraction" refers to a subset of analytes (e.g., polypeptides) within a sample that have been sorted from the remainder of the sample or organelle using a physical or chemical separation method, e.g., fractionation by size, hydrophobicity, isoelectric point, affinity, etc. Separation methods include HPLC separation, gel separation, affinity separation, cell fractions, organelle fractions, tissue fractions, etc. Physical properties such as flow rate, magnetism, current, mass, density, etc. can also be used for separation.

[0058] As used herein, the term "fraction barcode" refers to a single- or double-stranded nucleic acid molecule of about 4 bases to about 100 bases (including 4 bases, 100 bases, and any integers therebetween) that contains identifying information for an analyte (e.g., a polypeptide) within a fraction.

[0059] As used herein, the term "coding tag" refers to a polynucleotide having any suitable length, e.g., a nucleic acid molecule of about 2 bases to about 100 bases, including any integer between 2 and 100, inclusive, that contains identifying information for its associated binding agent. "Coding tags" can also be made from "sequenceable polymers" (see, e.g., Niu et al., 2013, Nat. Chem. 5:282-292; Roy et al., 2015, Nat. Commun. 6:7237; Lutz et al., 2015, Macromolecules 48:4759-4767, each of which is incorporated by reference in its entirety). Coding tags can include an encoder sequence, optionally flanked by a spacer on one side or, optionally, by spacers on both sides. Coding tags can also be comprised of an optional UMI and / or an optional binding cycle-specific barcode. The coding tag can be single-stranded or double-stranded. The double-stranded coding tag can include blunt ends, overhanging ends, or both. The coding tag can refer to the coding tag directly attached to the binding agent, the complementary sequence hybridized to the coding tag directly attached to the binding agent (e.g., in the case of a double-stranded coding tag), or the coding tag information present in the extension recording tag. In certain embodiments, the coding tag can further include a binding cycle-specific spacer or barcode, a unique molecular identifier, a universal priming site, or any combination thereof.

[0060] It will be understood that aspects and embodiments of the invention described herein include "consisting of" and / or "consisting essentially of" aspects and embodiments.

[0061] Throughout this disclosure, various aspects of the invention are presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Thus, the description of a range should be considered to specifically disclose all possible subranges and individual numerical values ​​within that range. For example, the description of a range such as 1-6 should be considered to specifically disclose subranges such as 1-3, 1-4, 1-5, 2-4, 2-6, 3-6, and individual numbers within that range (e.g., 1, 2, 3, 4, 5, and 6). This applies regardless of the breadth of the range.

[0062] Other objects, advantages and features of the present invention will become apparent from the following specification taken in conjunction with the accompanying drawings.

[0063] I. Methods for Preparing Analytes and Generating Nucleic Acid-Analyte Conjugates Provided herein are methods and kits for preparing an analyte (e.g., a polymer or polymers, peptides, polypeptides, and proteins). In some embodiments, the methods and kits are for processing the analyte in preparation for sequencing and / or analysis. In some embodiments, the method includes attaching the analyte to a solid support. In some embodiments, the nucleic acid-analyte conjugate is configured for analysis of the analyte, e.g., the analysis uses barcoding and nucleic acid encoding of molecular recognition events and / or detectable labels. In some embodiments, the method includes attaching the analyte to a bait nucleic acid to generate a nucleic acid-analyte chimera. In some embodiments, the method further includes hybridizing a bait nucleic acid in the nucleic acid-analyte chimera to a capture nucleic acid attached to the solid support, thereby bringing the nucleic acid-analyte chimera into proximity with the solid support, and covalently hybridizing the nucleic acid-analyte chimera to the solid support. In some embodiments, a plurality of nucleic acid-analyte chimeras are coupled on a solid support, and any adjacently coupled nucleic acid-analyte chimeras are spaced apart from each other by an average distance of about 50 nm or more. Adjacently coupled nucleic acid-analytes or adjacently coupled nucleic acid-analyte chimeras can refer to molecules adjacent to each other in any orientation in two-dimensional space. In some cases, adjacently coupled nucleic acid-analytes or adjacently coupled nucleic acid-analyte chimeras can refer to molecules adjacent to each other in any orientation in three-dimensional space. In some embodiments, the analyte comprises a plurality of analytes (e.g., two or more) obtained from a biological sample. In some cases, the analyte is a protein. In some embodiments, the analyte is a peptide, e.g., a peptide generated from a fragmented protein obtained from a sample. Also provided are nucleic acid-analyte conjugates generated according to any of the methods described herein.In some embodiments, the methods and conjugates described herein are for preparing analytes compatible with protein analysis using barcoding and nucleic acid encoding of molecular recognition events and / or detectable labels.

[0064] A. Analytes and Samples In one aspect, the present disclosure relates to the preparation and processing of analytes, such as macromolecules including proteins, polypeptides, and peptides. In some cases, the macromolecule is any large molecule composed of smaller subunits. In certain embodiments, the macromolecule is a protein, a protein complex, a polypeptide, a peptide, a nucleic acid molecule, a carbohydrate, a lipid, a macrocycle, or a chimeric macromolecule. In certain embodiments, the protein analyte is attached to a solid support via covalent coupling.

[0065] In some of any of the provided embodiments, the analytes (e.g., macromolecules, proteins, polypeptides, peptides) prepared or processed according to the kits and methods disclosed herein can be obtained from biological samples such as cells (both primary cells and cultured cell lines), cell lysates or extracts, organelles or vesicles (including exosomes, tissues and tissue extracts); biopsies; fecal material; bodily fluids of virtually any organism (blood, whole blood, serum, plasma, urine, lymph, bile, cerebrospinal fluid, interstitial fluid, aqueous or vitreous humor, colostrum, sputum, amniotic fluid, saliva, anal and vaginal secretions, sweat and semen, transudates, exudates (e.g., fluid obtained from an abscess or any other site of infection or inflammation), and the like. The analytes may be obtained from any suitable source or sample, including, but not limited to, fluids obtained from the body) or joints (normal joints or joints affected by diseases such as rheumatoid arthritis, osteoarthritis, gout or septic arthritis) (human-derived samples are particularly preferred, including microbiome-containing samples); environmental samples (such as air, agricultural, water, and soil samples); samples derived from microbial biofilms and / or communities, and microbial samples including microbial spores; and research samples including extracellular fluids, extracellular supernatants from cell cultures, inclusion bodies in bacteria, cellular and subcellular compartments including the mitochondrial compartment, and cellular periplasm. In some cases, the analytes are obtained from multiple samples, and the multiple samples are pooled.

[0066] In certain embodiments, the analyte is a protein, a protein complex, a polypeptide, or a peptide. For example, the evaluation of the analyte may include determining amino acid sequence information and post-translational modifications of the peptide, polypeptide, or protein by generating a nucleic acid-encoded library that can be analyzed via next-generation sequencing methods. The peptide, polypeptide, protein, or protein complex may include standard naturally occurring amino acids, modified amino acids (e.g., post-translational modifications), amino acid analogs, amino acid mimetics, or any combination thereof. In some embodiments, the peptide, polypeptide, or protein is naturally occurring, synthetically produced, or recombinantly expressed. In any of the foregoing embodiments, the peptide, polypeptide, protein, or protein complex may further include post-translational modifications.

[0067] Post-translational modifications (PTMs) of peptides, polypeptides, or proteins can be covalent or enzymatic modifications. Examples of post-translational modifications include acylation, acetylation, alkylation (including methylation), biotinylation, butyrylation, carbamylation, carbonylation, deamidation, deiminiation, diphthamide formation, disulfide bridge formation, eliminylation, flavin attachment, formylation, gamma carboxylation, glutamylation, glycylation, glycosylation (e.g., N-linked, O-linked, C-linked phosphoglycosylation), glypiation, heme C attachment, hydroxyl esterification, and cytosine cleavage. Post-translational modifications include, but are not limited to, hypusine formation, iodination, isoprenylation, lipidation, lipoylation, malonylation, methylation, myristolylation, oxidation, palmitoylation, pegylation, phosphopantetheination, phosphorylation, propionylation, retinylidene Schiff base formation, S-glutathionylation, S-nitrosylation, S-sulfenylation, selenation, succinylation, sulfination, ubiquitination, and C-terminal amidation. Post-translational modifications include modifications of the amino and / or carboxyl termini of peptides, polypeptides, or proteins. Modifications of terminal amino groups include, but are not limited to, desamino, N-lower alkyl, N-di-lower alkyl, and N-acyl modifications. Modifications of the terminal carboxy group include, but are not limited to, amide, lower alkyl amide, dialkyl amide, and lower alkyl ester modifications (e.g., lower alkyl is C1-C4 alkyl). Post-translational modifications also include modifications of amino acids between the amino and carboxy termini of a peptide, polypeptide, or protein (e.g., but are not limited to, those listed above). Post-translational modifications can regulate the "biology" of a protein within a cell, such as its activity, structure, stability, or localization. Phosphorylation is the most common post-translational modification and plays an important role in protein regulation, especially cell signaling (Prabakaran et al., (2012) Wiley Interdiscip Rev Syst Biol Med 4:565-583).The addition of sugars to proteins, such as glycosylation, has been shown to facilitate protein folding, improve stability, and alter regulatory function. Lipids can be attached to proteins to target them to cell membranes. Post-translational modifications can also include peptide, polypeptide, or protein modifications to include one or more detectable labels.

[0068] In certain embodiments, the analyte (e.g., peptide, polypeptide, or protein) can be fragmented. For example, the fragmented peptide can be obtained by fragmenting a protein from a sample, such as a biological sample. The peptide, polypeptide, or protein can be fragmented by any means known in the art, including fragmentation by a protease or endopeptidase. For example, the analyte (e.g., peptide, polypeptide, or protein) is treated with trypsin, LysN, or LysC.

[0069] In some embodiments, fragmentation of peptide, polypeptide, or protein analytes is targeted by the use of specific proteases or endopeptidases that bind and cleave specific consensus sequences (e.g., TEV protease specific for the ENLYFQ\S consensus sequence). In other embodiments, fragmentation of peptides, polypeptides, or proteins is untargeted or random by the use of non-specific proteases or endopeptidases. Non-specific proteases may bind and cleave specific amino acid residues rather than consensus sequences (e.g., proteinase K is a non-specific serine protease). Proteinases and endopeptidases are known in the art and may be used to cleave proteins or polypeptides into smaller peptide fragments. Examples include proteinase K, trypsin, chymotrypsin, pepsin, thermolysin, thrombin, factor Xa, furin, endopeptidase, papain, pepsin, subtilisin, elastase, enterokinase, Genenase™ I, endoproteinase LysC, endoproteinase AspN, endoproteinase GluC, and the like (Granvogl et al., 2007 Anal Bioanal Chem 389:991-1002). In certain embodiments, peptides, polypeptides or proteins are fragmented by proteinase K, or, optionally, a thermolabile version of proteinase K, allowing for rapid inactivation. Proteinase K is highly stable with denaturing reagents such as urea and SDS, allowing for digestion of fully denatured proteins. Fragmentation of proteins and polypeptides into peptides can be carried out before or after attachment to a bait nucleic acid or other nucleic acid moiety.

[0070] Chemical reagents can also be used to digest proteins into peptide fragments. Chemical reagents may cleave at specific amino acid residues (e.g., cyanogen bromide hydrolyzes peptide bonds C-terminal to methionine residues). Chemical reagents for fragmenting polypeptides or proteins into smaller peptides include cyanogen bromide (CNBr), hydroxylamine, hydrazine, formic acid, BNPS-skatole [2-(2-nitrophenylsulfenyl)-3-methylindole], iodosobenzoic acid, ·NTCB+Ni (2-nitro-5-thiocyanobenzoic acid), etc.

[0071] In some embodiments, the analyte attached to the bait nucleic acid comprises a fragmented protein or peptide. In certain embodiments, following enzymatic or chemical cleavage, the resulting peptide fragments are of approximately the same desired length, e.g., from about 10 amino acids to about 70 amino acids, from about 10 amino acids to about 60 amino acids, from about 10 amino acids to about 50 amino acids, from about 10 amino acids to about 40 amino acids, from about 10 amino acids to about 30 amino acids, from about 20 amino acids to about 70 amino acids, from about 20 amino acids to about 60 amino acids, from about 20 amino acids to about 50 amino acids, from about 20 amino acids to about 40 amino acids, from about 20 amino acids to about 30 amino acids, from about 30 amino acids to about 70 amino acids, from about 30 amino acids to about 60 amino acids, from about 30 amino acids to about 50 amino acids, or from about 30 amino acids to about 40 amino acids. The cleavage reaction can be monitored in real time, for example, by spiking a protein or polypeptide sample with a short test FRET (fluorescence resonance energy transfer) peptide that contains a peptide sequence that includes a proteinase or endopeptidase cleavage site. In an intact FRET peptide, a fluorescent group and a quencher group are attached to either end of the peptide sequence that contains the cleavage site, resulting in low fluorescence due to fluorescence resonance energy transfer between the quencher and the fluorophore. Upon cleavage of the test peptide by a protease or endopeptidase, the quencher and fluorophore are separated and fluorescence increases significantly. The cleavage reaction can be stopped when a specific fluorescence intensity is reached, allowing reproducible cleavage end points to be achieved.

[0072] In certain embodiments, a plurality of protein analytes are attached to a solid support. For example, a protein sample is obtained from a biological sample and fragmented. In some embodiments, a plurality of fragmented proteins are attached to a solid support (e.g., a plurality of solid supports) by performing any of the methods provided herein. In some embodiments, a plurality of fragmented peptides are attached to beads. In some cases, the fragmented proteins attached to the solid support (e.g., beads) are random portions of the entire fragmented protein. In some cases, the identity of the analyte attached to the solid support is unknown. In some embodiments, the analyte attached to the solid support is not targeted. In some embodiments, the identity of the analyte attached to the solid support is unknown, and the methods provided herein generate nucleic acid-analyte conjugates for use in analytical methods that can be used to characterize, evaluate, identify, analyze, and / or sequence the analyte.

[0073] In some embodiments, the analyte is obtained from a sample and the analyte can undergo a protein fractionation method prior to attachment to the bait nucleic acid. In some embodiments, the analyte is obtained from a sample and the analyte can undergo a protein fractionation method after attachment to the bait nucleic acid. In some embodiments, the analyte is obtained from a sample and the analyte can undergo a protein fractionation method prior to attachment to the solid support. In some embodiments, the analyte is obtained from a sample and the analyte can undergo a protein fractionation method after attachment to the solid support.

[0074] In some embodiments, analytes (e.g., proteins or peptides) are separated using one or more characteristics, such as cellular location, molecular weight, hydrophobicity, or isoelectric point, or protein enrichment methods. Alternatively, or in addition, protein enrichment methods can be used to select specific proteins or peptides (see, e.g., Whiteaker et al., (2007) Anal. Biochem. 362:44-54, incorporated by reference in its entirety), or to select specific post-translational modifications (see, e.g., Huang et al., 2014. J. Chromatogr. A 1372:1-17, incorporated by reference in its entirety). Alternatively, one or more specific classes of proteins, such as immunoglobulins, or immunoglobulin (Ig) isotypes, such as IgG, can be affinity enriched or selected for analysis. In the case of immunoglobulin molecules, analysis of the sequence and abundance or frequency of hypervariable sequences involved in affinity binding is of particular interest, especially as they change in response to disease progression or correlate with health, immune, and / or disease phenotypes. Standard immunoaffinity methods can also be used to subtract overabundant proteins from samples. Removal of abundant proteins can be useful for plasma samples where more than 80% of the protein content is albumin and immunoglobulins. Several commercial products are available for depletion of plasma samples of overabundant proteins, such as PROTIA and PROT20 (Sigma-Aldrich).

[0075] In certain embodiments, the analyte comprises a protein or polypeptide. In one embodiment, a protein or polypeptide analyte is attached to a nucleic acid polymer (e.g., a bait nucleic acid). In some embodiments, the analyte is directly attached to the bait nucleic acid. In some embodiments, the analyte is indirectly attached to the bait nucleic acid (e.g., via a linker). A variety of linkers are known in the art and can optionally be used to attach the analyte to the bait nucleic acid. In some embodiments, the protein or polypeptide is labeled with a reactive coupling moiety, such as an amine-reactive coupling agent, for attachment to the bait nucleic acid. For example, a lysine residue of the protein or polypeptide is labeled with a reactive coupling moiety.

[0076] In some embodiments, the analyte and / or the bait nucleic acid comprises a reactive coupling moiety. The bait nucleic acid can be attached to the analyte in any suitable position and configuration, so long as it is compatible with the method used to transfer the coding tag information to the nucleic acid in a protein sequencing or analytical assay. In some embodiments, the analyte is attached to the bait nucleic acid (directly or using a suitable linker) at various positions of the bait nucleic acid, such as the 3' or 5' end of the bait nucleic acid. In some embodiments, the analyte is attached to the bait nucleic acid (directly or using a suitable linker) at an internal position of the bait nucleic acid.

[0077] In some embodiments, the bait nucleic acid includes a modified base (e.g., i5-octadiynyl dU). For example, the modified base includes an alkyne or the modified base is configured to insert a reactive coupling moiety (e.g., an alkyne) into the bait nucleic acid. In some examples, the reactive coupling moiety is for attaching the bait nucleic acid to the analyte. In some embodiments, the analyte is attached to the bait nucleic acid using chemical ligation. The bait nucleic acid can be attached to the analyte using one or more linkers.

[0078] In certain embodiments, the bait nucleic acid comprises a reactive coupling moiety (e.g., for conjugation to an analyte), a linker, a universal priming sequence, a barcode (e.g., a compartment tag, a partition barcode, a sample barcode, a fraction barcode, or any combination thereof), an optional UMI, and a spacer (Sp) sequence. In some embodiments, the bait nucleic acid comprises a spacer sequence to facilitate information transfer from another nucleic acid polymer.

[0079] B. Coupling of analytes to a solid support via hybridization of bait and capture nucleic acids In some embodiments, the methods and conjugates provided herein include processing the analyte, including attaching the analyte to a bait nucleic acid to generate a nucleic acid-analyte chimera, and bringing the nucleic acid-analyte chimera into proximity with a solid support by hybridizing a bait nucleic acid in the nucleic acid-analyte chimera to a capture nucleic acid attached to the solid support. In some embodiments, one or more of the capture nucleic acid, nucleic acid-analyte chimera, and / or bait nucleic acid further comprises a barcode or other nucleic acid moiety. In some cases, the methods provided include attaching a barcode to the coupled nucleic acid-analyte chimera on the solid support prior to coupling to the solid support.

[0080] In some embodiments, the nucleic acid components and nucleic acid tags (e.g., bait or capture nucleic acids, barcodes, UMIs) may comprise strands of DNA or RNA, or chimeric DNA-RNA strands, or nucleic acid-like compounds such as peptide nucleic acids. In some embodiments, the nucleic acid strands may also comprise modified DNA or RNA bases, such as those known in the art.

[0081] In some embodiments, the bait nucleic acid comprises a single-stranded region for hybridizing to the capture nucleic acid. In some embodiments, the bait nucleic acid comprises at least one nucleic acid region that is substantially complementary to the capture nucleic acid. In some examples, the bait nucleic acid comprises a sequence of nucleotides that selectively bind to the capture nucleic acid sequence. In some embodiments, the capture nucleic acid comprises a single-stranded region that is substantially complementary to the bait nucleic acid. "Substantially complementary" refers to a sequence that can hybridize to a target nucleic acid sequence under the conditions used. In preferred embodiments, a "substantially complementary" single-stranded region is exactly complementary to the target nucleic acid sequence. For example, the single-stranded region of the capture nucleic acid that is complementary to the bait nucleic acid can have at least 5 bases, at least 6 bases, at least 7 bases, at least 8 bases, at least 9 bases, at least 10 bases, at least 12 bases, at least 14 bases, at least 16 bases, at least 20 bases, at least 24 bases, at least 30 bases, or at least 34 bases. In some embodiments, the single-stranded region of the capture nucleic acid that is complementary to the bait nucleic acid has fewer than 40 bases, fewer than 30 bases, or fewer than 25 bases.

[0082] In some cases, hybridization of the bait nucleic acid to the capture nucleic acid comprises hybridization of 8 or more complementary bases, 16 or more complementary bases, 18 or more complementary bases, 24 or more complementary bases, 34 or more complementary bases. In one embodiment, hybridization of the bait nucleic acid to the capture nucleic acid comprises hybridization of 16 or more complementary bases. In some embodiments, hybridization of the bait nucleic acid to the capture nucleic acid comprises hybridization of 18 or more complementary bases. In some embodiments, hybridization of the bait nucleic acid to the capture nucleic acid comprises hybridization of 20 or more complementary bases. In some embodiments, hybridization of the bait nucleic acid to the capture nucleic acid comprises hybridization of 24 or more complementary bases. One of skill in the art can select a complementary region having a sufficient number of bases to form a stable hybridization region between the bait nucleic acid and the capture nucleic acid. In some embodiments, the region of the capture nucleic acid for hybridizing to the bait nucleic acid is located at the 3' or 5' end of the capture nucleic acid.

[0083] In some embodiments, the capture nucleic acid comprises a splint nucleic acid strand, where the splint bridges the capture nucleic acid and the bait via hybridization, allowing for efficient ligation or chemical coupling. In some embodiments, the splint nucleic acid is separate from the capture nucleic acid. In some embodiments, the bait nucleic acid comprises a splint nucleic acid strand, where the splint bridges the capture nucleic acid and the bait via hybridization, allowing for efficient ligation or chemical coupling. In some embodiments, the splint nucleic acid is separate from the bait nucleic acid.

[0084] In some provided embodiments, the bait nucleic acid is coupled to the capture nucleic acid. In some instances, the coupling of the bait nucleic acid to the capture nucleic acid is by covalent coupling. In some instances, the 5' end of the bait nucleic acid is coupled to the 3' end of the capture nucleic acid. In some instances, the 3' end of the bait nucleic acid is coupled to the 5' end of the capture nucleic acid. For example, an analyte-bait nucleic acid conjugate hybridizes to the nucleic acid-analyte chimera and is attached to the 5' end of the capture nucleic acid (FIGS. 1C-1D).

[0085] In some cases, the capture nucleic acid is directly or indirectly immobilized on the solid support. In some embodiments, the capture nucleic acid is attached to the solid support before hybridizing the bait nucleic acid to the capture nucleic acid. Hybridization of the bait and capture nucleic acid increases the efficiency of immobilization, for example, compared to chemical coupling. In some embodiments, the capture nucleic acid comprises a reactive coupling moiety. In some embodiments, the solid support comprises a reactive coupling moiety. In some embodiments, the reactive coupling moiety is attached to the solid support before or at the same time as attaching the solid support to the capture nucleic acid.

[0086] In some embodiments, the capture and / or bait nucleic acids include reactive coupling moieties. For example, the reactive coupling moieties are for covalently coupling the bait and capture nucleic acids. In some embodiments, the bait nucleic acid is coupled to the capture nucleic acid using a chemical bond. Standard chemical ligation or "click chemistry" can be used to couple the bait and capture nucleic acids (Gunderson et al., Genome Res (1998) 8(11):1142-1153; Peng et al., European J Org Chem (2010) (22):4194-4197; El-Sagheere et al., Proc Natl Acad Sci USA (2011) 108(28):11338-11343; El-Sagheer et al., Org Biomol Chem (2011) 9(1):232-235; Sharma et al., Anal Chem (2012) 84(14):6104-6109; Roloff et al., Bioorg Med Chem (2013) 21(12):3458-3464; Litovchick et al., Artif DNA PNA XNA (2014) 5(1):e27896, Roloff et al., Methods Mol Biol (2014) 1050:131-141). In some embodiments, the bait nucleic acid is coupled to the capture nucleic acid using light or light-activated coupling (e.g., photocrosslinking). One of skill in the art can determine how to couple various binding moieties to the bait nucleic acid. For example, the bait nucleic acid or nucleic acid-analyte chimera includes a photoactive moiety. In some embodiments, cell lines can be engineered to produce specific moieties for attachment. In some embodiments, a photoactive benzophenone moiety is added to the bait nucleic acid. In some specific cases, the photoactive benzophenone moiety is attached to the bait nucleic acid using an alkyne-benzophenone and an azide-oligo. In some examples, the capture nucleic acid attached to the solid support includes a reactive psoralen moiety.In some embodiments, the analyte is immobilized on a surface derivatized with a complementary capture nucleic acid by hybridization of the bait nucleic acid to the complementary capture nucleic acid. The capture nucleic acid may contain a reactive psoralen moiety, and exposure to UV light covalently couples the bait and capture nucleic acids (Figures 2A-2C).

[0087] In one embodiment, the bait and capture nucleic acids do not comprise a nucleic acid hairpin. In some embodiments, the hybridized bait and capture nucleic acids form a double-stranded nucleic acid structure. In one embodiment, the bait nucleic acid hybridizes to the capture nucleic acid and the nucleic acid-analyte chimera is directly or indirectly attached to a solid support.

[0088] In some cases, the bait nucleic acid is attached to the capture nucleic acid using ligation. Enzymatic ligation of DNA requires the 5' phosphate of the capture nucleic acid to ligate to the 3' hydroxyl of the bait nucleic acid. In some other cases, the 5' phosphate of the bait nucleic acid is required to ligate to the 3' hydroxyl of the capture nucleic acid. In some of any of the provided embodiments, the attachment can be to an additional nucleic acid sequence (e.g., barcode, UMI, spacer) attached to the bait or capture nucleic acid.

[0089] In one embodiment, the bait or capture nucleic acid comprises a splint nucleic acid strand, and the splint bridges the bait and capture nucleic acids via hybridization, allowing for efficient ligation or chemical coupling. In some embodiments, the capture nucleic acid comprises a splint nucleic acid strand. In some embodiments, the splint nucleic acid strand is used temporarily. In some embodiments, the splint nucleic acid strand is removed after the bait nucleic acid-analyte chimera is attached or coupled to a solid support, bead, via the capture nucleic acid. In another embodiment, the bait or capture nucleic acid comprises a nucleic acid hairpin (see, e.g., Riccelli et al., Nucleic Acids Res. (2001) 29(4):996-1004). A nucleic acid hairpin is a unimolecular nucleic acid-containing structure that comprises at least two mutually complementary nucleic acid regions such that at least one intramolecular duplex can be formed (see, e.g., U.S. Patent Publication No. 5,770,365). In certain embodiments, the mutually complementary nucleic acid regions are connected via a nucleic acid strand. In some examples, the hairpin comprises a single strand of nucleic acid.

[0090] In some specific examples, the hairpin of the capture nucleic acid forms at least one intramolecular duplex with a length of at least 2 base pairs, at least 4 base pairs, at least 8 base pairs, at least 16 base pairs, at least 24 base pairs, at least 32 base pairs, and at least 40 base pairs. Those skilled in the art will be able to adjust the size, number, and composition of base pairs in the duplex region to achieve any desired relative stability of duplex formation. In some embodiments, the intramolecular duplex comprises a length of less than about 40 base pairs, less than 30 base pairs, or less than 20 base pairs. In some examples, the hairpin of the capture nucleic acid forms at least one intramolecular duplex with a length of 16 base pairs.

[0091] In some embodiments, the capture nucleic acid comprises a region connecting the regions of mutual complementarity, referred to herein as a "loop" or "linker." In preferred embodiments, the loop comprises a strand of nucleic acid or a modified nucleic acid. In some examples, the nucleic acid loop comprises 2-20 nucleotides, e.g., 3-8 nucleotides. In other embodiments, the loop comprises a linker region that is not nucleic acid based. A variety of non-nucleic acid linkers suitable for use in the loop region, including, for example, alkyl chains, are known in the art (see, e.g., Doktycz et al. (1993) Biopolymers 33:1765). In some embodiments, the size, composition, and configuration of the loop or linker are selected to allow the regions of mutual complementarity to form an intramolecular duplex. In some cases, the hairpin can form multiple loops.

[0092] In some embodiments, at least one of the bait nucleic acids further comprises a barcode. In some embodiments, at least one of the bait nucleic acids further comprises a unique molecular identifier (UMI). In some embodiments, at least one of the capture nucleic acids further comprises a barcode. In some embodiments, at least one of the capture nucleic acids further comprises a unique molecular identifier (UMI). In some embodiments, the barcode comprises a UMI. In some embodiments, the barcode comprises a sample barcode, a fraction barcode, a spatial barcode, a compartment tag, or any combination thereof. In some examples, the barcode and / or UMI comprises a DNA molecule, a DNA with pseudo-complementary bases, an RNA molecule, a BNA molecule, an XNA molecule, an LNA molecule, a PNA molecule, a γPNA molecule, a non-nucleic acid sequenceable polymer, such as a polysaccharide, a polypeptide, a peptide, or a polyamide, or a combination thereof.

[0093] The UMI can be a unique identifier tag for each analyte (e.g., macromolecule, protein, polypeptide, peptide). The UMI can be about 3 to about 40 bases, about 3 to about 30 bases, about 3 to about 20 bases, or about 3 to about 10 bases, or about 3 to about 8 bases. In some embodiments, the UMI is about 3 bases, 4 bases, 5 bases, 6 bases, 7 bases, 8 bases, 9 bases, 10 bases, 11 bases, 12 bases, 13 bases, 14 bases, 15 bases, 16 bases, 17 bases, 18 bases, 19 bases, 20 bases, 25 bases, 30 bases, 35 bases, or 40 bases in length. The UMI can be used to deconvolute sequencing data from the method used to sequence the analyte and identify sequence reads from individual analytes. In some embodiments, within a library of analytes, each analyte is associated with a single unique UMI. In other embodiments, the analyte may be fragmented and multiple portions of the analyte may be associated with the same UMI, in some embodiments, the UMI has a base sequence that is distinct from the spacer or other barcode sequences to facilitate distinguishing these components during sequence analysis.

[0094] In some embodiments, one or more barcodes are attached to the bait nucleic acid, capture nucleic acid, and / or nucleic acid-analyte conjugate. In some other embodiments, one or more barcodes are attached or placed on a nucleic acid-analyte conjugate coupled to a solid support. In some embodiments, the nucleic acid-analyte chimera can be labeled with a nucleic acid tag, such as a barcode, for example, prior to coupling to the solid support. In some examples, the nucleic acid-analyte chimera can first be labeled with a universal DNA tag. In some cases, the barcode can include information representing the sample, compartment, physical location, spatial barcode, etc. See, e.g., International Patent Publication No. WO2014 / 201273. In some cases, the barcode or other nucleic acid tag is attached to the protein through an enzymatic or chemical coupling step.

[0095] In some embodiments, the capture nucleic acid comprises a hairpin that may include one or more barcode sequences for various types of identification information. For example, the capture nucleic acid may include a barcode that includes information about the support (e.g., bead) to which the polypeptide is immobilized. In some embodiments, the bait nucleic acid may include one or more barcode sequences for various types of identification information. For example, the bait nucleic acid may include a sample barcode and / or a barcode useful for identifying a control peptide. The capture nucleic acid and / or the bait nucleic acid may include an optional UMI sequence in addition to one or more barcode sequences.

[0096] In some embodiments, the methods provided herein for preparing an analyte further include attaching one or more barcodes to a bait nucleic acid. In some embodiments, the methods provided herein for preparing an analyte further include attaching one or more barcodes to a capture nucleic acid. Attaching the one or more barcodes includes enzymatic or chemical methods. In some embodiments, the barcodes are attached using nucleic acid extension (e.g., PCR extension). In some embodiments, the barcodes are attached to the bait or capture nucleic acid using a ligation reaction. In some examples, two or more barcodes are attached to the bait nucleic acid. In some examples, two or more barcodes are attached to the capture nucleic acid.

[0097] In some embodiments, the barcode is attached to the 5' end of the bait nucleic acid. In some embodiments, the barcode is attached to the 3' end of the bait nucleic acid. In some embodiments, the barcode is attached to the 5' end of the capture nucleic acid. In some embodiments, the barcode is attached to the 3' end of the capture nucleic acid. In some embodiments, the barcode is attached to the 5' end of the nucleic acid-analyte chimera. In some embodiments, the barcode is attached to the 3' end of the nucleic acid-analyte chimera. In some embodiments, the barcode is attached to the 5' end of a nucleic acid-analyte conjugate coupled to a solid support. In some embodiments, the barcode is attached to the 3' end of a nucleic acid-analyte conjugate coupled to a solid support. In some particular embodiments, the 5' end of the barcode is phosphorylated.

[0098] In some embodiments, the methods provided herein are used to prepare a solid support coupled with a bait nucleic acid to which an analyte is attached such that the analyte is barcoded. In some embodiments, the solid support is coupled with multiple nucleic acids associated with each analyte, and the barcodes used include different barcode sequences.

[0099] The barcode can be added using a barcode template (BC') that includes a nucleic acid sequence complementary to the bait nucleic acid. In some embodiments, the barcode template is or includes DNA. In some embodiments, the barcode template is or includes RNA. In some embodiments, the barcode template used to attach the barcode to the bait or capture nucleic acid is configured to hybridize to the bait or capture nucleic acid. In some embodiments, the method for attaching the barcode can further include a digestion reaction. In some embodiments, the digestion reaction is performed after the barcode is transferred from the barcode template. In some embodiments, the barcode is attached to the bait nucleic acid before attaching the analyte to the bait nucleic acid. In some embodiments, the barcode is attached to the bait nucleic acid after attaching the analyte to the bait nucleic acid. In some examples, the attachment of the barcode can be performed using extension, primer extension, or ligation. In some embodiments, the nucleic acid-analyte chimera with the newly installed barcode is washed, treated with digestive enzymes, and / or treated with heat.

[0100] 3-9 are schematic diagrams illustrating exemplary methods for attaching a barcode to a bait nucleic acid, a capture nucleic acid, a nucleic acid-analyte chimera, or a nucleic acid-analyte conjugate coupled to a solid support.

[0101] In some specific embodiments, the analyte is attached to a bait nucleic acid. A barcode template (BC') is hybridized to the nucleic acid-analyte chimera. An extension reaction is used to extend the 3' end of the bait nucleic acid to include the barcode sequence. The nucleic acid-analyte chimera with the newly extended barcode is brought into proximity with a solid support by hybridizing the bait nucleic acid (containing the analyte and barcode) to a capture nucleic acid attached to the solid support. The nucleic acid-analyte chimera is covalently coupled to the solid support by attaching (e.g., via ligation) the capture and bait nucleic acids (Figure 3).

[0102] In some specific embodiments, the analyte is attached to a bait nucleic acid. The nucleic acid-analyte chimera is brought into proximity with the solid support by hybridizing the bait nucleic acid (containing the analyte) to a capture nucleic acid attached to the solid support. The nucleic acid-analyte chimera is covalently coupled to the solid support by attaching (e.g., via ligation) the capture nucleic acid and the bait nucleic acid. A barcode template (BC') is used to extend the 3' end of the bait nucleic acid to include a barcode sequence. A digestion reaction is used to release the barcode template from the nucleic acid-analyte conjugate coupled to the solid support (Figure 4).

[0103] In some embodiments, attaching the barcode may include primer extension. In some examples, primer extension is performed by incubating at 25° C.-37° C. with a reaction solution including Klenow fragment (exo-) and the template barcode such that the barcode is placed on the bait nucleic acid. In some examples, the barcode template includes a dU-containing nucleic acid. In some embodiments, a wash step is performed after the barcode is placed. In some embodiments, the capture nucleic acid includes a sequence of a nucleic acid that is complementary to the barcode template. In some cases, the bait or capture nucleic acid is configured to allow hybridization to the barcode template. In some examples, an extension reaction is performed by incubating the nucleic acid-analyte conjugate coupled to the solid support with a reaction solution including Klenow fragment (exo-) for 5 minutes to extend the bait nucleic acid and place the barcode. In some embodiments, the nucleic acid-analyte conjugate with the barcode placed by extension is washed and treated with USER enzyme (New England Biolabs) to remove any digested strands for the assay.

[0104] In some specific embodiments, the analyte is attached to a bait nucleic acid. A ligation reaction is used to attach the bait nucleic acid to the barcode. The nucleic acid-analyte chimera with the barcode attached is brought into proximity with the solid support by hybridizing the bait nucleic acid (comprising the analyte and barcode) to a capture nucleic acid attached to the solid support. The nucleic acid-analyte chimera is covalently coupled to the solid support by attaching the capture nucleic acid and the bait nucleic acid (e.g., via ligation). In one embodiment, the bait nucleic acid includes a splint nucleic acid strand, and the splint bridges the bait nucleic acid and the barcode via hybridization, allowing for efficient ligation or chemical coupling. (FIG. 5).

[0105] 6 and 7 show coupling of a nucleic acid-analyte chimera to a solid support by attachment of a barcode to the 3' end of the capture nucleic acid and attachment of a bait nucleic acid to the 5' capture nucleic acid. In some particular embodiments, the analyte is attached to the bait nucleic acid. The nucleic acid-analyte chimera is brought into proximity with the solid support by hybridizing the bait nucleic acid to the capture nucleic acid attached to the solid support. The nucleic acid-analyte chimera is covalently coupled to the solid support by attaching (e.g., via ligation) the 5' end of the capture nucleic acid and the 3' bait nucleic acid. A barcode is attached (e.g., via ligation) to the 3' end of the capture nucleic acid (FIG. 6). In some embodiments, the bait nucleic acid of the nucleic acid-analyte chimera is attached to the 5' end of the capture nucleic acid that is attached to the solid support, and the capture nucleic acid includes a barcode sequence (FIG. 7).

[0106] In some embodiments, attaching the barcode may include using a nucleic acid barcode template that includes a dU. In some embodiments, attaching the barcode may further include treating the bait nucleic acid, capture nucleic acid, or nucleic acid-analyte chimera with a USER enzyme. In some embodiments, the methods provided for attaching or placing a barcode include treating the barcoded nucleic acid with a USER enzyme. For example, the chimera is hybridized to a nucleic acid barcode template that includes multiple dUs, UMIs, barcodes, and / or spacer sequences. Primer extension is performed at 25°C to 37°C in a reaction that includes Klenow fragment (exo-) to place the UMIs, barcodes, and / or spacers from the template to the bait nucleic acid (attached to the analyte). The resulting dsDNA is treated with USER enzyme (New England Biolabs) to digest the dU sites and heated to remove the digested fragments (Figure 8).

[0107] In some embodiments, attaching the barcode may include using an RNA barcode template. For example, a reverse transcription reaction may be used to place the barcode on the bait nucleic acid. In some embodiments, the barcode template may include using an RNA template that includes a UMI, barcode, and / or spacer sequence. For example, reverse transcription is performed in a reaction that includes reverse transcriptase (RNase H-) to place the UMI, barcode, and / or spacer sequence on the bait nucleic acid. In some cases, the reaction with reverse transcriptase may be treated with heat to inactivate the reverse transcriptase. In some cases, the resulting RNA / DNA hybrid is treated with RNase A and T1 cocktail (Thermo Fisher) and RNase H to digest the RNA barcode template (FIG. 9). In some embodiments, the nucleic acid-analyte chimera with the newly placed barcode is then brought into proximity with a solid support by hybridizing the bait nucleic acid (along with the analyte and barcode) to a capture nucleic acid that is attached to the solid support. The nucleic acid-analyte chimera is covalently coupled to the solid support by attaching (eg, via ligation) a capture nucleic acid and a bait nucleic acid.

[0108] The bait nucleic acid and / or capture nucleic acid may further comprise other functional components, such as a universal priming site, a spacer sequence complementary to a spacer sequence attached to another nucleic acid moiety, or any combination thereof. In some embodiments, the capture nucleic acid comprises an adapter sequence for use in a downstream sequencing step (e.g., a flow cell adapter sequence that anneals to a complementary oligonucleotide on a flow cell surface for a next generation sequencing platform). In certain embodiments, the universal DNA sequence is a universal priming sequence. When the universal sequence on the label protein hybridizes to the complementary sequence of the bait or capture nucleic acid (e.g., bound to a bead), the annealed universal sequence can be extended via primer extension. In some embodiments, the universal priming site comprises a priming site for amplification, sequencing, or both. In some embodiments, the universal reverse priming site is an Illumina P7 primer (5'-CAAGCAGAAGACGGCATACGAGAT-3'-SEQ ID NO:2) or an Illumina P5 primer (5'-AATGATACGGCGACCACCGA-3'-SEQ ID NO:1). In some embodiments, the universal priming site used comprises the sequences 5'-ACACTCTTTCCCTACACGACGCTCTTCCGATCT-3' (SEQ ID NO:32) and 5'-GACTGGAGTTCAGACGTGTGCTCTTCCGATCT-3' (SEQ ID NO:33).

[0109] In some embodiments, the downstream sequencing step may use an adapter on one or both ends of the recording tag nucleic acid. Sequencing can be accomplished by any of the commercially available sequencing instruments or by any known method. In some examples, the capture nucleic acid includes an index sequence, an adapter sequence, a nucleic acid domain that specifically binds to a sequencing platform oligonucleotide attached to a surface, or any combination thereof. In one example, the adapter is included in the capture nucleic acid and is designed to be used with an Illumina sequencing machine. Sequence platforms of interest include, but are not limited to, Illumina®'s HiSeq™, MiSeq™, and Genome Analyzer™ sequencing systems; Ion Torrent™'s Ion PGM™ and Ion Proton™ sequencing systems; Pacific Biosciences' PACBIO RS II sequencing system, Life Technologies™'s SOLid sequencing system, Roche's 454 GS FLX+ and GS Junior sequencing systems, or any other sequencing platform.

[0110] In some embodiments, the bait nucleic acid comprises a spacer polymer at its 5' and / or 3' end. In some embodiments, the capture nucleic acid comprises a spacer polymer at its 5' and / or 3' end. The spacer sequence is, in some instances, at the 3' end of the bait nucleic acid. The spacer sequence is, in some instances, at the 5' end of the bait nucleic acid. In some embodiments, the spacer sequence is configured to enable transfer of nucleic acid information using polymerase extension to the bait or capture nucleic acid. In some embodiments, the spacer sequence is configured to enable transfer of nucleic acid information using polymerase extension to a nucleic acid-analyte conjugate coupled to a solid support.

[0111] In some embodiments, the spacer polymer comprises at least 1 nucleotide, at least 2 nucleotides, at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 15 nucleotides, or at least 20 nucleotides or more. The spacer polymer can comprise any suitable nucleic acid, such as a DNA molecule, a DNA with pseudo-complementary bases, an RNA molecule, a BNA molecule, an XNA molecule, an LNA molecule, a PNA molecule, a gamma PNA molecule; a non-nucleic acid sequenceable polymer, such as a polysaccharide, a polypeptide, a peptide, or a polyamide, or a combination thereof.

[0112] In some particular embodiments, the bait nucleic acid further comprises at its 5' or 3' end a universal primer site for PCR reaction, a UMI, a sample barcode, and a spacer (universal sequence). In some particular embodiments, the capture nucleic acid further comprises at its 5' or 3' end a spacer (universal sequence), a sample barcode, a UMI, and a universal primer site for PCR reaction. In some aspects, the order of the nucleic acid components can be combined in various ways. In some preferred embodiments, the spacer sequence is preferably at the 3' end of the nucleic acid to which the identification information from the binder is transferred in embodiments in which polymerase extension is used to transfer coding tag information to a nucleic acid associated with an analyte.

[0113] The solid support can be any support surface, including, but not limited to, beads, microbeads, arrays, glass surfaces, silicon surfaces, plastic surfaces, filters, membranes, PTFE membranes, nylon, silicon wafer chips, flow cells, flow-through chips, biochips including signal transduction electronics, microtiter wells, ELISA plates, rotating interferometer disks, nitrocellulose membranes, nitrocellulose-based polymer surfaces, nanoparticles, or microspheres. Materials of the solid support include, but are not limited to, acrylamide, agarose, cellulose, dextran, nitrocellulose, glass, gold, quartz, polystyrene, polyethylene vinyl acetate, polypropylene, polyester, polymethacrylate, polyacrylate, polyethylene, polyethylene oxide, polysilicate, polycarbonate, polyvinyl alcohol (PVA), Teflon, fluorocarbon, nylon, silicone rubber, silica, polyanhydrides, polyglycolic acid, polyvinyl chloride, polylactic acid, polyorthoesters, functionalized silanes, polypropyl fumerate, collagen, glycosaminoglycans, polyamino acids, or any combination thereof. In certain embodiments, the solid support is a bead, such as a polystyrene bead, a polymer bead, a polyacrylate bead, an agarose bead, a cellulose bead, a dextran bead, an acrylamide bead, a solid core bead, a porous bead, a paramagnetic bead, a glass bead, a silica-based bead, or a controlled porosity bead, or any combination thereof.

[0114] In some embodiments, the capture nucleic acid is derivatized or includes a moiety (e.g., a reactive coupling moiety) that allows for binding to a solid support. In some embodiments, the capture nucleic acid includes a moiety (e.g., a reactive coupling moiety) that allows for binding to a bait nucleic acid. In some other embodiments, the bait nucleic acid is derivatized or includes a moiety (e.g., a reactive coupling moiety) that allows for binding to a solid support. Methods of derivatizing nucleic acids for binding to a solid support and reagents to achieve the same are known in the art. To this end, any reaction that is preferably rapid and substantially irreversible can be used to attach the nucleic acid to the solid support. The capture nucleic acid can be bound to the solid support via covalent or non-covalent bonds. In a preferred embodiment, the capture nucleic acid is covalently bound to biotin to form a biotinylated conjugate. The biotinylated conjugate is then bound to the solid surface, for example, by binding to a solid insoluble support derivatized with avidin or streptavidin. The capture nucleic acid can be derivatized for binding to a solid support by incorporating a modified nucleic acid in the loop region. In other embodiments, the capture moiety is derivatized in a region other than the loop region.

[0115] Exemplary reactions include copper-catalyzed reactions of azides and alkynes to form triazoles (Huisgen 1,3-dipolar cycloaddition), strain-promoted azide-alkyne cycloaddition (SPAAC), reactions of dienes and dienophiles (Diels-Alder), strain-promoted alkyne-nitrone cycloaddition, reactions of strained alkenes with azides, tetrazines, or tetrazoles, alkene and azide [3+2] cycloadditions, alkene and tetrazine inverse electron demand Diels-Alder (IEDDA) reactions (e.g., m-tetrazine (mTet) or phenyltetrazine (pTet) and trans-cyclooctene (TCO), or pTet and alkenes), alkene and tetrazole photochemical reactions, Staudinger ligation of azides and phosphines, and various substitution reactions such as replacement of leaving groups by nucleophilic attack on an electrophilic atom (Horisawa 2014, Knall, Hollauf et al. 2014). Exemplary substitution reactions include reactions of amines with activated esters, N-hydroxysuccinimide esters, isocyanates, isothiocyanates, aldehydes, epoxides, and the like.

[0116] In some embodiments, iEDDA click chemistry is used to immobilize polypeptides to solid supports because it is rapid and achieves high yields at low input concentrations. In another embodiment, m-tetrazine is used in iEDDA click chemistry rather than tetrazine because m-tetrazine has improved binding stability. In another embodiment, phenyltetrazine (pTet) is used in iEDDA click chemistry.

[0117] In some embodiments, multiple capture nucleic acids are coupled to a solid support. In some cases, the sequence region on the capture nucleic acid that is complementary to the bait nucleic acid is the same among the multiple capture nucleic acids. In some cases, the bait nucleic acid attached to the various analytes contains the same complementary sequence as the capture nucleic acid.

[0118] In some embodiments, the surface of the solid support is passivated (blocked). A "passivated" surface refers to a surface that has been treated with an outer layer of material. Methods for passivating surfaces include standard methods from the literature for fluorescent single molecule analysis, such as polymer-like polyethylene glycol (PEG) (Pan et al., 2015, Phys. Biol. 12:045006), polysiloxanes (e.g., Pluronic F-127), star-shaped polymers (e.g., star-shaped PEG) (Groll et al., 2010, Methods Enzymol. 472:1-18), hydrophobic dichlorodimethylsilane (DDS) + self-assembled Tween®-20 (Hua et al., 2014, Nat. Methods 11:1233-1236), diamond-like carbon (DLC), DLC + PEG (Stavis et al., 2011, Proc. Natl. Acad. Sci. USA 108:983-988), and passivating the surface with zwitterionic moieties (e.g., U.S. Patent Application Publication No. US2006 / 0183863). In addition to covalent surface modification, many passivation agents can also be used, including surfactants such as Tween®-20, polysiloxanes (Pluronic series) in solution, polyvinyl alcohol (PVA), and proteins such as BSA and casein. Alternatively, the density of the analyte (e.g., protein, polypeptide, or peptide) can be titrated on the surface or within the volume of the solid substrate by spiking a competitor or "dummy" reactive molecule when the protein, polypeptide, or peptide is immobilized on the solid substrate. In some embodiments, PEG of various molecular weights can also be used for passivation from about 300 Da to molecular weights of 50 kDa or more.

[0119] In certain embodiments where multiple nucleic acid-analyte chimeras are immobilized on the same solid support, the nucleic acid-analyte chimeras can be appropriately spaced to accommodate the analytical method used to evaluate the analyte. For example, it may be advantageous to optimally space the nucleic acid-analyte chimeras to allow for the execution of a nucleic acid-based method for evaluating and sequencing the analyte. In some embodiments, the method for evaluating and sequencing the analyte includes a binding agent that binds to the analyte, and the binding agent includes a coding tag that carries information that is transferred to a nucleic acid (e.g., a bait or capture nucleic acid) attached to the analyte. In some cases, the information transfer from the coding tag of the binding agent bound to one analyte may reach an adjacent analyte.

[0120] To control analyte (e.g., protein, polypeptide, or peptide spacing) or nucleic acid-analyte chimera spacing on a solid support, the density of functional coupling groups (e.g., TCO) can be titrated on the substrate surface. In some embodiments, adjacently coupled analytes or nucleic acid-analyte chimeras are spaced from one another on the surface or within the volume of a solid support (e.g., a porous support) by an average distance of about 50 nm to about 500 nm, or about 50 nm to about 400 nm, or about 50 nm to about 300 nm, or about 50 nm to about 200 nm, or about 50 nm to about 100 nm. In some embodiments, adjacently coupled analytes or nucleic acid-analyte chimeras are spaced apart from one another on the surface of the solid support by an average distance of at least 50 nm, at least 60 nm, at least 70 nm, at least 80 nm, at least 90 nm, at least 100 nm, at least 150 nm, at least 200 nm, at least 250 nm, at least 300 nm, at least 350 nm, at least 400 nm, at least 450 nm, or at least 500 nm. In some embodiments, adjacently coupled analytes or nucleic acid-analyte chimeras are spaced apart from one another on the surface of the solid support by an average distance of at least 50 nm. In some embodiments, adjacently coupled analytes or nucleic acid-analyte chimeras are spaced apart from one another on the surface or within the volume of the solid support such that, empirically, the relative frequency of intermolecular events versus intramolecular events (e.g., transfer of information) is <1:10, <1:100, <1:1,000, or <1:10,000.

[0121] In some embodiments, the plurality of nucleic acid-analyte chimeras may be any adjacently coupled nucleic acid-analyte chimera having a length of about 50-100 nm, about 50-250 nm, about 50-500 nm, about 50-750 nm, about 50-1000 nm, about 50-1500 nm, about 50-2000 nm, about 100-250 nm, about 100-500 nm, about 200-500 nm, about 30 are coupled on the solid support so as to be spaced from each other by an average distance in the range of about 0-500 nm, about 100-1000 nm, about 500-600 nm, about 500-700 nm, about 500-800 nm, about 500-900 nm, about 500-1000 nm, about 500-2000 nm, about 500-5000 nm, about 1000-5000 nm, or about 3000-5000 nm.

[0122] In some embodiments, the spacing of the analytes on the solid support is achieved by controlling the concentration and / or number of capture nucleic acids on the solid support. In some embodiments, any adjacently coupled capture nucleic acids are spaced apart from one another on the surface or within the volume of the solid support (e.g., a porous support) by a distance of about 50 nm to about 500 nm, or about 50 nm to about 400 nm, or about 50 nm to about 300 nm, or about 50 nm to about 200 nm, or about 50 nm to about 100 nm. In some embodiments, any adjacently coupled capture nucleic acids are spaced apart from one another on the surface of the solid support by an average distance of at least 50 nm, at least 60 nm, at least 70 nm, at least 80 nm, at least 90 nm, at least 100 nm, at least 150 nm, at least 200 nm, at least 250 nm, at least 300 nm, at least 350 nm, at least 400 nm, at least 450 nm, or at least 500 nm. In some embodiments, any adjacently coupled capture nucleic acids are spaced apart from one another on the surface of the solid support by an average distance of at least 50 nm. In some embodiments, any adjacently coupled capture nucleic acids are spaced apart from one another on the surface or within the volume of the solid support such that, empirically, the relative frequency of intermolecular events versus intramolecular events (e.g., transfer of information) is <1:10, <1:100, <1:1,000, or <1:10,000.

[0123] A suitable spacing frequency can be empirically determined using functional assays and can be achieved by dilution and / or spiking with "dummy" spacer molecules that compete for attachment sites on the substrate surface. For example, PEG-5000 (molecular weight: about 5000) is used to block the gaps between peptides on the substrate surface (e.g., bead surface). In addition, peptides are coupled to functional moieties that are also attached to the PEG-5000 molecule. In some embodiments, the functional moiety is an aldehyde, an azide / alkyne, or a malemide / thiol, or an epoxide / nucleophile, or an inverse electron demand Diels-Alder (iEDDA) group, or a moiety for the Staudinger reaction. In some embodiments, the functional moiety is an aldehyde group.

[0124] In a preferred embodiment, this is accomplished by coupling a mixture of NHS-PEG-5000-TCO+NHS-PEG-5000-methyl to the amine-derivatized beads. The stoichiometric ratio between the two PEGs (TCO to methyl) is titrated to generate a suitable density of functional coupling moieties (TCO groups) on the substrate surface. Methyl PEG is inert to coupling. The effective spacing between TCO groups can be calculated by measuring the density of TCO groups on the surface. In certain embodiments, the average spacing between coupling moieties (e.g., TCO) on the solid surface is at least 50 nm, at least 100 nm, at least 250 nm, or at least 500 nm. After PEG5000-TCO / methyl derivatization of the beads, excess NH2 groups on the surface are quenched with a reactive anhydride (such as succinic anhydride or succinic anhydride).

[0125] In some embodiments, the spacing is achieved by titrating the ratio of available attachment molecules on the substrate surface. In some examples, the substrate surface (e.g., bead surface) is functionalized with carboxyl groups (COOH) that are treated with an activator (e.g., the activator is EDC and sulfo-NHS). In some examples, the substrate surface (e.g., bead surface) contains NHS moieties. In some embodiments, mPEG n -NH2 and NH2-PEG n A mixture of mPEG3-NH2 (not available for coupling) and NH2-PEG4-mTet is added to the activated beads (n is any number, e.g., any number from n=1 to n=100 or more). In one example, the ratio between mPEG3-NH2 (not available for coupling) and NH2-PEG4-mTet (available for coupling) is titrated to generate an appropriate density of functional moieties available for attaching analytes onto the substrate surface. In certain embodiments, the average spacing between coupling moieties (e.g., NH2-PEG4-mTet) on the solid surface is at least 50 nm, at least 100 nm, at least 250 nm, or at least 500 nm. In some particular embodiments, the NH2-PEG n -mTet and mPEG n In some further embodiments, the capture nucleic acid is about or greater than 1:1000, about or greater than 1:10,000, about or greater than 1:100,000, about or greater than 1:100,000, or about or greater than 1:1,000,000. n -attach to mTet.

[0126] In some embodiments, spacing of analytes on a solid support is achieved by controlling the concentration and / or number of available capture nucleic acids on the solid support. In some embodiments, spacing of analytes on a solid support is achieved by controlling the concentration and / or number of available COOH or other functional groups on the solid support. In some specific examples, capture nucleic acids can be made unavailable by binding to bait nucleic acids that are not attached to analytes. In some cases, the ratio of available and unavailable capture nucleic acids is titrated and determined.

[0127] II. Exemplary Uses of Prepared or Processed Analytes in Protein Analysis Assays Provided herein are methods of processing analytes and immobilizing the analytes in a format compatible with analysis. For example, the prepared analytes immobilized on a solid support are in a format compatible with degradation-based polypeptide sequencing assays. In some cases, the format of the nucleic acid-analyte conjugate coupled to the support is available for the addition of other macromolecules. The added macromolecules may contain information about the sequence of the analyte (or a portion thereof). In some examples, the added macromolecule is a nucleic acid that is added to a bait or capture nucleic acid. In some specific embodiments, for this purpose, the nucleic acid component of the nucleic acid-analyte conjugate coupled to the solid support can hold, copy, or store information.

[0128] In some embodiments, the analytical method is for determining the sequence of at least a portion of an analyte (e.g., a polypeptide or peptide). In some cases, the analytical method may include performing any of the methods described in International Patent Publication Nos. WO2017 / 192633, WO2019 / 089836, WO2019 / 089846, and WO2019 / 089851. In some cases, the sequence of a polypeptide is analyzed by constructing an extended nucleic acid sequence representing the polypeptide sequence, such as an extended nucleic acid on a bait or capture nucleic acid (or any additional barcode or tag attached thereto). In some cases, the methods provided herein for processing an analyte can be applied to or used in combination with a ProteoCode assay.

[0129] In some embodiments, it is desirable for the components (nucleic acids and analytes) to remain attached or immobilized and available for use in protein analytical assays involving various chemical and / or enzymatic reactions, hi some embodiments, the assays may involve multiple cycles and treatments with chemical reagents and / or enzymes.

[0130] In some embodiments, the methods provided herein for processing an analyte further include contacting the analyte with a binding agent capable of binding to the analyte (wherein the binding agent comprises a coding tag having identifying information for the binding agent) and transferring the identifying information of the coding tag to a bait or capture nucleic acid. In some embodiments, the transfer of the identifying information to the bait or capture nucleic acid forms an extended nucleic acid. This extended nucleic acid may also be attached (e.g., indirectly) to a bead. In some cases, the method further includes contacting the analyte with an additional binding agent capable of binding to the analyte (wherein the additional binding agent comprises a coding tag having identifying information for the additional binding agent) and transferring the identifying information of the coding tag for the additional binding agent to the bait or capture nucleic acid (or an extension thereof), repeating one or more times. In some examples, the transfer of the identifying information of the coding tag to the bait or capture nucleic acid is mediated by a ligase (e.g., a DNA ligase). In some examples, the transfer of the identifying information of the coding tag to the bait or capture nucleic acid is mediated by a polymerase (e.g., a DNA polymerase). In some examples, the transfer of the identifying information of the coding tag to the bait or capture nucleic acid is mediated by chemical ligation.

[0131] A. Characterization of polypeptides by cyclic rounds of amino acid recognition, information transfer, and amino acid removal In an exemplary workflow for analysis of polypeptide analytes, polypeptide processing and analysis is as follows: A large collection of polypeptides (e.g., 50 million to 1 billion or more) from a proteolytic digest is attached to a bait nucleic acid to form a nucleic acid-analyte chimera, which is then randomly immobilized at appropriate intramolecular spacing on a single molecule sequencing substrate (e.g., beads). Immobilization of peptide analytes to beads is performed using any of the methods described in Section I. Periodically, the terminal amino acid (e.g., the N-terminal amino acid) of each peptide analyte is labeled (e.g., PTC, modified PTC, Cbz, DNP, SNP, acetyl, guanidinyl, biheterocyclic methanimine). In some cases, labeling of the terminal amino acid can be performed as a later step. The N-terminal amino acid (or a labeled N-terminal amino acid, e.g., PITC-NTAA, Cbz-NTAA, DNP-NTAA, SNP-NTAA, acetyl-NTAA, guanidinylated-NTAA, diheterocyclic methanimine modified NTAA) of each immobilized peptide is bound by a cognate NTAA binder attached to a coding tag and the identifying information from the coding tag associated with the bound NTAA binder is transferred to a bait or capture nucleic acid associated with the immobilized peptide analyte, thereby generating an extended nucleic acid containing information from the coding tag. In some embodiments, one or more binders are removed or released from the polypeptide. The labeled NTAA is removed enzymatically or chemically. One or more cycles of labeling, contacting with binder, transfer of identifying information, and removal of the terminal amino acid can be performed.

[0132] As described herein, the nucleic acid to which the identifying information from the coding tag is transferred can be a bait nucleic acid, a capture nucleic acid, or a portion thereof. In some embodiments, the identifying information from the coding tag is transferred to a barcode or other nucleic acid component attached to the bait or capture nucleic acid. In some embodiments, the identifying information from the coding tag is transferred to an extension nucleic acid on the bait or capture nucleic acid that is part of the bait or capture nucleic acid. In some embodiments, the bait nucleic acid or capture nucleic acid (including any additional barcodes or other nucleic acid components attached thereto), or a portion thereof, can function as a "recording tag." A "recording tag" or a portion of a bait or capture nucleic acid that includes a nucleic acid sequence for use as a recording tag refers to or can be a moiety, such as a chemical coupling moiety, a nucleic acid molecule, a polynucleotide sequence, or a sequenceable polymer molecule (see, e.g., Niu et al., 2013, Nat. Chem. 5:282-292; Roy et al., 2015, Nat. Commun. 6:7237; Lutz, 2015, Macromolecules 48:4759-4767, each of which is incorporated by reference in its entirety), to which the identity of the coding tag can be transferred. Recording tags can include DNA, RNA, or polynucleotide analogs, including PNA, gPNA, GNA, HNA, BNA, XNA, TNA, or combinations thereof. The identity of the coding tag can be transferred to a bait or capture nucleic acid that also includes other nucleic acid components. Identifying information can include any information that characterizes a molecule, such as information regarding identity, sample, fraction, partition, spatial location, interacting neighbor molecules, cycle number, etc. Additionally, the presence of UMI information can be classified as identifying information. In certain embodiments, after a binding agent binds to a polypeptide, information from a coding tag linked to the binding agent can be transferred to a bait or capture nucleic acid (or portion thereof) associated with the polypeptide while the binding agent is bound to the polypeptide.In other embodiments, after a binding agent binds to a polypeptide, information from a recording tag associated with the polypeptide can be transferred to a coding tag linked to the binding agent while the binding agent is bound to the polypeptide. In some embodiments, the identifying information of the coding tag is transferred to the 3' end of the bait or capture nucleic acid in embodiments in which polymerase extension is used to transfer the coding tag information.

[0133] A coding tag associated with a binding agent is or includes a polynucleotide of any suitable length, e.g., a nucleic acid molecule of about 2 bases to about 100 bases, including any integer between 2 and 100, inclusive, that includes identifying information for its associated binding agent. A "coding tag" can also be made from a "sequenceable polymer" (see, e.g., Niu et al., 2013, Nat. Chem. 5:282-292; Roy et al., 2015, Nat. Commun. 6:7237; Lutz 2015, Macromolecules 48:4759-4767, each of which is incorporated by reference). A coding tag can include an encoder sequence, or a sequence with identifying information, optionally flanked by a spacer on one side, or optionally flanked by spacers on both sides. A coding tag can also be comprised of an optional UMI and / or any binding cycle-specific barcode. The coding tag can be single-stranded or double-stranded. The double-stranded coding tag can include blunt ends, overhanging ends, or both. The coding tag can refer to a coding tag directly attached to the binder, a complementary sequence hybridized to a coding tag directly attached to the binder (e.g., in the case of a double-stranded coding tag), or coding tag information present in an extended nucleic acid on the bait or capture nucleic acid. In certain embodiments, the coding tag can further include a binding cycle-specific spacer or barcode, a unique molecular identifier, a universal priming site, or any combination thereof.

[0134] In some embodiments, the order of steps in the process of a peptide or polypeptide sequencing assay by degradation can be reversed or performed in a different order, for example, in some embodiments, terminal amino acid labeling can be performed before and / or after conjugation of the polypeptide to a binding agent.

[0135] In some embodiments, the identifying information from the coding tag includes information regarding the identity of the amino acid on the analyte bound by the binding agent.

[0136] In some examples, the final extended nucleic acid (bait or capture nucleic acid including any additional barcodes attached thereto) containing information from one or more binders is optionally flanked by sequences (e.g., adapter sequences and / or universal priming sites) to facilitate downstream amplification and / or DNA sequencing. A forward universal priming site (e.g., Illumina's P5-S1 sequence) can be part of the original design of the bait or capture nucleic acid, and a reverse universal priming site (e.g., Illumina's P7-S2' sequence) can be added as a final step in the extension of the nucleic acid. In some embodiments, the universal priming site used comprises any of the sequences set forth in SEQ ID NOs: 1, 2, 32, and 33. In some embodiments, the addition of the forward and reverse priming sites can be done independently of the binders.

[0137] In the methods described herein, when a binder binds to a polypeptide analyte, the identity of its linked coding tag is transferred to the nucleic acid associated with the polypeptide analyte, thereby generating an extended nucleic acid. The nucleic acid associated with the polypeptide analyte can be a bait nucleic acid or a capture nucleic acid, as described in Section I. In some embodiments, the bait nucleic acid or capture nucleic acid further comprises a barcode and / or other nucleic acid component. In certain embodiments, the identity from the coding tag of the binder is transferred to the bait or capture nucleic acid or added to any existing barcode (or other nucleic acid component) attached thereto. The transfer of the identity of the coding tag to the nucleic acid associated with the analyte can be performed using extension or ligation. In some embodiments, a spacer is added to the end of the capture or bait nucleic acid, the spacer comprising a sequence that can hybridize with a sequence on the coding tag to facilitate the transfer of identity information.

[0138] The bait or capture nucleic acid, or a portion thereof, configured to be used as a recording tag can be a moiety, such as a chemical coupling moiety, a nucleic acid molecule, or a sequenceable polymer molecule (see, e.g., Niu et al., 2013, Nat. Chem. 5:282-292; Roy et al., 2015, Nat. Commun. 6:7237; Lutz, 2015, Macromolecules 48:4759-4767, each of which is incorporated by reference in its entirety), to which the identifying information of the coding tag can be transferred, or from which identifying information (e.g., UMI information) regarding the macromolecule associated with the recording tag can be transferred to the coding tag. In certain embodiments, after the binding agent binds to the polypeptide, information from the coding tag linked to the binding agent can be transferred to the nucleic acid associated with the polypeptide while the binding agent is bound to the polypeptide.

[0139] The extended nucleic acid associated with an analyte having identifying information from the coding tag may include information from the binding agent's coding tag representing each binding cycle carried out. However, in some cases, the extended nucleic acid may also experience "missed" binding cycles, for example, when the binding agent is unable to bind to the polypeptide analyte, due to a missing, damaged, or defective coding tag, or due to a failed primer extension reaction. Even if a binding event does occur, the transfer of information from the coding tag may be incomplete or less than 100% accurate, for example, due to an error in the primer extension reaction, due to a damaged or defective coding tag). Thus, the extended nucleic acid may represent 100% of the binding events that have occurred with its associated polypeptide, or up to 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 65%, 55%, 50%, 45%, 40%, 35%, 30%, or any subrange thereof. Furthermore, the coding tag information present in the extended nucleic acid may have at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% identity to the corresponding coding tag.

[0140] In certain embodiments, the extension nucleic acid on the bait or capture nucleic acid associated with the immobilized peptide analyte may contain information from multiple coding tags representing multiple consecutive binding events. In these embodiments, a single linked extension nucleic acid on the bait or capture nucleic acid associated with the immobilized peptide analyte may represent a single polypeptide. As referred to herein, the transfer of coding tag information to the bait or capture nucleic acid associated with the immobilized peptide analyte also includes the transfer to the extension nucleic acid on the bait or capture nucleic acid so that it occurs in a manner that includes multiple consecutive binding events.

[0141] In certain embodiments, binding event information is periodically transferred from the coding tag to the bait or capture nucleic acid associated with the immobilized peptide. Cross-reactive binding events can be informally excluded after sequencing by requiring that at least two different coding tags that identify two or more independent binding events map to the same class of binders (cognate to a particular protein). The coding tag can include one or more spacer sequences, plus an optional UMI sequence. A universal priming sequence can also be included in the extension nucleic acid on the bait or capture nucleic acid associated with the immobilized peptide analyte for amplification and NGS sequencing.

[0142] The coding tag information associated with a particular binding agent can be transferred using various methods. In certain embodiments, the coding tag information is transferred to the nucleic acid on the bait or capture nucleic acid associated with the immobilized peptide analyte via primer extension (Chan et al., 2015, Curr Opin Chem Biol. 26:55-61). The spacer sequence at the 3' end of the bait or capture nucleic acid or the nucleic acid attached to the bait or capture nucleic acid anneals to the complementary spacer sequence at the 3' end of the coding tag, and a polymerase (e.g., a strand-displacing polymerase) extends the nucleic acid sequence on the bait or capture nucleic acid using the annealed coding tag as a template. In some embodiments, an oligonucleotide complementary to the coding tag encoder sequence and the 5' spacer can be pre-annealed to the coding tag to prevent hybridization of the coding tag to the internal encoder and spacer sequences present in the extended nucleic acid. The 3' terminal spacer on the coding tag, which is still single-stranded, preferably binds to the terminal 3' spacer on the bait or capture nucleic acid (or any barcode or other nucleic acid component). In other embodiments, the nascent nucleic acid on the bait or capture nucleic acid associated with the immobilized peptide analyte can be coated with a single-stranded binding protein to prevent annealing of the coding tag to an internal site. Alternatively, the nascent nucleic acid can be coated with RecA (or a related homologue such as uvsX) to promote invasion of the 3' end into the fully double-stranded coding tag (Bell et al., 2012, Nature 491:274-278). This configuration prevents the double-stranded coding tag from interacting with internal nucleic acid elements on the bait or capture nucleic acid associated with the immobilized peptide analyte, but makes it susceptible to strand invasion by the RecA-coated 3' tail of the extended nucleic acid (Bell, et al., 2015, Elife 4:e08646). The presence of a single-stranded binding protein may promote strand displacement reactions.

[0143] In some embodiments, the DNA polymerase used for primer extension has strand displacement activity and has limited or no 3'-5 exonuclease activity. Some of the many examples of such polymerases include Klenow exo- (Klenow fragment of DNA Pol1), T4 DNA polymerase exo-, T7 DNA polymerase exo- (Sequenase 2.0), Pfu exo-, Vent exo-, Deep Vent exo-, Bst DNA polymerase large fragment exo-, Bca Pol, 9°N Pol, and Phi29 Pol exo-. In a preferred embodiment, the DNA polymerase is active at room temperature and up to 45°C. In another embodiment, a "warm start" version of a thermophilic polymerase is employed such that the polymerase is activated and used at about 40°C to 50°C. An exemplary warm start polymerase is Bst 2.0 Warm Start DNA polymerase (New England Biolabs).

[0144] Additives useful for strand displacement replication include any of the numerous single-stranded DNA binding proteins (SSB proteins) from bacteria, viruses, or eukaryotes, such as the E. coli SSB protein, phage T4 gene 32 product, phage T7 gene 2.5 protein, phage Pf3 SSB, replication protein A RPA32 and RPA14 subunits (Wold, 1997); other DNA binding proteins, such as adenovirus DNA binding protein, herpes simplex protein ICP8, BMRF1 polymerase accessory subunit, herpes virus UL29 SSB-like protein; any of the numerous replication complex proteins known to be involved in DNA replication, such as phage T7 helicase / primase, phage T4 gene 41 helicase, E. coli Rep helicase, E. coli recBCD helicase, recA, E. coli, eukaryotic topoisomerases (Annu Rev Biochem. (2001) 70:369-413).

[0145] Mispriming or self-priming events, such as when the terminal spacer sequence of the recoding tag primes the extension self-extension, can be minimized by including single-stranded binding protein (e.g., T4 gene 32, E. coli SSB), DMSO (1-10%), formamide (1-10%), BSA (10-100ug / ml), TMACl (1-5mM), ammonium sulfate (10-50mM), betaine (1-3M), glycerol (5-40%), or ethylene glycol (5-40%) in the primer extension reaction.

[0146] Most type A polymerases, such as Klenow exo-, T7 DNA polymerase exo- (Sequenase 2.0), lack 3' exonuclease activity (intrinsic or engineered removal), and Taq polymerase catalyzes the non-templated addition of nucleotides, preferably adenosine bases (and to a lesser extent G bases, depending on sequence association), to the 3' blunt ends of duplex amplification products. For Taq polymerase, 3' pyrimidines (C>T) minimize non-templated adenosine addition, whereas 3' purine nucleotides (G>A) favor non-templated adenosine addition. In some embodiments, using Taq polymerase for primer extension, the placement of thymidine bases in the coding tag between the spacer sequence distal from the binder and the adjacent barcode sequence (e.g., the encoder sequence or cycle-specific sequence) corresponds to the sporadic inclusion of non-templated adenosine nucleotides at the 3' end of the spacer sequence of the bait or capture nucleic acid. In this way, the extended nucleic acid on the bait or capture nucleic acid associated with the immobilized peptide analyte (with or without a non-templated adenosine base) can anneal to the coding tag and undergo primer extension.

[0147] Alternatively, non-templated base addition can be reduced by using mutant polymerases (mesophilic or thermophilic) in which non-templated terminal transferase activity, particularly in the O-helical region, has been greatly reduced by one or more point mutations (see U.S. Pat. No. 7,501,237) (Yang et al., Nucleic Acids Res. (2002) 30(19):4314-4320). Pfu exo-, which is 3' exonuclease deficient and capable of strand displacement, also does not have non-templated terminal transferase activity.

[0148] In another embodiment, the polymerase extension buffer is comprised of 40-120 mM of a buffer such as Tris-acetate, Tris-HCl, HEPES, etc., with a pH value of 6-9.

[0149] Self-priming / mispriming events initiated by self-annealing of the terminal spacer sequence of the extended nucleic acid with an internal region of the extended nucleic acid can be minimized by including pseudo-complementary bases in the nucleic acid on the bait or capture nucleic acid (Lahoud et al., Nucleic Acids Res. (2008) 36:3409-3419), (Hoshika et al., Angew Chem Int Ed Engl (2010) 49(32):5554-5557). Pseudo-complementary bases show a greatly reduced hybridization affinity for forming a duplex with each other due to the presence of chemical modifications. However, many pseudo-complementary modified bases can form strong base pairs with natural DNA or RNA sequences. In certain embodiments, the coding tag spacer sequence is composed of multiple A and T bases, and the commercially available pseudo-complementary bases 2-aminoadenine and 2-thiothymine are incorporated into the bait or capture nucleic acid using phosphoramidite oligonucleotide synthesis. Additional pseudo-complementary bases can be incorporated into the extended nucleic acid during primer extension by adding pseudo-complementary nucleotides to the reaction (Gamper et al., Biochemistry. (2006) 45(22):6978-86).

[0150] In some embodiments, to minimize non-specific interactions between the coding tag-labeled binder in solution and the nucleic acid of the immobilized protein analyte, a competitor (also called blocking) oligonucleotide that is complementary to the nucleic acid containing a spacer sequence can be added to the binding reaction to minimize non-specific interactions. In some embodiments, the blocking oligonucleotide contains a sequence complementary to the coding tag attached to the binder or a portion thereof. For example, the blocking oligonucleotide contains a sequence complementary to the spacer and / or barcode sequence of the coding tag. In some embodiments, the blocking oligonucleotide is relatively short. Excess competitor oligonucleotide is washed out of the binding reaction prior to primer extension, which effectively dissociates the annealed competitor oligonucleotide from the nucleic acid on the bait or capture nucleic acid, especially when exposed to slightly higher temperatures (e.g., 30-50°C). The blocking oligonucleotide may contain a terminator nucleotide at its 3' end to prevent primer extension.

[0151] In certain embodiments, the annealing of a spacer sequence on a bait or capture nucleic acid to a complementary spacer sequence on a coding tag is metastable under primer extension reaction conditions (i.e., the annealing Tm is similar to the reaction temperature), allowing the spacer sequence of the coding tag to displace any blocking oligonucleotides annealed to the spacer sequence of the bait or capture nucleic acid (or an extension thereof).

[0152] The coding tag information associated with a particular binder can also be transferred to the nucleic acid on the bait or capture nucleic acid associated with the immobilized peptide analyte via ligation. The ligation can be blunt-end ligation or sticky-end ligation. The ligation can be an enzymatic ligation reaction. Examples of ligases include, but are not limited to, CV DNA ligase, T4 DNA ligase, T7 DNA ligase, T3 DNA ligase, Taq DNA ligase, E. coli DNA ligase, 9°N DNA ligase, Electroligase® (see, for example, U.S. Patent Publication No. US2014 / 0378315). Alternatively, the ligation can be a chemical ligation reaction. In some embodiments, as illustrated in International Patent Publication No. WO2017 / 192633, spacer-free ligation is achieved by using hybridization of a "recording helper" sequence with the arms on the coding tag. The annealed complementary sequences are chemically ligated using standard chemical ligation or "click chemistry" (Gunderson et al., Genome Res (1998) 8(11):1142-1153; Peng et al., European J Org Chem (2010) (22):4194-4197; El-Sagheere et al., Proc Natl Acad Sci USA (2011) 108(28):11338-11343; El-Sagheer et al., Org Biomol Chem (2011) 9(1):232-235; Sharma et al., Anal Chem (2012) 84(14):6104-6109; Roloff et al., Bioorg Med Chem (2013) 21(12):3458-3464; Litovchick et al. al., Artif DNA PNA XNA(2014)5(1):e27896, Roloff et al., Methods Mol Biol(2014)1050:131-141).

[0153] In another embodiment, the transfer of PNA can be accomplished by chemical ligation using published techniques. The structure of PNA is such that it has a 5'N-terminal amine group and a non-reactive 3'C-terminal amide. Chemical ligation of PNA requires modification of the termini to make them chemically active. This is usually done by derivatizing the 5'N-terminus with a cysteinyl moiety and the 3'C-terminus with a thioester moiety. Such modified PNAs are easily coupled using standard native chemical ligation conditions (Roloff et al., (2013) Bioorgan. Med. Chem. 21:3458-3464).

[0154] In some embodiments, the coding tag information can be transferred using a topoisomerase, which can be used to ligate a topo-charged 3' phosphate on a bait or capture nucleic acid (or any nucleic acid extended or attached thereto) to the 5' end on the coding tag, or its complement (Shuman et al., 1994, J. Biol. Chem. 269:32678-32684).

[0155] As described herein, the binder may bind to post-translationally modified amino acids. Thus, in certain embodiments, the extended nucleic acid associated with the analyte includes the amino acid sequence of the polypeptide analyte and coding tag information associated with the post-translational modification. In some embodiments, detection of internal post-translationally modified amino acids (e.g., phosphorylation, glycosylation, succinylation, ubiquitination, S-nitrosylation, methylation, N-acetylation, lipidation, etc.) is accomplished prior to detection and desorption of the terminal amino acid (e.g., NTAA or CTAA). In one example, the peptide is contacted with the binder for PTM modification and transferred to the nucleic acid on the bait or capture nucleic acid associated with the immobilized peptide analyte. Once detection and transfer of the coding tag information associated with the amino acid modification is complete, the PTM modification group can be removed prior to detection and transfer of the coding tag information of the primary amino acid sequence using N-terminal or C-terminal degradation methods. Thus, the resulting extended nucleic acid indicates the presence of post-translational modifications in the peptide sequence along with the primary amino acid sequence information, but not in consecutive order.

[0156] In some embodiments, detection of internal post-translationally modified amino acids can be performed simultaneously with detection of the primary amino acid sequence. In one example, NTAA (or CTAA) is contacted with a binder specific for the post-translationally modified amino acid, either alone or as part of a library of binders (e.g., a library composed of binders for the 20 standard amino acids and selected post-translationally modified amino acids). Successive cycles of desorption of the terminal amino acid and contact with the binder (or library of binders) follow. Thus, the resulting extension nucleic acid on the bait or capture nucleic acid associated with the immobilized peptide analyte indicates the presence and order of the post-translational modifications in the context of the primary amino acid sequence.

[0157] In certain embodiments, an ensemble of nucleic acids on the bait or capture nucleic acid can be used for each polypeptide to improve the overall robustness and efficiency of coding tag information transfer. Using a collection of nucleic acids associated with a given polypeptide, rather than a single nucleic acid, can improve the efficiency of library construction.

[0158] For embodiments involving analysis of denatured analytes including proteins, polypeptides, and peptides, bound binding agents and annealed coding tags can be removed following transfer of identifying information (e.g., primer extension) by using highly denaturing conditions (e.g., 0.1-0.2 N NaOH, 6 M urea, 2.4 M guanidinium isothiocyanate, 95% formamide, etc.).

[0159] In certain embodiments related to the analysis of peptides, following binding of the binding agent and transfer of the coding tag information, the terminal amino acid is removed or cleaved from the peptide to expose a new terminal amino acid. In some embodiments, the terminal amino acid is NTAA. In other embodiments, the terminal amino acid is CTAA. Cleavage of the terminal amino acid can be achieved by any number of known techniques, including chemical cleavage and enzymatic cleavage.

[0160] In some embodiments, engineered enzymes that catalyze the removal of modified or labeled N-terminal amino acids or reagents that promote it are used. In some embodiments, terminal amino acids are removed or eliminated using any of the methods described in International Patent Publication No. WO2019 / 089846 or US Provisional Patent Application No. 62 / 841,171. In some embodiments, the cleavage of terminal amino acids uses carboxypeptidases, aminopeptidases, dipeptidyl peptidases, dipeptidyl aminopeptidases or variants, mutants, or modified proteins thereof; hydrolases or variants, mutants, or modified proteins thereof; mild Edman degradation reagents; Edmanase enzymes; anhydrous TFA, base; or any combination thereof.

[0161] In some embodiments, the mild Edman degradation uses dichloro or monochloro acid, the mild Edman degradation uses TFA, TCA, or DCA, or the mild Edman degradation uses triethylamine, triethanolamine, or triethylammonium acetate (Et3NHOAc). In some cases, the reagent for removing the amino acid includes a base. In some embodiments, the base is a hydroxide, an alkylating amine, a cyclic amine, a carbonate buffer, a trisodium phosphate buffer, or a metal salt. In some examples, the hydroxide is sodium hydroxide. The alkylating amine is selected from methylamine, ethylamine, propylamine, dimethylamine, diethylamine, dipropylamine, trimethylamine, triethylamine, tripropylamine, cyclohexylamine, benzylamine, aniline, diphenylamine, N,N-diisopropylethylamine (DIPEA), and lithium diisopropylamide (LDA). The cyclic amine is selected from pyridine, pyrimidine, imidazole, pyrrole, indole, piperidine, prolysine, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), and 1,5-diazabicyclo[4.3.0]non-5-ene (DBN). The carbonate buffer includes sodium carbonate, potassium carbonate, calcium carbonate, sodium bicarbonate, potassium bicarbonate, or calcium bicarbonate. The metal salt includes silver. Or the metal salt is AgClO4.

[0162] In some cases, enzymatic cleavage of NTAAs can be achieved by aminopeptidases or other peptidases. Aminopeptidases occur naturally as monomeric and multimeric enzymes and can be metal or ATP dependent. Natural aminopeptidases have very limited specificity and generally cleave the N-terminal amino acid in a processive manner, cleaving one amino acid after another. In the methods described herein, aminopeptidases (e.g., metalloenzyme aminopeptidases) can be engineered to have specific binding or catalytic activity to NTAAs only when modified with an N-terminal label. For example, aminopeptidases can be engineered to cleave the N-terminal amino acid only when modified with groups such as PTC, modified PTC, Cbz, DNP, SNP, acetyl, guanidinyl, diheterocyclic methanimine, etc. In this way, the aminopeptidase cleaves only a single amino acid at a time from the N-terminus, allowing control of the degradation cycle. In some embodiments, the modified aminopeptidase is selective for the N-terminal label while being non-selective with respect to the identity of the amino acid residue, while in other embodiments, the modified aminopeptidase is selective for both the identity of the amino acid residue and the N-terminal label.

[0163] In some embodiments, the method further comprises contacting the polypeptide with a proline aminopeptidase under conditions suitable for cleaving the N-terminal proline prior to step (b). In some examples, the proline aminopeptidase (PAP) is an enzyme capable of specifically cleaving the N-terminal proline from a polypeptide. PAP enzymes that cleave N-terminal prolines are also called proline iminopeptidases (PIPs). Known monomeric PAPs include family members from B. coagulans, L. delbrueckii, N. gonorrhoeae, F. meningosepticum, S. marcescens, T. acidophilum, and L. plantarum (MEROPS S33.001) (Nakajima et al., J Bacteriol. (2006) 188(4): 1599-606; Kitazono et al., Bacteriol (1992) 174(24): 7919-7925). Known multimeric PAPs include those from D. hansenii (Bolumar et al., (2003) 86(1-2):141-151) and similar homologues from other species (Basten et al., Mol Genet Genomics (2005) 272(6):673-679). Either naturally occurring or engineered variants / mutants of PAP can be used.

[0164] For embodiments related to CTAA binding agents, methods of cleaving CTAA from peptides are also known in the art. For example, US Patent No. 6,046,053 discloses a method of reacting a peptide or protein with an alkyl acid anhydride to convert the carboxy terminus to an oxazolone, and releasing the C-terminal amino acid by reaction with an acid and an alcohol or ester. Enzymatic cleavage of CTAA can also be achieved by carboxypeptidases. Some carboxypeptidases exhibit amino acid preferences, for example, carboxypeptidase B cleaves preferentially at basic amino acids such as arginine and lysine. As described above, carboxypeptidases can also be modified in the same manner as aminopeptidases to engineer carboxypeptidases that specifically bind to CTAA with a C-terminal label. In this way, the carboxypeptidase cleaves only a single amino acid at a time from the C-terminus, allowing control of the degradation cycle. In some embodiments, the modified carboxypeptidase is selective for the C-terminal label, while being non-selective with respect to the identity of the amino acid residue. In other embodiments, the modified carboxypeptidase is selective for both the identity of the amino acid residue and the C-terminal label.

[0165] B. Binding Agents for Amino Acid Recognition In certain embodiments, the methods for analyzing a polypeptide provided in the present disclosure include multiple binding cycles when the polypeptide analyte is contacted with multiple binding agents, and successive binding of the binding agents transfers previous binding information in the form of a nucleic acid-based coding tag to at least one nucleic acid (e.g., a bait or capture nucleic acid) associated with the polypeptide. In this way, a previous record containing information about multiple binding events is generated in a nucleic acid format.

[0166] In some embodiments, the binding agent may be a cognate binding agent of the analyte or any portion of the analyte. In certain embodiments, the binding agent may bind to NTAA, CTAA, an intervening amino acid, a dipeptide (a sequence of two amino acids), a tripeptide (a sequence of three amino acids), or a higher order peptide of a peptide molecule. In some embodiments, each binding agent in a library of binding agents selectively binds to a specific amino acid, for example, one of the 20 standard naturally occurring amino acids. Standard naturally occurring amino acids include alanine (A or Ala), cysteine ​​(C or Cys), aspartic acid (D or Asp), glutamic acid (E or Glu), phenylalanine (F or Phe), glycine (G or Gly), histidine (H or His), isoleucine (I or Ile), lysine (K or Lys), leucine (L or Leu), methionine (M or Met), asparagine (N or Asn), proline (P or Pro), glutamine (Q or Gln), arginine (R or Arg), serine (S or Ser), threonine (T or Thr), valine (V or Val), tryptophan (W or Trp), and tyrosine (Y or Tyr). In some embodiments, the binding agent binds to unmodified or naturally occurring amino acids. In some examples, the binders bind to unmodified or natural dipeptides (sequences of two amino acids), tripeptides (sequences of three amino acids), or higher order peptides of peptide molecules. Binders can be designed for high affinity for natural or unmodified NTAAs, high specificity for natural or unmodified NTAAs, or both. In some embodiments, binders can be developed through directed evolution of promising affinity scaffolds using phage display.

[0167] The binding agent may be attached to the N-terminal peptide, C-terminal peptide, or intervening peptide of a peptide, polypeptide, or protein molecule. The binding agent may be attached to the N-terminal amino acid, C-terminal amino acid, or intervening amino acid of a peptide molecule. The binding agent may be attached to a diamino acid moiety at the N-terminus or C-terminus. The binding agent may preferably be attached to a chemically modified or labeled amino acid. For example, the binding agent may preferably be attached to an amino acid functionalized with an acetyl moiety, a Cbz moiety, a guanyl moiety, a dansyl moiety, a PTC moiety, a DNP moiety, a SNP moiety, a heterocyclic methanimine moiety, etc., rather than an amino acid that does not have such a moiety. Modified or labeled NTAAs include phenylisothiocyanate, PITC, 1-fluoro-2,4-dinitrobenzene (Sanger's reagent, DNFB), benzyloxycarbonyl chloride or carbobenzoxy chloride (Cbz-Cl), N-(benzyloxycarbonyloxy)succinimide (Cbz-OSu or Cbz-O-NHS), dansyl chloride (DNS-Cl or 1-dimethylaminonaphthalene-5-sulfonyl chloride), 4-sulfonyl-2-nitrofluorobenzene (SNFB), N-acetyl-isatoic anhydride, isatoic anhydride, 2-pyridinecarboxaldehyde, 2-formylphenylboronic acid, 2-acetylphenylboronic acid, 1-fluoro-2,4-dinitrobenzene, succinic anhydride, 4-chloro-7-nitrobenzene, 1-fluoro-2,4-dinitrobenzene, succinic anhydride, 1-fluoro-2,4-dinitrobenzene ... Zofurazan, pentafluorophenyl isothiocyanate, 4-(trifluoromethoxy)-phenyl isothiocyanate, 4-(trifluoromethyl)-phenyl isothiocyanate, 3-(carboxylic acid)-phenyl isothiocyanate, 3-(trifluoromethyl)-phenyl isothiocyanate, 1-naphthyl isothiocyanate, N-nitroimidazole-1-carboximidamide, N,N,A≦-bis(pivaloyl)-1H-pyrazole-1-carboxamidine, N,N,A≦-bis(benzyloxycarbonyl)-1H-pyrazole-1-carboxamidine, acetylating reagents, guanidinylating reagents, thioacylating reagents, thioacetylating reagents, or thiobenzylating reagents, or functionalized with biheterocyclic methanimine reagents.In some instances, the binding agent is attached to the labeled amino acid by contacting it with a reagent or by using the methods described in International Patent Publication No. WO2019 / 089846 or U.S. Provisional Patent Application No. 62 / 841,171. In some instances, the binding agent is attached to an amino acid labeled with an amine-modifying reagent.

[0168] In some embodiments, the binding agent is partially specific or selective. In some embodiments, the binding agent preferentially binds to one or more amino acids. For example, the binding agent may preferentially bind to amino acids A, C, and G over other amino acids. In some other examples, the binding agent may selectively or specifically bind to multiple amino acids. In some embodiments, the binding agent may also preferentially bind to one or more amino acids at the second, third, fourth, fifth, etc. position from the terminal amino acid. In some cases, the binding agent preferentially binds to a particular terminal amino acid and one or more penultimate amino acids. In some cases, the binding agent preferentially binds to one or more particular terminal amino acids and one penultimate amino acid. For example, the binding agent may preferentially bind to AA, AC, and AG, or the binding agent may preferentially bind to AA, CA, and GA. In some particular examples, binding agents with different specificities can share the same coding tag.

[0169] In certain embodiments, the concentration of the binding agent in solution is controlled to reduce assay background and / or false positive results.

[0170] In some embodiments, the concentration of the binding agent can be any suitable concentration, for example, about 0.0001 nM, about 0.001 nM, about 0.01 nM, about 0.1 nM, about 1 nM, about 2 nM, about 5 nM, about 10 nM, about 20 nM, about 50 nM, about 100 nM, about 200 nM, about 500 nM, or about 1000 nM. In other embodiments, the concentration of soluble conjugate used in the assay is from about 0.0001 nM to about 0.001 nM, from about 0.001 nM to about 0.01 nM, from about 0.01 nM to about 0.1 nM, from about 0.1 nM to about 1 nM, from about 1 nM to about 2 nM, from about 2 nM to about 5 nM, from about 5 nM to about 10 nM, from about 10 nM to about 20 nM, from about 20 nM to about 50 nM, from about 50 nM to about 100 nM, from about 100 nM to about 200 nM, from about 200 nM to about 500 nM, from about 500 nM to about 1000 nM, or greater than about 1000 nM.

[0171] In some embodiments, the ratio between soluble binding agent molecules and immobilized polypeptides and / or nucleic acids (e.g., of a nucleic acid-analyte conjugate) can be in any suitable range, e.g., about 0.00001:1, about 0.0001:1, about 0.001:1, about 0.01:1, about 0.1:1, about 1:1, about 2:1, about 5:1, about 10:1, about 15:1, about 20:1, about 25:1, about 30:1, about 35:1, about 40:1, about 45:1, about 50:1, about 55:1, about 60:1, about 65:1, about 70:1, about 75:1, about 80:1, about 85:1, about 90:1, about 95:1, about 100:1, about 10 4 :1, about 10 5 :1, about 10 6 The ratio of soluble binding agent molecules to immobilized polypeptides and / or nucleic acids (e.g., of nucleic acid-analyte conjugates) can be 1:1, or more, or any ratio between the above ratios. Higher ratios between soluble binding agent molecules and immobilized polypeptides and / or nucleic acids (e.g., of nucleic acid-analyte conjugates) can be used to complete the binding and / or transfer of coding tag information. This can be particularly useful for detecting and / or analyzing low amounts of polypeptides in a sample.

[0172] In certain embodiments, the binding agent has a K of about 500 nM or less, about 200 nM or less, about 100 nM or less, about 50 nM or less, or about 10 nM or less, about 5 nM or less, about 1 nM or less, about 0.5 nM or less, or about 0.1 nM or less. d In certain embodiments, the binder has >10×, >100×, or >1000× its K d to the macromolecule at a concentration of 0.1 to 100 mM NaCl, and then the binding is completed. In particular, the high binding affinity with a low off-rate may be effective for information transfer between the coding tag and the recording tag.

[0173] In embodiments related to methods of analyzing peptides or polypeptides using an N-terminal degradation approach, a first binding agent is contacted and binds to the nNTAA of a peptide of n amino acids and transfers the coding tag information of the first binding agent to a nucleic acid associated with the peptide, thereby generating a primary extension nucleic acid (e.g., on a bait or capture nucleic acid), and the nNTAA is eliminated as described herein. Removal of the n labeled NTAA by contact with an enzyme or chemical reagent converts the n-1 amino acid of the peptide to an N-terminal amino acid, referred to herein as n-1 NTAA. A second binding agent is contacted with the peptide, binds to the n-1 NTAA, and transfers the coding tag information of a secondary binding agent to the primary extension nucleic acid, thereby generating a secondary extension nucleic acid (e.g., to generate a linked n-th extension nucleic acid representing the peptide). Elimination of the n-1 labeled NTAA converts the n-2 amino acid of the peptide to an N-terminal amino acid, referred to herein as n-2 NTAA. Additional binding, transfer, labeling, and removal can occur as above for up to n amino acids to generate an nth order extended nucleic acid or n separate extended nucleic acids collectively representing a peptide. As used herein, n "order" when used with respect to a binder, coding tag, or extended nucleic acid refers to the nth binding cycle in which a binder and its associated coding tag are used, or the nth binding cycle in which an extended nucleic acid is created (e.g., on a bait or capture nucleic acid). In some embodiments, the steps involving NTAA in the exemplary approaches described can instead be performed with a C-terminal amino acid (CTAA).

[0174] In some embodiments, the contacting of the first binding agent and the second binding agent to the polypeptide analyte, and optionally the contacting of any additional binding agent (e.g., a third binding agent, a fourth binding agent, a fifth binding agent, etc.) is performed simultaneously. For example, the first binding agent and the second binding agent, and optionally any higher order binding agent, can be pooled together to form, for example, a library of binding agents. In another example, the first binding agent and the second binding agent, and optionally any higher order binding agent, are added to the polypeptide simultaneously, rather than being pooled together. In one embodiment, the library of binding agents comprises at least 20 binding agents that selectively bind to the 20 standard naturally occurring amino acids. In some embodiments, the library of binding agents can comprise binding agents that selectively bind to modified amino acids.

[0175] In other embodiments, the first and second binding agents, and optionally any higher order binding agents, are each contacted with the polypeptide in separate binding cycles and added in sequential order.In certain embodiments, multiple binding agents are used in parallel at the same time.This parallel approach saves time and reduces non-specific binding of non-cognate binding agents to the site bound by cognate binding agents (because the binding agents compete with each other).

[0176] The length of the final extended nucleic acid (e.g., on a bait or capture nucleic acid) generated by the methods described herein depends on several factors, including the length of the coding tag (e.g., encoder sequence and spacer), the length of the nucleic acid (e.g., optionally any unique molecular identifier, spacer, universal priming site, barcode, or combinations thereof), the number of binding cycles performed, and whether the coding tag from each binding cycle is transferred to the same extended nucleic acid or to multiple extended nucleic acids. In some examples, if the coding tag has a 5 base encoder sequence flanked on either side by a 5 base spacer, the coding tag information of the final extended nucleic acid representing the history of the peptide binder is 10 bases x the number of cycles.

[0177] After the final binding cycle and transfer of the coding tag information of the final binder to the extended nucleic acid (e.g., on the bait or capture nucleic acid), the tag can be capped by adding a universal reverse priming site via ligation, primer extension, or other methods known in the art. In some embodiments, the universal forward priming site in the nucleic acid (e.g., on the bait or capture nucleic acid) is compatible with the universal reverse priming site added to the final extended nucleic acid. In some embodiments, after final transfer to the extended nucleic acid, a capping barcode can be introduced by adding a universal reverse priming site. In some cases, an optional UMI can also be added to the extended nucleic acid. In some embodiments, the universal reverse priming site is the Illumina P7 primer (5'-CAAGCAGAAGACGGCATACGAGAT-3'-SEQ ID NO:2) or the Illumina P5 primer (5'-AATGATACGGCGACCACCGA-3'-SEQ ID NO:1), or the sequence set forth in SEQ ID NO:32 or 33. Depending on the strand sense of the nucleic acid to which the identifying information from the coding tag is transferred, sense or antisense P7 can be added. The extended nucleic acid library can be cleaved or amplified directly from the solid support (e.g., beads) and used in conventional next-generation sequencing assays and protocols.

[0178] In some embodiments, a primer extension reaction is performed on a library of single-stranded extended nucleic acids (e.g., extended on a bait or capture nucleic acid) to copy its complementary strand. In some embodiments, a peptide sequencing assay (e.g., a ProteoCode assay) comprises several chemical and enzymatic steps in a cyclic progression. In some cases, one advantage of single molecule assays is their robustness against inefficiencies in the various cyclic chemical / enzymatic steps. In some embodiments, the use of cycle-specific barcodes present in the coding tag sequence confers an advantage to the assay.

[0179] C. Tag Processing and Analysis The extended nucleic acid associated with the analyte, which has identifying information from one or more coding tags and any other tags (barcode, UMI, etc.) that represent the polypeptide of interest, can be processed and analyzed using various nucleic acid sequencing methods. In some embodiments, the method includes analyzing identifying information on the binding agent transferred to the bait nucleic acid or capture nucleic acid. Examples of sequencing methods include, but are not limited to, chain termination sequencing (Sanger sequencing); next-generation sequencing methods such as sequencing by synthesis, sequencing by ligation, sequencing by hybridization, polony sequencing, ion semiconductor sequencing, pyrosequencing; and third-generation sequencing methods such as single-molecule real-time sequencing, nanopore-based sequencing, duplex interrupted sequencing, and direct imaging of DNA using advanced microscopes.

[0180] Suitable sequencing methods for use in the present invention include, but are not limited to, sequencing by hybridization, sequencing by synthesis technology (e.g., HiSeq™ and Solexa™, Illumina), SMRT™ (single molecule real-time) technology (Pacific Biosciences), true single molecule sequencing (e.g., HeliScope™, Helicos Biosciences), massively parallel next generation sequencing (e.g., SOLiD™, Applied Biosciences, Solexa and HiSeq™, Illumina), massively parallel semiconductor sequencing (e.g., Ion Torrent), pyrosequencing technology (e.g., GS FLX and GS Junior Systems, Roche / 454), and nanopore arrays (e.g., Oxford Nanopore Technologies).

[0181] A library of nucleic acids (e.g., extended nucleic acids) can be amplified in a variety of ways. A library of nucleic acids (e.g., extended nucleic acids) can undergo exponential amplification, for example, via PCR or emulsion PCR. Emulsion PCR is known to result in more uniform amplification (Hori, Fukano et al., Biochem Biophys Res Commun (2007) 352 (2): 323-328). Alternatively, a library of nucleic acids (e.g., extended nucleic acids) can undergo linear amplification, for example, via in vitro transcription of template DNA using T7 RNA polymerase. A library of nucleic acids (e.g., extended nucleic acids) can be amplified using primers compatible with the universal forward priming site and universal reverse priming site contained therein. A library of extended nucleic acids (e.g., on a bait or capture nucleic acid) can also be amplified using tailed primers to add sequences to either the 5' end, 3' end, or both ends of the extended nucleic acids. Sequences that can be added to the end of the extended nucleic acid include library-specific index sequences, and can multiplex multiple libraries in one sequencing run, adapter sequences, lead primer sequences, or other sequences to make the library of extended nucleic acids compatible with the sequencing platform. An example of library amplification in preparation for next-generation sequencing is as follows: A PCR reaction volume of 20 μl is set up using the extended nucleic acid library eluted from about 1 mg of beads (about 10 ng), 200 μM dNTPs, 1 μM each of forward and reverse amplification primers, 0.5 μl (1 U) Phusion Hot Start enzyme (New England Biolabs), and subjected to cycle conditions of 98°C for 30 seconds, followed by 20 cycles of 98°C for 10 seconds, 60°C for 30 seconds, 72°C for 30 seconds, and 72°C for 7 minutes, and then held at 4°C.

[0182] In certain embodiments, either before, during, or after amplification, a library of nucleic acids (e.g., extended nucleic acids) can undergo target enrichment. In some embodiments, target enrichment can be used to selectively capture or amplify extended nucleic acids representing polypeptides of interest from a library of extended nucleic acids prior to sequencing. In some aspects, target enrichment for protein sequencing is challenging due to the high cost and difficulty in producing highly specific binders for target proteins. In some cases, antibodies are notoriously non-specific and difficult to scale production across thousands of proteins. In some embodiments, the methods of the present disclosure circumvent this problem by converting the protein code into a nucleic acid code, which can then take advantage of a wide range of target DNA enrichment strategies available for DNA libraries. In some cases, peptides of interest can be enriched in a sample by enriching the corresponding extended nucleic acids. Methods of target enrichment are known in the art and include hybrid capture assays, PCR-based assays such as TruSeq custom amplicons (Illumina), padlock probes (also called molecular inversion probes), and the like (see Mamanova et al., (2010) Nature Methods 7:111-118; Bodi et al., J. Biomol. Tech. (2013) 24:73-86; Ballester et al., (2016) Expert Review of Molecular Diagnostics 357-372; Mertes et al., (2011) Brief Funct. Genomics 10:374-386; Nilsson et al., (1994) Science 265:2085-8, each of which is incorporated herein by reference in its entirety).

[0183] In one embodiment, a library of nucleic acids (e.g., extended nucleic acids) is enriched via a hybrid capture-based assay. In a hybrid capture-based assay, a library of extended nucleic acids is hybridized to a target-specific oligonucleotide labeled with an affinity tag (e.g., biotin). The extended nucleic acids hybridized to the target-specific oligonucleotide are "pulled down" via the affinity tag using an affinity ligand (e.g., streptavidin-coated beads) to wash away background (non-specific) extended nucleic acids. The enriched extended nucleic acids (e.g., extended nucleic acids) are then obtained for positive enrichment (e.g., eluted from the beads). In some embodiments, oligonucleotides complementary to the corresponding extended nucleic acid library representation of the peptide of interest can be used in the hybrid capture assay. In some embodiments, successive rounds or enrichments can also be performed using the same or different bait sets.

[0184] Bait oligonucleotides can be designed to "tile" across the entire nucleic acid representation of a protein in order to enrich for the entire length of a polypeptide within a library of extended nucleic acids representing its fragments (eg, peptides).

[0185] In another embodiment, primer extension and ligation-based mediated amplification enrichment (AmpliSeq, PCR, TruSeq TSCA, etc.) can be used to select and modularize enriched fractions of library elements representing subsets of polypeptides. Competing oligonucleotides can also be used to modulate the degree of primer extension, ligation, or amplification. In the simplest implementation, this can be accomplished by having a mixture of target-specific primers that contain a universal primer tail and competing primers that lack the 5' universal primer tail. After the first primer extension, only primers with the 5' universal primer sequence can be amplified. The ratio of primers with and without the universal primer sequence controls the proportion of targets that are amplified. In other embodiments, the inclusion of hybridizing but non-extendable primers can be used to modulate the proportion of library elements that undergo primer extension, ligation, or amplification.

[0186] Target enrichment methods can also be used in a negative selection mode to selectively remove extended nucleic acids from a library prior to sequencing. Examples of undesired extended nucleic acids that can be removed are those that represent overabundant polypeptide species, e.g., for proteins, albumins, immunoglobulins, etc.

[0187] Competitive oligonucleotide baits that hybridize to the target but lack a biotin moiety can also be used in the hybrid capture step to modulate the fraction of a particular locus enriched. The competitive oligonucleotide bait competes for hybridization to the target with a standard biotinylated bait, effectively modulating the proportion of the target pulled down during enrichment. The 10-order dynamic range of protein expression can be compressed by several orders of magnitude using this competitive inhibition approach, especially for overabundant species such as albumin. Thus, compared to standard hybrid capture, the fraction of library elements captured for a particular locus can be adjusted downward from 100% to 0% enrichment.

[0188] Additionally, library canonicalization techniques can be used to remove overabundant species from extended nucleic acid libraries. This approach is optimal for libraries of defined length derived from peptides generated by site-specific protease digestion such as trypsin, LysC, GluC, etc. In one example, canonicalization can be achieved by denaturing the double-stranded library and allowing the library elements to reanneal. Due to the second-order rate constant of bimolecular hybridization kinetics, abundant library elements reanneal more rapidly than less abundant elements (Bochman, Paeschke et al. 2012). The ssDNA library elements can be separated from the abundant dsDNA library elements using methods known in the art, such as chromatography on a hydroxyapatite column (VanderNoot, et al., 2012, Biotechniques 53:373-380), or treatment of the library with dual-specific nuclease (DSN) from king crab (Shagin et al., (2002) Genome Res. 12:1935-42), which destroys the dsDNA library elements.

[0189] Any combination of fractionation, enrichment, and subtraction methods of the polypeptides and / or the resulting extended nucleic acid library prior to attachment to the solid support can conserve sequencing reads and improve measurement of less abundant species.

[0190] In some embodiments, libraries of nucleic acids (e.g., extended nucleic acids) are linked by ligation or end-complementary PCR to create long DNA molecules each containing multiple different extended recorder tags, extended coding tags, or ditags (Du et al., (2003) BioTechniques 35:66-72; Muecke et al., (2008) Structure 16:837-841; U.S. Patent No. 5,834,252, each of which is incorporated by reference in its entirety). This embodiment is preferred for nanopore sequencing, where long strands of DNA are analyzed by a nanopore sequencing device.

[0191] In some embodiments, direct single molecule analysis is performed on the nucleic acid (e.g., extended nucleic acid) (see, e.g., Harris et al., (2008) Science 320:106-109). The nucleic acid (e.g., extended nucleic acid) can be analyzed directly on a solid support such as a flow cell or a bead (optionally microcell patterned) compatible for loading onto the flow cell surface, and the flow cell or bead can be integrated with a single molecule sequencer or single molecule decoding instrument. For single molecule decoding, pooled fluorescently labeled rounds of hybridization of decoding oligonucleotides (Gunderson et al., (2004) Genome Res. 14:970-7) can be used to confirm both the identity and order of the coding tags within the extended nucleic acid (e.g., on the bait or capture nucleic acid). In some embodiments, the binders can be labeled with cycle-specific coding tags as described above (see also Gunderson et al., (2004) Genome Res. 14:970-7). Cycle-specific coding tags will function both on a single linked extended nucleic acid representing a single polypeptide, or on a collection of extended nucleic acids representing a single polypeptide.

[0192] Following sequencing of the nucleic acid library (e.g., of the extended nucleic acid), the resulting sequences are folded by UMI, then associated with their corresponding polypeptides and aligned to the entire proteome. The resulting sequences can also be folded by their compartment tags and associated with their corresponding compartment proteomes, which in certain embodiments only contain a single or a very limited number of protein molecules. Both protein identification and quantification can be easily derived from this digital peptide information.

[0193] In some embodiments, the coding tag sequence can be optimized for a particular sequencing analysis platform. In certain embodiments, the sequencing platform is nanopore sequencing. In some embodiments, the sequencing platform has an error rate per base of >1%, >5%, >10%, >15%, >20%, >25%, or >30%. For example, when using a nanopore sequencing instrument to analyze elongated nucleic acids, barcode sequences (e.g., sequences that contain identifying information from the coding tag) can be designed to be optimally electrically distinguishable when passing through the nanopore. Furthermore, a technique called duplex interrupted nanopore sequencing (DI) can be used in nanopore strand sequencing without the need for molecular motors, greatly simplifying system design (Derrington et al., Proc Natl Acad Sci USA (2010) 107(37):16060-16065). The readout of the extended nucleic acid by DI nanopore sequencing requires annealing the spacer elements of the linked extended nucleic acid library with complementary oligonucleotides. The oligonucleotides used herein may contain LNA, or other modified nucleic acids or analogs to increase the effective Tm of the resulting duplex. When single-stranded extended nucleic acids decorated with these duplex spacer regions pass through the pore, the duplex region temporarily stalls in the constriction zone, allowing for current readout of approximately three bases adjacent to the duplex region. In a particular embodiment of DI nanopore sequencing, the encoder sequence containing the identification information from the coding tag is designed such that the three bases adjacent to the spacer element create a maximally electrically distinguishable nanopore signal (Derrington et al., Proc Natl Acad Sci USA (2010) 107 (37): 16060-16065).As an alternative to motor-free DI sequencing, spacer elements can be designed to adopt secondary structures, such as G-quartets, that would temporarily stall the extending nucleic acid as it passes through the nanopore allowing readout of the adjacent encoder sequence (Shim et al., Nucleic Acids Res (2009) 37(3):972-982; Zhang et al., mAbs (2016) 8, 524-535). After passing the stall, the next spacer would again create a temporary stall, allowing readout of the next encoder sequence, and so on.

[0194] The methods disclosed herein can be used for analysis, including detection, identification, quantification, and / or sequencing of multiple polypeptide analytes simultaneously (multiplexing). Multiplexing, as used herein, refers to the analysis of multiple polypeptides in the same assay. The multiple polypeptides can be from the same sample or different samples. The multiple polypeptides can be from the same subject or different subjects. The multiple polypeptides analyzed can be different polypeptides or the same polypeptide from different samples. The multiple polypeptides include 2 or more polypeptides, 5 or more polypeptides, 10 or more polypeptides, 50 or more polypeptides, 100 or more polypeptides, 500 or more polypeptides, 1000 or more polypeptides, 5,000 or more polypeptides, 10,000 or more polypeptides, 50,000 or more polypeptides, 100,000 or more polypeptides, 500,000 or more polypeptides, or 1,000,000 or more polypeptides.

[0195] Multiplexing of samples can be achieved by prior barcoding of nucleic acids (e.g., bait or capture nucleic acids) associated with the polypeptide samples. Each barcode represents a different sample, and samples can be pooled prior to cyclic binding assays or sequence analysis. In some embodiments, polypeptides immobilized on the same bead are barcoded with bead barcodes. For example, the capture nucleic acid may contain a bead barcode that allows samples with different bead barcodes to be combined and processed for some or all steps of the protein analysis assay. In this way, many barcode-labeled samples can be processed simultaneously in a single tube. This approach is a significant improvement over immunoassays performed on reverse-phase protein arrays (RPPA) (Akbani et al., Mol Cell Proteomics (2014) 13(7):1625-1643; Creighton et al., Drug Des Devel Ther (2015) 9:3519-3527; Nishizuka et al., Drug Metab Pharmacokinet (2016) 31(1):35-45). Thus, the present disclosure essentially provides a highly digitized sample- and analyte-multiplexed alternative to RPPA assays with a simple workflow.

[0196] III. KITS, COMPONENTS, AND ARTICLES OF MANUFACTURE Provided herein are kits and articles of manufacture that include components for processing or preparing analytes. In some embodiments, the kits include a plurality of bait nucleic acids configured to attach to an analyte, and a solid support that includes a plurality of attached capture nucleic acids, each of the capture nucleic acids including a sequence complementary to a corresponding bait nucleic acid, and any adjacently attached capture nucleic acids are spaced apart on the solid support by an average distance of about 50 nm or more. In some embodiments, the kits also include instructions for using the components for preparing and processing the analytes. In some embodiments, the kits provided herein are for use in processing analytes including peptides, polypeptides, and proteins for sequencing and / or analysis. In some embodiments, the kits provided herein are for preparing analytes for protein analysis using barcoding and nucleic acid encoding of molecular recognition events and / or detectable labels. In some embodiments, the kits also include other components for processing and analyzing polypeptides, and other reagents for polypeptide analysis.

[0197] In one aspect, provided herein are components used to prepare a reaction mixture. In preferred embodiments, the reaction mixture is a solution. In some preferred embodiments, the reaction mixture includes one or more of the following: a capture nucleic acid (e.g., attached to a solid or insoluble support) and a bait nucleic acid. In some embodiments, the kit is for preparing multiple analytes obtained from a sample, such as any of the samples described in Section IA. In some embodiments, the capture nucleic acid is provided on a solid support in a format compatible for performing a ProteoCode assay.

[0198] In some of any of the provided embodiments, the kit comprises a plurality of bait nucleic acids and a plurality of capture nucleic acids. In some embodiments, the kit comprises any of the bait nucleic acids described in Section I. In some embodiments, the bait nucleic acid is configured to allow an analyte to attach to the 3' end of the bait nucleic acid. In some embodiments, the bait nucleic acid is configured to allow an analyte to attach to the 5' end of the bait nucleic acid. In some cases, the bait nucleic acid is configured to allow an analyte to attach to an internal position of the bait nucleic acid. In some embodiments, the bait nucleic acid comprises a reactive coupling moiety. In some instances, the reactive coupling moiety is activated by application of light energy, a chemical reagent, or an enzymatic reagent.

[0199] In some embodiments, the kit includes any of the capture nucleic acids described in Section I. In some embodiments, the capture nucleic acid is provided on a solid support. In some embodiments, the capture nucleic acid includes one or more components for downstream sequencing, including a universal priming site and / or an adapter sequence. The capture nucleic acid can be provided in a format that allows for a desired spacing of the analytes, e.g., analytes in the form of a nucleic acid-analyte chimera, on the solid support. In some embodiments of the kit, the concentration of the capture nucleic acid can be titrated on the substrate surface. For example, the capture nucleic acid is configured to couple the analytes to the solid support such that any adjacently coupled analytes, e.g., analytes in the form of a nucleic acid-analyte chimera, are spaced apart from each other on the solid support by an average distance of 60 nm or more, 70 nm or more, 80 nm or more, 90 nm or more, 100 nm or more, 200 nm or more, 300 nm or more, 400 nm or more, 500 nm or more, or 1000 nm or more. In some cases, the capture nucleic acid may be such that any adjacently coupled analyte, e.g., an analyte in the form of a nucleic acid-analyte chimera, is about 50-100 nm, about 50-250 nm, about 50-500 nm, about 50-750 nm, about 50-1000 nm, about 50-1500 nm, about 50-2000 nm, about 100-250 nm, about 100-500 nm, about 200-500 nm, about 300-500 nm, about The capture nucleic acid is configured to couple the analytes to the solid support such that they are spaced apart from one another on the solid support at an average distance in the range of about 100-1000 nm, about 500-600 nm, about 500-700 nm, about 500-800 nm, about 500-900 nm, about 500-1000 nm, about 500-2000 nm, about 500-5000 nm, about 1000-5000 nm, or about 3000-5000 nm. In some preferred embodiments, the capture nucleic acid is configured to couple the analytes to the solid support such that any adjacently coupled analytes, e.g., analytes in the form of nucleic acid-analyte chimeras, are spaced apart from one another on the solid support at an average distance in the range of about 50-500 nm.

[0200] In some embodiments, any adjacently coupled capture nucleic acids are spaced apart from one another on the surface or within the volume of a solid support (e.g., a porous support) by a distance of about 50 nm to about 500 nm, or about 50 nm to about 400 nm, or about 50 nm to about 300 nm, or about 50 nm to about 200 nm, or about 50 nm to about 100 nm. In some embodiments, any adjacently coupled analytes, e.g., analytes in the form of nucleic acid-analyte chimeras, are spaced apart from one another on the surface of a solid support by an average distance of at least 50 nm, at least 60 nm, at least 70 nm, at least 80 nm, at least 90 nm, at least 100 nm, at least 150 nm, at least 200 nm, at least 250 nm, at least 300 nm, at least 350 nm, at least 400 nm, at least 450 nm, or at least 500 nm. In some embodiments, any adjacently coupled analytes, eg, analytes in the form of nucleic acid-analyte chimeras, are spaced from one another on the surface of the solid support by an average distance of at least 50 nm.

[0201] In some embodiments, the kit comprises a substrate or solid support to which the capture nucleic acid is attached. The solid support may be selected from the group consisting of beads, porous beads, magnetic beads, paramagnetic beads, porous matrices, arrays, surfaces, glass surfaces, silicon surfaces, plastic surfaces, slides, filters, nylon, chips, silicon wafer chips, flow-through chips, biochips with signal transduction electronics, wells, microtiter wells, plates, ELISA plates, disks, rotating interferometric disks, membranes, PTFE membranes, nitrocellulose membranes, nitrocellulose-based polymer surfaces, nanoparticles (e.g., including metals such as magnetic nanoparticles (Fe3O4), gold nanoparticles, and / or silver nanoparticles), quantum dots, nanoshells, nanocages, microspheres, and any combination thereof. In some embodiments, the kit comprises a plurality of substrates. In some cases, the surface of the solid support comprises a reactive coupling moiety. In some embodiments, the capture nucleic acid comprises a reactive coupling moiety.

[0202] In some embodiments, the kit and the article of manufacture further comprise a plurality of barcodes. The barcode may comprise a compartment barcode, a partition barcode, a sample barcode, a fraction barcode, or any combination thereof. In some cases, the barcode comprises a unique molecular identifier (UMI). In some examples, the barcode comprises a DNA molecule, a DNA with a pseudo-complementary base, an RNA molecule, a BNA molecule, an XNA molecule, an LNA molecule, a PNA molecule, a γPNA molecule, a non-nucleic acid sequenceable polymer, such as a polysaccharide, a polypeptide, a peptide, or a polyamide, or a combination thereof.

[0203] In some embodiments, the barcodes in the kit are attached to the bait nucleic acid and / or to the capture nucleic acid. In some embodiments, the barcodes in the kit are attached to a capture nucleic acid attached to a solid support (e.g., beads). In some cases, the barcodes are configured to be attached to the bait nucleic acid or the capture nucleic acid. In certain embodiments, each population of nucleic acid species is in a separate container. For example, the barcodes are provided in individual containers, where each container holds a plurality of barcodes that are the same. The barcodes can also be provided in any suitable material or structure with compartments such that the various barcodes are spatially separated from one another. For example, a microplate is used to provide 96 barcodes, where each well contains a plurality of the same barcode. Any suitable container for providing barcodes can be used, including, but not limited to, microplates with 6, 24, 96, 384, 1536, 3456, or 9600 wells. In some embodiments, the kits and articles of manufacture further include a plurality of UMIs (e.g., polynucleotides that contain UMIs).

[0204] In some embodiments, the kits and articles of manufacture further comprise a coupling reagent. For example, the coupling reagent can be an enzyme or a chemical coupling reagent. The reagent can be used to attach a bait nucleic acid to a capture nucleic acid, to attach a bait nucleic acid to a solid support, to attach an analyte to a bait nucleic acid, and / or to attach any two or more nucleic acid components. The kits may further comprise any associated components necessary to activate the coupling reagent. In some particular embodiments, the kits further comprise a ligase.

[0205] In some embodiments, the kit further comprises a reagent for processing the analyte. Any combination of analyte fractionation, enrichment, and subtraction methods can be performed. For example, the reagent can be used to fragment or digest the analyte. In some cases, the kit comprises reagents and components for fractionation, isolation, subtraction, and enrichment of the analyte. In some examples, the kit further comprises a protease, such as trypsin, LysN, or LysC.

[0206] In some embodiments, the kit also includes one or more buffers or reaction fluids necessary for any of the desired reactions to occur. Buffers, including wash buffers, reaction buffers, and binding buffers, elution buffers, and the like, are known to those of skill in the art. In some embodiments, the kit further includes buffers and other components that accompany the other reagents described herein. The reagents, buffers, and other components may be provided in vials (such as sealed vials), containers, ampoules, bottles, jars, flexible packaging (e.g., sealed Mylar or plastic bags), and the like. Any of the kit components may be sterilized and / or sealed.

[0207] In some embodiments, the kit comprises one or more reagents for nucleic acid sequence analysis.In some examples, the reagents for sequence analysis are for use in sequencing by synthesis, sequencing by ligation, sequencing by hybridization, polony sequencing, ion semiconductor sequencing, pyrosequencing, single molecule real-time sequencing, nanopore-based sequencing, or direct imaging of DNA using advanced microscopy, or any combination thereof.

[0208] In some embodiments, the kit or article of manufacture may further include instructions for the methods and uses described herein. In some embodiments, the instructions are directed to methods for preparing and processing the polypeptide. The kits described herein may also include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, syringes, and inserts with instructions for carrying out any of the methods described herein.

[0209] Any of the above-mentioned kit components, as well as any molecules, molecular complexes or conjugates, reagents (e.g., chemical or biological reagents), agents, structures (e.g., supports, surfaces, particles, or beads), reaction intermediates, reaction products, binding complexes, or any other articles of manufacture disclosed and / or used in the exemplary kits and methods, may be provided separately or in any suitable combination to form a kit.

[0210] IV. Illustrative Embodiments Among the embodiments provided are the following: 1. A method for processing an analyte, comprising: attaching the analyte to a bait nucleic acid to generate a nucleic acid-analyte chimera; bringing the nucleic acid-analyte chimera into proximity with a solid support by hybridizing a bait nucleic acid in the nucleic acid-analyte chimera to a capture nucleic acid attached to the solid support; covalently coupling the nucleic acid-analyte chimera to a solid support; A method wherein a plurality of nucleic acid-analyte chimeras are coupled on a solid support, such that any adjacently coupled nucleic acid-analyte chimeras are separated from one another by an average distance of about 50 nm or more. 2. The method of embodiment 1, wherein the analyte is attached to the 3' end of the bait nucleic acid. 3. The method of embodiment 1, wherein the analyte is attached to the 5' end of the bait nucleic acid. 4. The method of embodiment 1, wherein the analyte is attached to an internal position of the bait nucleic acid. 5. The method of any one of embodiments 1-4, wherein any adjacently coupled nucleic acid-analyte chimeras are separated by an average distance of about 60 nm or more, 70 nm or more, 80 nm or more, 90 nm or more, 100 nm or more, 200 nm or more, 300 nm or more, 400 nm or more, 500 nm or more, or 1000 nm or more. 6. Any adjacently coupled nucleic acid-analyte chimera may be about 50-100 nm, about 50-250 nm, about 50-500 nm, about 50-750 nm, about 50-1000 nm, about 50-1500 nm, about 50-2000 nm, about 100-250 nm, about 100-500 nm, about 200-500 nm, about 300-500 nm, about 100- The method according to any one of the preceding embodiments, wherein the nanoparticles are spaced apart by an average distance in the range of 1000 nm, about 500-600 nm, about 500-700 nm, about 500-800 nm, about 500-900 nm, about 500-1000 nm, about 500-2000 nm, about 500-5000 nm, about 1000-5000 nm, or about 3000-5000 nm. 7. The method of any one of embodiments 1-4, wherein any adjacently coupled nucleic acid-analyte chimeras are separated by an average distance in the range of about 50-500 nm. 8. The method of any one of the preceding claims, wherein the capture nucleic acid, the nucleic acid-analyte chimera, and / or the bait nucleic acid further comprises a barcode. 9. The method of any one of embodiments 1 to 8, further comprising attaching a barcode to the coupled nucleic acid-analyte chimera. 10. The method of embodiment 8 or embodiment 9, wherein the barcode comprises a compartment barcode, a partition barcode, a sample barcode, a fraction barcode, or any combination thereof. 11. The method of any one of embodiments 8 to 10, wherein the barcode comprises a unique molecular identifier (UMI). 12. The method of any one of the preceding claims, wherein the capture nucleic acid, the nucleic acid-analyte chimera, the bait nucleic acid, and / or the coupled nucleic acid-analyte chimera further comprises a unique molecular identifier (UMI). 13. The method of any one of embodiments 9 to 12, wherein the barcode comprises a DNA molecule, a DNA with pseudo-complementary bases, an RNA molecule, a BNA molecule, an XNA molecule, an LNA molecule, a PNA molecule, a γPNA molecule, a non-nucleic acid sequenceable polymer, such as a polysaccharide, a polypeptide, a peptide, or a polyamide, or a combination thereof. 14. The method of any one of embodiments 1 to 13, wherein the nucleic acid-analyte chimera is directly or indirectly covalently coupled to a solid support. 15. The method of any one of the preceding embodiments, wherein the bait nucleic acid is covalently coupled to the capture nucleic acid. 16. The method of embodiment 15, wherein the covalent coupling is carried out using a ligation reagent. 17. The method of embodiment 15 or embodiment 16, wherein the 5' end of the bait nucleic acid is coupled to the 3' end of the capture nucleic acid. 18. The method of embodiment 15 or embodiment 16, wherein the 3' end of the bait nucleic acid is coupled to the 5' end of the capture nucleic acid. 19. The method of any one of embodiments 1-18, wherein the capture nucleic acid comprises a nucleic acid hairpin. 20. The method of any one of embodiments 1 to 19, wherein the capture nucleic acid comprises a splint nucleic acid. 21. The method of embodiment 20, wherein the splint nucleic acid comprises a sequence complementary to the capture nucleic acid and / or the bait nucleic acid. 22. The method of any one of the preceding embodiments, wherein the capture nucleic acid comprises a reactive coupling moiety. 23. The method of embodiment 22, wherein the capture nucleic acid is attached to the solid support via a reactive coupling moiety. 24. The method of embodiment 22, wherein the capture nucleic acid is attached to the bait nucleic acid via a reactive coupling moiety. 25. The method of any one of embodiments 1 to 24, wherein the analyte is obtained from a biological sample. 26. The method of any one of embodiments 1 to 25, wherein hybridization of the bait nucleic acid to the capture nucleic acid comprises hybridization of 8 or more complementary bases, 16 or more complementary bases, 24 or more complementary bases, 34 or more complementary bases. 27. The method of any one of embodiments 1 to 26, wherein hybridization of the bait nucleic acid to the capture nucleic acid comprises hybridization of 18 or more complementary bases. 28. The method of any one of the preceding embodiments, wherein the analyte is a polypeptide. 29. The method of embodiment 28, wherein the analyte is a protein or peptide. 30. The method of embodiment 29, wherein the peptide is obtained by fragmenting a protein, e.g. a protein from a biological sample. 31. The method of embodiment 30, wherein fragmentation is carried out by contacting the protein with a protease. 32. The method of embodiment 31, wherein the protease is trypsin, LysN, or LysC. 33. The method of any one of embodiments 1-32, wherein the analyte comprises analytes from a plurality of pooled samples. 34. The method of any one of the preceding embodiments, wherein the analyte and / or the bait nucleic acid comprises a reactive coupling moiety. 35. The method of any one of embodiments 1 to 34, wherein the analyte is attached to the bait nucleic acid using chemical ligation. 36. The method of any one of embodiments 1 to 35, wherein the analyte is directly or indirectly attached to the bait nucleic acid. 37. After coupling the nucleic acid-analyte chimera to a solid support, The 5' end of the bait nucleic acid is available for reaction. The 5' end of the capture nucleic acid is available for reaction; the 3' end of the bait nucleic acid is available for reaction, and / or 37. The method of any one of embodiments 1 to 36, wherein the 3' end of the capture nucleic acid is available for reaction. 38. The method of embodiment 37, wherein the nucleic acid is available for an extension reaction, such as a PCR extension reaction, and / or a ligation reaction. 39. The method of any one of embodiments 1 to 38, wherein the bait nucleic acid and / or the capture nucleic acid further comprises a spacer polymer. 40. The method of embodiment 39, wherein the spacer polymer comprises at least 1 nucleotide, at least 2 nucleotides, at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 15 nucleotides, or at least 20 nucleotides or more. 41. The method of embodiment 39 and embodiment 40, wherein the spacer polymer comprises a DNA molecule, a DNA with pseudocomplementary bases, an RNA molecule, a BNA molecule, an XNA molecule, an LNA molecule, a PNA molecule, a γPNA molecule, a non-nucleic acid sequenceable polymer, such as a polysaccharide, a polypeptide, a peptide, or a polyamide, or a combination thereof. 42. The method of any one of embodiments 39 to 41, wherein the bait nucleic acid comprises a spacer polymer at its 5'-end and / or 3'-end. 43. The method of any one of embodiments 39 to 41, wherein the capture nucleic acid comprises a spacer polymer at its 5'-end and / or 3'-end. 44. The method of any one of embodiments 1 to 43, wherein the bait nucleic acid and / or the capture nucleic acid further comprises a universal priming site. 45. The method of embodiment 44, wherein the universal priming site comprises priming sites for amplification, sequencing, or both. 46. ​​The method of any one of embodiments 1 to 45, wherein the capture nucleic acid comprises an adapter nucleic acid sequence for use in sequencing. 47. The method of embodiment 46, wherein the adapter nucleic acid sequence is for use with an Illumina sequencing platform or a Pacific Biosciences of California sequencing platform. 48. The method of any one of embodiments 1 to 47, wherein the solid support is a bead, a porous bead, a porous matrix, an array, a glass surface, a silicon surface, a plastic surface, a filter, a membrane, nylon, a PTFE membrane, nylon, a silicon wafer chip, a flow-through chip, a biochip containing signal transduction electronics, a microtiter well, an ELISA plate, a rotating interferometer disk, a nitrocellulose membrane, a nitrocellulose-based polymer surface, a nanoparticle, or a microsphere. 49. The method of embodiment 48, wherein the solid support comprises polystyrene beads, polyacrylate beads, polymeric beads, agarose beads, cellulose beads, dextran beads, acrylamide beads, solid core beads, porous beads, paramagnetic beads, glass beads, controlled porosity beads, silica-based beads, or any combination thereof. 50. contacting the analyte with a binding agent capable of binding to the analyte, the binding agent comprising a coding tag having identifying information regarding the binding agent; 50. The method of any one of the preceding claims, further comprising transferring the identity of the coding tag to a bait or capture nucleic acid. 51. contacting the analyte with an additional binding agent capable of binding to the analyte, the additional binding agent comprising a coding tag having identifying information regarding the additional binding agent; 51. The method of embodiment 50, further comprising transferring the identity of the coding tag for the additional binding agent to the bait or capture nucleic acid, and repeating this one or more times. 52. The method according to embodiment 50 or embodiment 51, wherein the transfer of the identification information of the coding tag to the bait or capture nucleic acid is mediated by DNA ligase. 53. The method according to embodiment 50 or embodiment 51, wherein the transfer of the identification information of the coding tag to the bait or capture nucleic acid is mediated by a DNA polymerase. 54. The method according to embodiment 50 or embodiment 51, wherein the transfer of the identification information of the coding tag to the bait or capture nucleic acid is mediated by chemical ligation. 55. The method of any one of embodiments 50 to 54, wherein the coding tag further comprises a spacer, a binding cycle specific sequence, a unique molecular identifier, a universal priming site, or any combination thereof. 56. attaching the analyte to a bait nucleic acid to generate a nucleic acid-analyte chimera; bringing the nucleic acid-analyte chimera into proximity with a solid support by hybridizing a bait nucleic acid in the nucleic acid-analyte chimera to a capture nucleic acid attached to the solid support; and A nucleic acid-analyte conjugate produced by covalently coupling the nucleic acid-analyte chimera to a solid support, A nucleic acid-analyte conjugate, wherein a plurality of nucleic acid-analyte chimeras are coupled on a solid support, such that any adjacently coupled nucleic acid-analyte chimeras are separated by an average distance of about 50 nm or more. 57. The nucleic acid-analyte conjugate of embodiment 56, wherein the analyte is attached to the 3' end of the bait nucleic acid. 58. The nucleic acid-analyte conjugate of embodiment 56, wherein the analyte is attached to the 5' end of the bait nucleic acid. 59. The nucleic acid-analyte conjugate of embodiment 56, wherein the analyte is attached to an internal position of the bait nucleic acid. 60. The nucleic acid-analyte conjugate of any one of embodiments 56-59, wherein any adjacently coupled nucleic acid-analyte chimeras are separated by an average distance of about 60 nm or more, 70 nm or more, 80 nm or more, 90 nm or more, 100 nm or more, 200 nm or more, 300 nm or more, 400 nm or more, 500 nm or more, or 1000 nm or more. 61. Any adjacently coupled nucleic acid-analyte chimera may have a diameter of about 50-100 nm, about 50-250 nm, about 50-500 nm, about 50-750 nm, about 50-1000 nm, about 50-1500 nm, about 50-2000 nm, about 100-250 nm, about 100-500 nm, about 200-500 nm, about 300-500 nm, about 100-1000 nm 61. The nucleic acid-analyte conjugate of any one of embodiments 56-60, wherein the conjugates are spaced apart by an average distance in the range of about 500-600 nm, about 500-700 nm, about 500-800 nm, about 500-900 nm, about 500-1000 nm, about 500-2000 nm, about 500-5000 nm, about 1000-5000 nm, or about 3000-5000 nm. 62. A nucleic acid-analyte conjugate according to any one of embodiments 56 to 61, wherein any adjacently coupled nucleic acid-analyte chimeras are separated by an average distance in the range of about 50 to 500 nm. 63. The nucleic acid-analyte conjugate of any one of embodiments 56 to 62, wherein the capture nucleic acid, the nucleic acid-analyte chimera, and / or the bait nucleic acid further comprises a barcode. 64. The nucleic acid-analyte conjugate of any one of embodiments 56 to 63, wherein the coupled nucleic acid-analyte chimera further comprises a barcode. 65. The nucleic acid-analyte conjugate of embodiment 64, wherein the barcode comprises a compartment barcode, a partition barcode, a sample barcode, a fraction barcode, or any combination thereof. 66. A nucleic acid-analyte conjugate according to any one of embodiments 62 to 64, wherein the barcode comprises a unique molecular identifier (UMI). 67. The nucleic acid-analyte conjugate of any one of embodiments 56 to 66, wherein the capture nucleic acid, the nucleic acid-analyte chimera, the bait nucleic acid, and / or the coupled nucleic acid-analyte chimera further comprises a unique molecular identifier (UMI). 68. A nucleic acid-analyte conjugate according to any one of embodiments 64 to 67, wherein the barcode comprises a DNA molecule, a DNA with pseudo-complementary bases, an RNA molecule, a BNA molecule, an XNA molecule, an LNA molecule, a PNA molecule, a γPNA molecule, a non-nucleic acid sequenceable polymer, such as a polysaccharide, a polypeptide, a peptide, or a polyamide, or a combination thereof. 69. A nucleic acid-analyte conjugate according to any one of embodiments 56 to 68, wherein the nucleic acid-analyte chimera is directly or indirectly covalently coupled to a solid support. 70. The nucleic acid-analyte conjugate according to any one of embodiments 56 to 69, wherein the bait nucleic acid is covalently coupled to the capture nucleic acid. 71. The nucleic acid-analyte conjugate according to embodiment 70, wherein the covalent coupling is carried out using a ligation reagent. 72. The nucleic acid-analyte conjugate according to embodiment 70 or embodiment 71, wherein the 5' end of the bait nucleic acid is coupled to the 3' end of the capture nucleic acid. 73. The nucleic acid-analyte conjugate according to embodiment 70 or embodiment 71, wherein the 3' end of the bait nucleic acid is coupled to the 5' end of the capture nucleic acid. 74. The nucleic acid-analyte conjugate of any one of embodiments 56 to 73, wherein the capture nucleic acid comprises a nucleic acid hairpin. 75. The nucleic acid-analyte conjugate of any one of embodiments 56 to 74, wherein the capture nucleic acid comprises a splint nucleic acid. 76. The nucleic acid-analyte conjugate of embodiment 75, wherein the splint nucleic acid comprises a sequence complementary to the capture nucleic acid and / or the bait nucleic acid. 77. The nucleic acid-analyte conjugate of any one of embodiments 56 to 76, wherein the capture nucleic acid comprises a reactive coupling moiety. 78. The nucleic acid-analyte conjugate of embodiment 77, wherein the capture nucleic acid is attached to the solid support via a reactive coupling moiety. 79. The nucleic acid-analyte conjugate of embodiment 77, wherein the capture nucleic acid is attached to the bait nucleic acid via a reactive coupling moiety. 80. The nucleic acid-analyte conjugate of any one of embodiments 56 to 79, wherein the analyte is obtained from a biological sample. 81. The nucleic acid-analyte conjugate of any one of embodiments 56 to 80, wherein hybridization of the bait nucleic acid to the capture nucleic acid comprises hybridization of 8 or more complementary bases, 16 or more complementary bases, 24 or more complementary bases, 34 or more complementary bases. 82. The nucleic acid-analyte conjugate of any one of embodiments 56 to 80, wherein hybridization of the bait nucleic acid to the capture nucleic acid comprises hybridization of 16 or more complementary bases. 83. The nucleic acid-analyte conjugate according to any one of embodiments 56 to 82, wherein the analyte is a polypeptide. 84. The nucleic acid-analyte conjugate of embodiment 82, wherein the analyte is a protein or peptide. 85. The nucleic acid-analyte conjugate of embodiment 84, wherein the peptide is obtained by fragmenting a protein, e.g. a protein from a biological sample. 86. The nucleic acid-analyte conjugate of embodiment 85, wherein the fragmentation is carried out by contacting the protein with a protease. 87. The nucleic acid-analyte conjugate of embodiment 86, wherein the protease is trypsin, LysN, or LysC. 88. The nucleic acid-analyte conjugate of any one of embodiments 56 to 87, wherein the analyte comprises analytes from a plurality of pooled samples. 89. A nucleic acid-analyte conjugate according to any one of embodiments 56 to 88, wherein the analyte and / or the bait nucleic acid comprises a reactive coupling moiety. 90. A nucleic acid-analyte conjugate according to any one of embodiments 56 to 89, wherein the analyte is attached to the bait nucleic acid using chemical ligation. 91. A nucleic acid-analyte conjugate according to any one of embodiments 56 to 90, wherein the analyte is directly or indirectly attached to the bait nucleic acid. 92. After coupling the nucleic acid-analyte chimera to a solid support, The 5' end of the bait nucleic acid is available for reaction. The 5' end of the capture nucleic acid is available for reaction; the 3' end of the bait nucleic acid is available for reaction, and / or The nucleic acid-analyte conjugate of any one of embodiments 56-91, wherein the 3' end of the capture nucleic acid is available for reaction. 93. The nucleic acid-analyte conjugate of embodiment 92, wherein the nucleic acid is available for an extension reaction, such as a PCR extension reaction, and / or a ligation reaction. 94. The nucleic acid-analyte conjugate according to any one of embodiments 54 to 93, wherein the bait nucleic acid and / or the capture nucleic acid further comprises a spacer polymer. 95. The nucleic acid-analyte conjugate of embodiment 94, wherein the spacer polymer comprises at least 1 nucleotide, at least 2 nucleotides, at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 15 nucleotides, or at least 20 nucleotides or more. 96. The nucleic acid-analyte conjugate of embodiment 94 or embodiment 95, wherein the spacer polymer comprises a DNA molecule, a DNA with pseudo-complementary bases, an RNA molecule, a BNA molecule, an XNA molecule, an LNA molecule, a PNA molecule, a γPNA molecule, a non-nucleic acid sequenceable polymer, such as a polysaccharide, a polypeptide, a peptide, or a polyamide, or a combination thereof. 97. A nucleic acid-analyte conjugate according to any one of embodiments 94 to 96, wherein the bait nucleic acid comprises a spacer polymer at its 5'-end and / or 3'-end. 98. The nucleic acid-analyte conjugate according to any one of embodiments 94 to 96, wherein the capture nucleic acid comprises a spacer polymer at its 5'-end and / or 3'-end. 99. A nucleic acid-analyte conjugate according to any one of embodiments 56 to 98, wherein the bait nucleic acid and / or the capture nucleic acid further comprises a universal priming site. 100. The nucleic acid-analyte conjugate of embodiment 99, wherein the universal priming site comprises a priming site for amplification, sequencing, or both. 101. A nucleic acid-analyte conjugate according to any one of embodiments 56 to 100, wherein the capture nucleic acid comprises an adapter nucleic acid sequence for use in sequencing. 102. The nucleic acid-analyte conjugate of embodiment 101, wherein the adapter nucleic acid sequence is for use with an Illumina sequencing platform or a Pacific Biosciences of California sequencing platform. 103. The nucleic acid-analyte conjugate according to any one of embodiments 56 to 102, wherein the solid support is a bead, a porous bead, a porous matrix, an array, a glass surface, a silicon surface, a plastic surface, a filter, a membrane, a PTFE membrane, a nylon, a silicon wafer chip, a flow-through chip, a biochip comprising signal transduction electronics, a microtiter well, an ELISA plate, a rotating interferometer disk, a nitrocellulose membrane, a nitrocellulose-based polymer surface, a nanoparticle, or a microsphere. 104. The nucleic acid-analyte conjugate of embodiment 103, wherein the solid support comprises polystyrene beads, polyacrylate beads, polymer beads, agarose beads, cellulose beads, dextran beads, acrylamide beads, solid core beads, porous beads, paramagnetic beads, glass beads, controlled porosity beads, silica-based beads, or any combination thereof. 105. A kit comprising: (a) a plurality of bait nucleic acids, each of the bait nucleic acids configured to attach to an analyte; (b) a solid support comprising a plurality of attached capture nucleic acids, each of the capture nucleic acids comprising a sequence complementary to a corresponding bait nucleic acid, and any adjacently attached capture nucleic acids are separated on the solid support by an average distance of about 50 nm or more. 106. The kit of embodiment 105, wherein at least one of the bait nucleic acids is configured to allow attachment of the analyte to the 3' end of the bait nucleic acid. 107. The kit of embodiment 105, wherein at least one of the bait nucleic acids is configured to allow attachment of the analyte to the 5' end of the bait nucleic acid. 108. The kit of embodiment 105, wherein at least one of the bait nucleic acids is configured to allow attachment of the analyte to an internal location of the bait nucleic acid. 109. The kit of any one of embodiments 105 to 108, wherein any adjacently attached capture nucleic acids are configured to couple the analyte to the solid support at an average distance of about 60 nm or more, 70 nm or more, 80 nm or more, 90 nm or more, 100 nm or more, 200 nm or more, 300 nm or more, 400 nm or more, 500 nm or more, or 1000 nm or more on the solid support. 110. Any adjacently attached capture nucleic acid is about 50-100 nm, about 50-250 nm, about 50-500 nm, about 50-750 nm, about 50-1000 nm, about 50-1500 nm, about 50-2000 nm, about 100-250 nm, about 100-500 nm, about 200-500 nm, about 300-500 nm, about 100-1000 nm, about 500-600 nm on the solid support. 109. The kit according to any one of embodiments 105 to 109, wherein the kit is configured to couple the analyte to the solid support at an average distance in the range of about 500 to 700 nm, about 500 to 800 nm, about 500 to 900 nm, about 500 to 1000 nm, about 500 to 2000 nm, about 500 to 5000 nm, about 1000 to 5000 nm, or about 3000 to 5000 nm. 111. A kit according to any one of embodiments 105 to 109, wherein adjacently attached capture nucleic acids are spaced apart on the solid support by an average distance in the range of about 50 to 500 nm and configured to couple the analyte to the solid support. 112. The kit of any one of embodiments 105 to 111, further comprising a plurality of barcodes. 113. The barcode is attached to a bait or capture nucleic acid, or 113. The kit of embodiment 112, wherein the barcode is configured to be attached to a bait nucleic acid or a capture nucleic acid. 114. The kit of embodiment 112 or embodiment 113, wherein the barcode comprises a compartment barcode, a partition barcode, a sample barcode, a fraction barcode, or any combination thereof. 115. A kit according to any one of embodiments 112 to 114, wherein the barcode comprises a unique molecular identifier (UMI). 116. A kit according to any one of embodiments 105 to 115, wherein at least one of the capture nucleic acids and / or at least one of the bait nucleic acids further comprises a unique molecular identifier (UMI). 117. A kit according to any one of embodiments 109 to 116, wherein the barcode comprises a DNA molecule, a DNA with pseudo-complementary bases, an RNA molecule, a BNA molecule, an XNA molecule, an LNA molecule, a PNA molecule, a γPNA molecule, a non-nucleic acid sequenceable polymer, such as a polysaccharide, a polypeptide, a peptide, or a polyamide, or a combination thereof. 118. A kit according to any one of embodiments 105 to 117, wherein at least one of the bait nucleic acids comprises a reactive coupling moiety. 119. The kit according to any one of embodiments 105 to 118, wherein the surface of the solid support comprises a reactive coupling moiety. 120. A kit according to any one of embodiments 105 to 119, wherein at least one of the capture nucleic acids comprises a reactive coupling moiety. 121. A kit according to any one of embodiments 118 to 120, wherein the reactive coupling moiety is configured to be activated by application of light energy, a chemical reagent, or an enzymatic reagent. 122. The kit according to embodiment 121, wherein the enzyme reagent is a ligase. 123. The kit according to any one of embodiments 105 to 122, further comprising a coupling reagent. 124. The kit according to embodiment 123, wherein the coupling reagent is an enzymatic coupling reagent or a chemical coupling reagent. 125. The kit according to embodiment 124, wherein the enzymatic coupling reagent is a ligase. 126. The kit according to any one of embodiments 105 to 125, further comprising a protease. 127. The kit according to embodiment 126, wherein the protease is trypsin, LysN, or LysC. 128. The kit according to any one of embodiments 105 to 127, wherein at least one of the capture nucleic acids comprises a nucleic acid hairpin. 129. A kit according to any one of embodiments 105 to 128, wherein the capture nucleic acid comprises a splint nucleic acid. 130. The kit of embodiment 129, wherein the splint nucleic acid comprises a sequence complementary to the capture nucleic acid and / or the bait nucleic acid. 131. The kit according to any one of embodiments 105 to 130, wherein the complementary sequence of at least one of the bait nucleic acids to at least one of the capture nucleic acids comprises 8 or more complementary bases, 16 or more complementary bases, 24 or more complementary bases, 34 or more complementary bases. 132. The kit according to any one of embodiments 105 to 130, wherein the complementary sequence of at least one of the bait nucleic acids to at least one of the capture nucleic acids comprises 16 or more complementary bases. 133. The kit according to any one of embodiments 105 to 132, further comprising a chemical ligation reagent. 134. A kit according to any one of embodiments 105 to 133, wherein at least one of the bait nucleic acids and / or at least one of the capture nucleic acids further comprises a spacer polymer. 135. The kit of embodiment 134, wherein the spacer polymer comprises a DNA molecule, a DNA with pseudocomplementary bases, an RNA molecule, a BNA molecule, an XNA molecule, an LNA molecule, a PNA molecule, a γPNA molecule, a non-nucleic acid sequenceable polymer, such as a polysaccharide, a polypeptide, a peptide, or a polyamide, or a combination thereof. 136. A kit according to any one of embodiments 105 to 135, wherein at least one of the bait nucleic acids and / or at least one of the capture nucleic acids further comprises a universal priming site. 137. The kit of embodiment 136, wherein the universal priming site comprises priming sites for amplification, sequencing, or both. 138. A kit according to any one of embodiments 105 to 137, wherein the capture nucleic acid comprises an adapter nucleic acid sequence for use in sequencing. 139. The kit of embodiment 138, wherein the adapter nucleic acid sequence is for use with an Illumina sequencing platform or a Pacific Biosciences sequencing platform. 140. A kit according to any one of embodiments 134 to 139, wherein at least one of the bait nucleic acids comprises a spacer polymer at its 5'-end and / or 3'-end. 141. The kit according to any one of embodiments 134 to 140, wherein at least one of the capture nucleic acids comprises a spacer polymer at its 5'-end and / or 3'-end. 142. The kit according to any one of embodiments 105 to 141, wherein the solid support is a bead, a porous bead, a porous matrix, an array, a glass surface, a silicon surface, a plastic surface, a filter, a membrane, a PTFE membrane, a nylon, a silicon wafer chip, a flow-through chip, a biochip containing signal transduction electronics, a microtiter well, an ELISA plate, a rotating interferometer disk, a nitrocellulose membrane, a nitrocellulose-based polymer surface, a nanoparticle, or a microsphere. EXAMPLES

[0211] The following examples are provided to illustrate, but not limit, the methods, compositions, and uses provided herein.

[0212] Example 1: Evaluation of analyte immobilization using nucleic acid hybridization and coupling to a solid support This example describes an exemplary method for coupling a nucleic acid-peptide analyte chimera to a solid support and evaluation of an encoding assay using the immobilized analyte.

[0213] In the hybridization-based immobilization method, the nucleic acid-peptide chimera was hybridized and ligated to a hairpin capture DNA that was chemically immobilized on magnetic beads. The capture nucleic acid was conjugated to the beads using trans-cyclooctene (TCO) and methyltetrazine (mTet)-based click chemistry. A short hairpin capture nucleic acid (16-base pair stem, 5-base loop, 24-base 5' overhang) modified with TCO was reacted with mTet-coated magnetic beads. Phosphorylated nucleic acid-peptide chimera (10 nM) was annealed to the hairpin DNA attached to the beads in 5 × SSC, 0.02% SDS and incubated at 37 °C for 30 min. The beads were washed once with PBST and resuspended in 1 × Quick ligation solution (New England Biolabs, USA) containing T4 DNA ligase. After incubation at 25 °C for 30 min, the beads were washed twice with PBST and resuspended in 50 μL of PBST. Immobilized total nucleic acid-peptide chimeras, including amino FA terminal peptide (FAGVAMPGAEDDVVGSGSK, SEQ ID NO: 3), amino AFA terminal peptide (AFAGVAMPGAEDDVVGSGSK, SEQ ID NO: 4), and amino AA terminal peptide (AAGVAMPGAEDDVVGSGSK, SEQ ID NO: 5), were quantified by qPCR using specific primer sets. For comparison, a non-hybridization-based method without a ligation step was used to immobilize peptides on beads. The non-hybridization-based method was performed by incubating 30 μM TCO-modified DNA-tagged peptides, including amino FA terminal peptide, amino AFA terminal peptide, and amino AA terminal peptide, with mTet-coated magnetic beads overnight at 25 °C.

[0214] As shown in Table 1, similar Ct values ​​were observed for the non-hybridization preparation with a grafting density of 1:100,000 and the hybridization-based preparation with a grafting density of 1:10,000. The loading amount of DNA-tagged peptides for the hybridization-based preparation was 1 / 3000 compared to that for the non-hybridization preparation. In general, it was observed that less starting material was required for the hybridization-based immobilization method. [Table 1]

[0215] Furthermore, the peptides prepared and immobilized as described above were used for peptide sequencing using the ProteoCode assay. The peptides were immobilized on the substrate as described in the two methods above (hybridization and non-hybridization). Exemplary peptides tested in the assay include an amino FA terminal peptide (FAGVAMPGAEDDVVGSGSK, SEQ ID NO:3), an amino AFA terminal peptide (AFAGVAMPGAEDDVVGSGSK, SEQ ID NO:4), and an amino AA terminal peptide (AAGVAMPGAEDDVVGSGSK, SEQ ID NO:5). Oligonucleotides without peptides attached were also tested as controls.

[0216] An exemplary binder that binds to phenylalanine when phenylalanine is the N-terminal amino acid residue was conjugated to a coding tag (F binder). In the assay, the F binder conjugated to the coding tag was incubated with beads with immobilized nucleic acid-peptide chimeras for 30 minutes at 37°C. After PBST washing, the beads were incubated with an encoding mixture containing 50 mM Tris-HCl (pH 7.5), 2 mM MgSO4, 50 mM NaCl, 1 mM DTT, 0.1% Tween® 20, 0.1 mg / mL BSA, 0.125 mM dNTPs, 0.125 units / μL Klenow fragment (3'->5' exo-) (MCLAB, USA) for 5 minutes at 37°C. The beads were washed once with PBST + 10% formamide, once with 0.1 M NaOH, and once with PBST containing 10% formamide. The resulting beads were resuspended in PBST. After successful binding of the N-terminal amino acid of the tested peptide with the F-binder, the information of the coding tag was transferred to the nucleic acid attached to the immobilized peptide (extended recording tag). The extended recording tag of the assay was subjected to PCR amplification and analyzed by next-generation sequencing (NGS). [Table 2]

[0217] High encoding efficiency was observed for recording tags attached to amino FA-terminated peptides in both hybridization- and non-hybridization-based preparation methods, indicating that the information of the coding tag was transferred to the recording tag corresponding to the N-terminal F bond. Higher encoding efficiency of amino FA-terminated peptides was observed in samples prepared using the hybridization-based method compared to samples prepared using the non-hybridization method. Furthermore, lower encoding efficiency of AA and AFA negative control peptides was observed in samples prepared using the hybridization-based method. The signal-to-noise ratio (%FA encoding / %AA encoding) was 34 in samples prepared using the hybridization-based method.

[0218] Example 2: Evaluation of encoding functionality of analytes prepared and barcoded using various methods This example describes exemplary methods for coupling nucleic acid-analyte conjugates to a solid support, as well as various methods for attaching barcodes, UMIs, or other nucleic acid tags or moieties to the bait or capture nucleic acid. In this example, the formats tested for immobilizing peptide analytes included nucleic acid sequences selected from Table 3. [Table 3]

[0219] Five different methods for placing barcode sequences and immobilizing peptides were implemented and tested. In the methods described below, barcode sequences and spacer sequences were placed. In some cases, a unique molecular identifier (UMI) can be included in the bait or reverse bait nucleic acid or can be added together with the barcode. In some of the exemplary methods implemented, a universal priming site (or a part thereof) was included in the bait nucleic acid or the barcode sequence was added. In the methods described in this example, hybridization-based immobilization of peptides was carried out substantially as described in Example 1, except that in methods 1, 2, and 3, beads were washed three times after ligation (PBST, NaOH, and PBST).

[0220] In method 1, using the scheme generally depicted in Figure 3, an aminoFA peptide (FAGVAMPGAEDDVVGSGSK, SEQ ID NO: 3) was attached to a bait nucleic acid (SEQ ID NO: 6). Barcoding was performed at 37°C for 5 min in 50 μL of barcoding mixture containing 1× custom buffer (New England BioLabs, USA), 0.125 mM dNTPs, 1 μM bait nucleic acid-peptide chimera, 1.5 μM barcode template (CACTCAGTCCATTAACNNNNNNNNNNNCTAGTGTCGCGGACUACGCAUTACUGAGAACUTG, SEQ ID NO: 12), and 0.125 units / μL Klenow fragment (3'->5' exo-) (MCLAB, USA). The barcode templates each contained four dU sites. After the barcode was transferred to the bait nucleic acid (with peptide attached) by extension, the barcoded template was digested by incubation with 2.5 units of USER enzyme (New England BioLabs, USA) for 30 minutes at 37°C. EDTA was added to the reaction at 50 mM to quench the polymerase. The resulting barcoded bait nucleic acid (with peptide attached) was diluted to 10 nM for hybridization-based immobilization and attachment of the peptide to the capture nucleic acid (sequence set forth in SEQ ID NO:8).

[0221] In method 2, using the scheme generally shown in FIG. 4, an amino FA peptide (FAGVAMPGAEDDVVGSGSK, SEQ ID NO: 3) was attached to a bait nucleic acid (SEQ ID NO: 6). The bait nucleic acid-peptide chimera was loaded onto beads with attached capture nucleic acids. The capture nucleic acids on the beads contained a barcode template (CACTCAGTCCATTAACNNNNNNNNNNCTAGTGTCGCGGACUACGCATTACTGAGAAGCTTGCTAGTCGACGTGGTCCTT / iAmMC6T / TTGGACCACGTCGACTAG, SEQ ID NO: 9) at the 5' end of the capture nucleic acid. The barcode templates each contained one dU site. The bait nucleic acid-peptide chimera was attached to the capture nucleic acid using immobilization and coupling of a hybridized base. Barcoding was performed using bead extension using the barcode template at the 5' end of the capture nucleic acid. A 50 μL barcoding mixture containing 1× custom buffer (New England BioLabs, USA), 0.125 mM dNTPs, and 0.125 units / μL Klenow fragment (3'->5' exo-) (MCLAB, USA) was used and the reaction was incubated at 37°C for 5 min. After the barcode was transferred to the bait nucleic acid by extension, the beads were washed twice with PBST. The barcode template on the capture nucleic acid used for extension was digested by incubating with 2.5 units of USER enzyme (New England BioLabs, USA) for 30 min at 37°C. In this way, a Hind III restriction site was formed when extension occurred on a capture nucleic acid that did not have a bait nucleic acid-peptide chimera attached. 50 μL of restriction enzyme solution containing 1× custom buffer and 2.5 units of Hind III (New England BioLabs, USA) was added to the samples and incubated at 37° C. for 30 min to digest those captured nucleic acids that were barcoded but did not have a bait nucleic acid-peptide chimera attached. If a bait nucleic acid-peptide chimera was attached to the captured nucleic acid and barcoding occurred by extension to the bait nucleic acid, no Hind III sites would be formed. The resulting beads were washed once with PBST, once with 0.1 M NaOH, and once with PBST.

[0222] In method 3, using the scheme generally depicted in FIG. 5, an amino FA peptide (FAGVAMPGAEDDVVGSGSK, SEQ ID NO: 3) was attached to a bait nucleic acid (SEQ ID NO: 6). A splint DNA containing a sequence complementary to a portion of the bait nucleic acid and a portion of the barcode was used to crosslink the bait nucleic acid and the barcode via hybridization. Barcoding was performed at 25° C. for 5 min in 50 μL of barcoding mixture containing 1× Quick Ligase buffer (New England BioLabs, USA), 1.5 μM splint DNA (CCATTAACCTAGTGTCGC, SEQ ID NO: 14), 2 μM barcode ( / 5Phos / GTTAATGGACTGAGTG, SEQ ID NO: 15), 1 μM bait nucleic acid tagged peptide, and 2.5 units of Quick Ligase (New England BioLabs, USA). After the barcode was attached to the bait nucleic acid of the bait nucleic acid-peptide chimera, EDTA was added to the reaction at 50 mM to quench the ligase and the splint DNA was washed away with NaOH. The resulting barcoded bait nucleic acid-peptide chimera was diluted to 10 nM and attached to the capture nucleic acid (sequence set forth in SEQ ID NO:8) using a hybridization-based method.

[0223] In method 4, using the scheme generally depicted in Figure 6, an amino FA peptide (FAGVAMPGAEDDVVGSGSK, SEQ ID NO: 3) was attached to a bait nucleic acid (reverse, SEQ ID NO: 7). The bait nucleic acid-peptide chimera (10 nM) was mixed with 5 nM barcode ( / 5Phos / CAAGTTCTCAGTAATGCGTAGTCCGCGACACTAGNNNNNNNNNNGTTAATGGACTGAGTG, SEQ ID NO: 13) in 50 μL of annealing solution containing 5x SSC, 0.02% SDS and incubated with beads immobilized with phosphorylated capture nucleic acid (SEQ ID NO: 10) for 30 min at 37°C. The beads were washed once with PBST and resuspended in 1x Quick ligation solution containing T4 DNA ligase (New England BioLabs, USA) to ligate both the nucleic acid-peptide chimera and the barcode to the capture nucleic acid. After incubation at 25°C for 30 min, the beads were washed twice with PBST and resuspended in 50 μl of PBST.

[0224] In method 5, using the scheme generally depicted in FIG. 7, an amino FA peptide (FAGVAMPGAEDDVVGSGSK, SEQ ID NO: 3) was attached to a bait nucleic acid (reverse, SEQ ID NO: 7). The bait nucleic acid-peptide chimera (10 nM) was annealed to a phosphorylated capture nucleic acid containing a barcode sequence (SEQ ID NO: 11) immobilized on beads in 5×SSC, 0.02% SDS and incubated at 37° C. for 30 min. The beads were washed once with PBST and resuspended in 1×Quick ligation solution (New England BioLabs, USA) containing T4 DNA ligase to attach the bait nucleic acid-peptide chimera to the capture nucleic acid. After incubation at 25° C. for 30 min, the beads were washed twice with PBST and resuspended in 50 μl of PBST.

[0225] The immobilized peptides were used for peptide sequencing using the ProteoCode assay substantially as described above, using an exemplary binder (with a coding tag attached) that binds to phenylalanine when phenylalanine is the N-terminal amino acid residue. An exemplary peptide with an amino FA terminus (FAGVAMPGAEDDVVGSGSK, SEQ ID NO: 3) was used. An oligonucleotide without a peptide attached was also tested as a control. The extended recording tag of the assay was subjected to PCR amplification and analyzed by next generation sequencing (NGS). As shown in Table 4, all methods tested for immobilizing peptides and placing barcodes resulted in encoding. [Table 4]

[0226] Example 3: Evaluation of Encoding Peptides with Functionalized N-Terminal Amino Acids This example describes an exemplary encoding assay for evaluating immobilized peptides, which is performed using a binder that recognizes a functionalized (e.g., modified) N-terminal amino acid on the peptide.

[0227] Nucleic acid-peptide chimeras (peptides conjugated to bait nucleic acids) were hybridized and ligated to hairpin capture DNA that was chemically immobilized on agarose beads substantially as described in Example 1. In this experiment, the hairpin capture DNA contained a hybridization sequence complementary to a portion of the bait nucleic acid. After ligation with the bait nucleic acid, the hairpin capture DNA-bait nucleic acid contained an adapter sequence (universal forward priming site) for downstream sequencing analysis. Various peptides were tested in the encoding assay as described in SEQ ID NOs: 25-31, each associated with a nucleic acid sequence shown in Table 5 that was used as a recording tag (RT) in the assay. [Table 5]

[0228] In this exemplary model system, a cognate binder configured to bind to a modified N-terminal phenylalanine residue (F) on an immobilized peptide was used. Encoding occurred by transferring information from a coding tag associated with the binder to a recording tag associated with the peptide, thereby generating an extended recording tag. For the encoding assay, 200 nM of an exemplary binder for phenylalanine (F), which recognizes the modified NTAA, was incubated for 30 min at room temperature with a peptide treated with an exemplary chemical reagent for modifying NTAA. After a quick wash with PBST buffer to remove excess binder, the mixture was incubated for 5 min at room temperature with 0.125 units / μL Klenow fragment (3'->5' exo-) (MCLAB, USA), dNTP mix (125 μM each), 50 mM Tris-HCl (pH 7.5), 2 mM MgSO4, 50 mM NaCl, 1 mM DTT, 0.1% Tween® 20, and 0.1 mg / mL BSA. After washing and capping with a DNA sequence containing a universal reverse priming site (sequence numbers 34-45), the extended recording tags of the assays were subjected to PCR amplification and analyzed by next-generation sequencing (NGS). In this experiment, samples from each well were capped with capping DNA containing a barcode that allows the identity of the sample well to be determined in a later step, although samples from different wells were pooled for processing.

[0229] FIG. 10 shows the encoding efficiency using F binders for the peptides tested, including peptides with N-terminal phenylalanine and other N-terminal amino acids. A control of recording tags only (RT only) not associated with the peptide was also used. In summary, an increase in F binders encoding peptides ending with N-terminal phenylalanine was detected, demonstrating the use of hybridization-based immobilization of peptides and exemplary nucleic acids in encoding assays.

[0230] The present disclosure is not intended to be limited in scope to the specific disclosed embodiments, which are provided, for example, to illustrate various aspects of the present invention. Various modifications to the compositions and methods described will become apparent from the description and teachings herein. Such modifications can be made without departing from the true scope and spirit of the present disclosure, and are intended to be within the scope of the present disclosure. These and other modifications can be made to the embodiments in light of the above detailed description. In general, in the following claims, the terms used should not be construed to limit the claims to the specific embodiments disclosed in the specification and claims, but should be construed to include all possible embodiments along with the full scope of equivalents to which such claims are entitled. The claims are therefore not limited by the present disclosure. [Table 6-1] [Table 6-2]

Claims

1. 1. A method for processing a polypeptide analyte, comprising: attaching the polypeptide analyte to a bait nucleic acid to generate a nucleic acid-analyte chimera, wherein the bait nucleic acid is covalently attached to the polypeptide analyte to generate the nucleic acid-analyte chimera; bringing the nucleic acid-analyte chimera into proximity with a solid support by hybridizing the bait nucleic acid in the nucleic acid-analyte chimera to a capture nucleic acid attached to the solid support; covalently coupling said nucleic acid-analyte chimera to said solid support, a plurality of said nucleic acid-analyte chimeras are coupled on said solid support, and adjacent nucleic acid-analyte chimeras coupled on said solid support are separated from each other by an average distance of 50 nm or more; contacting the polypeptide analyte covalently coupled to the solid support with a binding agent capable of binding to the polypeptide analyte, the binding agent comprising a coding tag that comprises identifying information regarding the binding agent; transferring said identifying information about said binding agent from said coding tag to said bait nucleic acid or a capture nucleic acid attached to said polypeptide analyte; A method comprising:

2. 2. The method of claim 1, further comprising attaching a barcode to the coupled nucleic acid-analyte chimera, wherein the barcode comprises a compartment barcode, a partition barcode, a sample barcode, a fraction barcode, or any combination thereof.

3. contacting the analyte with an additional binding agent capable of binding to the analyte, the additional binding agent comprising a coding tag having identifying information regarding the additional binding agent; and transferring the identification information of the coding tag for the additional binding agent to the bait or capture nucleic acid one or more times.

4. 1. A nucleic acid-analyte composition comprising a plurality of nucleic acid-analyte chimeras and a plurality of capture nucleic acids attached to a solid support, said nucleic acid-analyte composition comprising: attaching a polypeptide analyte to a bait nucleic acid to generate a nucleic acid-analyte chimera, said bait nucleic acid being covalently attached to said polypeptide analyte to generate said nucleic acid-analyte chimera; bringing the nucleic acid-analyte chimera into proximity with a solid support by hybridizing the bait nucleic acid in the nucleic acid-analyte chimera to a capture nucleic acid attached to the solid support; and covalently coupling the nucleic acid-analyte chimera to the solid support, said plurality of nucleic acid-analyte chimeras being coupled on said solid support, wherein adjacent nucleic acid-analyte chimeras coupled on said solid support are separated by an average distance of 50 nm or more; contacting the polypeptide analyte covalently coupled to the solid support with a binding agent capable of binding to the polypeptide analyte, the binding agent comprising a coding tag that comprises identifying information regarding the binding agent; and transferring said identifying information about said binding agent from said coding tag to said bait nucleic acid or a capture nucleic acid attached to said polypeptide analyte; A nucleic acid-analyte composition produced by

5. The nucleic acid-analyte composition of claim 4, wherein the capture nucleic acid, the nucleic acid-analyte chimera, and / or the bait nucleic acid further comprises a barcode.

6. The nucleic acid-analyte composition of claim 4 or claim 5, wherein the capture nucleic acid comprises a nucleic acid hairpin.

7. A kit for polypeptide analysis comprising: (a) a plurality of bait nucleic acids, each of the bait nucleic acids configured to covalently attach to a polypeptide analyte; (b) a solid support comprising a plurality of attached capture nucleic acids, each of the capture nucleic acids comprising a sequence complementary to a corresponding bait nucleic acid of the plurality of bait nucleic acids and configured to covalently couple the polypeptide analyte to the solid support; a solid support, wherein adjacent capture nucleic acids attached to the solid support are spaced apart by an average distance of 50 nm or more on the solid support; (c) one or more binding agents capable of binding to the polypeptide analyte, each binding agent comprising a coding tag that includes identifying information for the binding agent, the coding tag being configured to enable transfer of the identifying information for the binding agent to the bait nucleic acid or a capture nucleic acid attached to the polypeptide analyte immobilized on the solid support; Including the kit.

8. a plurality of barcodes, the barcodes being attached to the bait nucleic acid or the capture nucleic acid; or The kit of claim 7 , wherein the barcode is configured to be attached to the bait nucleic acid or the capture nucleic acid.

9. 9. The kit of claim 7 or claim 8, wherein at least one of the bait nucleic acids comprises a reactive coupling moiety configured for attachment to at least one of the polypeptide analyte or the capture nucleic acid.

10. The kit of any one of claims 7 to 9, wherein at least one of the capture nucleic acids comprises a nucleic acid hairpin.

Citation Information

Patent Citations

  • Nucleic acid capture component

    JP2001517068A

  • Nucleic acid capture moieties

    US5770365A

  • Macromolecule analysis employing nucleic acid encoding

    WO2017192633A1